Top

Wai-Kwan Alfred Yung, M.D.

Department of Neuro-Oncology, Division of Cancer Medicine

About Dr. Wai-Kwan Alfred Yung

Dr. Yung is professor of Neuro-oncology at The University of Texas MD Anderson Cancer Center, where he held the Margaret and Ben Love Chair of Clinical Cancer Care and dual appointment as professor of Cancer Biology. He is also a faculty member at the UT Graduate School of Biomedical Sciences in Houston. He earned his undergraduate degree from the University of Minnesota, Minneapolis and his medical degree from the University of Chicago Pritzker School of Medicine. Internship and residency training followed at the University of California, San Diego. He completed chief residency and a fellowship at Cornell University School of Medicine and Memorial Sloan-Kettering Cancer Center. Dr. Yung joined MD Anderson as assistant professor in 1981 and rose quickly through the faculty ranks. He was co-director (1999-2015) of the MDACC Brain Tumor Center, which he expanded with co-director Raymond Sawaya, M.D. Dr. Yung has led the department of Neuro-Oncology as ad interim chair (1999-2002) and as chair (2002-2015). During his tenure, the department has expanded to 24 faculty who have achieved much under his guidance, including development of a National Cancer Institute (NCI)-funded Brain Tumor Clinical Trial Consortium, a Brain Specialized Program of Research Excellence (SPORE), and the groundbreaking D24 smart oncolytic virus program. Dr. Yung’s extensive experience and expertise in brain tumor research has included more than three decades of basic, translational and clinical studies at MD Anderson. Published more than 400 peer-reviewed journals, his research aims to develop new therapeutic approaches to block the regulatory mechanisms of brain cancer cells. His primary focus is on development of molecular therapeutic strategies targeting the EGFR and PTEN/PI3 kinase pathways and tumor resistant mechanisms that are crucial to the progression of human glioma. Dr. Yung’s many significant contributions to his field include discovery of the PTEN gene with Peter Steck; leading the study that led to FDA approval of temozolomide for glioblastoma and co-leadership of the registration study which led to approval of the drug bevacizumab for recurrent glioblastoma; co-chair of the TCGA GBM and LGG committees; development and funding of the National Cancer Institute (NCI)-funded Brain Tumor SPORE; building of the D24 smart oncolytic virus program; leadership in the NCI- funded CNS tumor clinical trial consortia and creation of the GBM Agile, a global adaptive clinical trial platform. Dr. Yung served as Editor-in-Chief of Neuro-Oncology (2007-2014), and co-chair of the NCI Brain Malignancy Steering Committee (2011-2017). He was appointed to Vice President Biden’s Cancer Moonshot Blue Ribbon Panel in 2016. He is currently serving as Special Scientific Advisor of National Brain Tumor Society (NBTS), Chair of SAB for Asia Foundation for Cancer Research (AFCR), member of SAC for Ludwig Institute of Cancer Research (LICR), member of SAB for Roche, ILCT Inc, Quadriga, Denovo, Calidi, and a member of the MDACC Cancer Moonshot Leadership Committee.

Primary Appointment

Moonshot Executive Committee, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Senior Advisor, Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor of Cancer Biology, Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor of Neurology, Department of Neurology, The University of Texas Medical School, Houston, TX

Dual/Joint/Adjunct Appointment

Moonshot Executive Committee, The University of Texas MD Anderson Cancer Center, Houston, TX

Regular Member, Department of UT Health Science Center, Graduate School of Biomedical Sciences, Houston, TX

Professor of Cancer Biology, Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Member, Department of Virology & Gene Therapy Program, UT Health Science Center, Graduate School of Biomedical Sciences, Houston, TX

Professor of Neurology, Department of Neurology, The University of Texas Medical School, Houston, TX

Professor, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1975	University of Chicago, Chicago, Illinois, US, MD
1971	University of Minnesota, Minneapolis, Minnesota, US, BS in Biochemistry

Postgraduate Training

1978-1979	Chief Resident, Neurology, Memorial Sloan-Kettering Cancer Center, NY, New York
1978-1981	Fellowship, Neuro-Oncology, Memorial Sloan-Kettering Cancer Center, NY, New York
1975-1975	Residency, Neurology, University of California, San Diego, California

Licenses & Certifications

1981	Texas
1980	American Board of Psychiatry and Neurology
1976	California

Experience & Service

Faculty Academic Appointments

Margaret & Ben Love Chair in Clinical Cancer in Honor of Dr. Charles A. LeMaistre, The University of Texas MD Anderson Cancer Center, Houston, TX, 2002 - 2016

Associate Member, Graduate School of Biomedical Sciences, The University of Texas Health Science Center, Houston, TX, 2002 - 2006

Florence M. Thomas Professor of Cancer Research, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1996 - 2002

Professor, Department of Dept of Tumor Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1992 - 1999

Associate Professor, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1986 - 1992

Associate Professor, Department of Neurology, The University of Texas Medical School, Houston, TX, 1986 - 1992

Associate Professor, Department of Tumor Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1986 - 1992

Assistant Professor, Department of Tumor Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1985 - 1986

Faculty Member, Graduate School of Biomedical Sciences, The University of Texas Health Science Center, Houston, TX, 1983 - 2001

Assistant Professor, Department of Neurology, The University of Texas Medical School, Houston, TX, 1981 - 1986

Assistant Professor, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1981 - 1986

Administrative Appointments/Responsibilities

Senior Advisor, Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - Present

Co-Director, The University of Texas MD Anderson Brain Tumor Center, Houston, TX, 2002 - 2015

Department Chair, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2002 - 2015

Department Chair ad interim, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1999 - 2002

Medical Director, Department of Neuro & Supportive Care Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 1995 - 1999

Chief, Section of Consultative Neuro-Oncology, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1991 - 2015

Deputy Chair, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1984 - 1999

Other Professional Positions

SAC Member, Ludwig Institute of Cancer Research, New York, 2017 - Present

Member, Blue Ribbon Panel for Biden Cancer Moonshot Initiative, Washington, DC, 2016 - Present

Special Scientific Advisor, National Brain Tumor Society, Watertown, MA, 2016 - Present

SAB Member, MSKCC Brain Tumor Center, New York, 2011 - Present

Chairman, Strategic Advisory Board, National Brain Tumor Society, Watertown, MA, 2011

Co-Chair, The Cancer Genome Atlas Low-Grade Glioma Disease Working Group, NIH, Bethesda, MD, 2010 - Present

Co-Chair, NCI Brain Malignancies Steering Committee, Rockville, MD, 2010 - 2016

Advisory Board Member, Merck & Company, North Wales, PA, 2010 - Present

Consultantships, Actelion, Basel Switzerland, 2010 - 2015

Advisory Board Member, 2005-2010, Goldhirsh Foundation Board, Boston MA, 2009 - 2010

Consultant, The National Brain Tumor Society, Boston, MA, 2009 - Present

Consultant, Terry Fox Research Institute, Vancouver, BC, Canada, 2009 - Present

Advisory Board Member, Merck OncoNet, North Wales, PA, 2009 - 2010

Adjunct Professor, The Chinese University of Hong Kong, Hong Kong, 2008 - Present

Scientific Advisory Board, Eden Therapeutics Inc, Cambridge, MA, 2008 - 2013

Member, The Cancer Genome Atlas GBM Disease Working Group, NIH, Bethesda, MD, 2007 - 2015

Member, Steering Committee, The Cancer Genome Atlas, Bethesda, MD, 2007 - 2015

Advisory Board Member, Novartis Pharmaceuticals Corporation, East Hanover NJ, 2006 - 2016

Editor-in-Chief, Neuro-Oncology, Society of Neuro-Oncology, Oxford Press, Houston, TX, 2006 - 2013

Advisory Board Member, Myriad Pharmaceuticals, Inc, Salt Lake City UT, 2006 - 2009

Advisory Board Member, CytoDome, Atlanta GA, 2005 - 2010

Scientific Advisory Board, DNAtrix, Houston TX, 2005 - Present

Advisory Board Member, Eli Lilly Company, Indianapolis IN, 2005 - 2015

Glioma Advisory Board Member, Genetech, Inc, South San Francisco CA, 2005 - 2012

Advisory Board Member, ImClone Systems, New York NY, 2004 - 2005

Advisory Board Member, Semafore Pharmaceuticals, Indianapolis IN, 2004 - 2007

Advisory Board Member, Regeneron Pharmaceuticals, Tarrytown NY, 2004 - 2007

Advisory Board Member, Accelerate Brain Cancer Cure (ABC2), Burlingame CA, 2002 - 2010

Advisory Board Member, Pediatric Brain Tumor Foundation of USA, Asheville SC, 2000 - 2002

Advisory Board Member, American Brain Tumor Assocation, Des Plaines IL, 2000 - Present

Advisory Board Member, Schering-Plough Research Institute, Kenilworth NJ, 2000 - 2010

Advisory Board Member, Antisense Pharma, Inc, Regensburg Germany, 2000 - 2011

Staff Neurology Consultant, Hermann Hospital, Houston, TX, 1981 - 2016

Extramural Institutional Committee Activities

Member, Enhancing Industry Partnership Working Group, The University of Texas MD Anderson Cancer Center, 2013 - 2015

Member, ICT Chair Search Committee, The University of Texas MD Anderson Cancer Center, 2012 - 2013

Advisory Committee Member, Research Cost Working Group, The University of Texas MD Anderson Cancer Center, 2012 - 2015

Member, Bridge Funding Advisory Panel, The University of Texas MD Anderson Cancer Center, 2011 - Present

Member, Molecular Testing Evaluation Committee, The University of Texas MD Anderson Cancer Center, 2010 - Present

Member, Institute of Personalized Cancer Therapy (IPCT) Committee, The University of Texas MD Anderson Cancer Center, 2009 - Present

Chair, Global Academic Oversight Steering Committee, The University of Texas MD Anderson Cancer Center, 2009 - 2012

Member, Experimental Diagnostic Imaging Search Committee, The University of Texas MD Anderson Cancer Center, 2008 - 2009

Member, Small Animal Imaging Liaison Committee, The University of Texas MD Anderson Cancer Center, 2008 - 2015

Member, Search Committee, Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, 2008 - Present

Member, Division of Cancer Medicine Physician Scientist Committee, The University of Texas MD Anderson Cancer Center, 2007 - 2010

Member, Pharmaceutical Development Center (PDC) Oversight Committee, The University of Texas MD Anderson Cancer Center, 2007 - 2012

Member, Division of Cancer Medicine CTRC Steering Committee, The University of Texas MD Anderson Cancer Center, 2006 - 2015

Member, Global Academic Oversight Steering Committee, The University of Texas MD Anderson Cancer Center, 2005 - 2012

Member, Clinica Alemana Steering Committee, The University of Texas MD Anderson Cancer Center, 2005 - 2011

Chair, Search Committee Anesthesiology/Pain Medicine & Critical Care Deputy Division, The University of Texas MD Anderson Cancer Center, 2005

Member, Psychosocial Committee, The University of Texas MD Anderson Cancer Center, 2004 - 2007

Member, Search Committee Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 2004 - 2005

Member, Search Committee International Center Medical Director, The University of Texas MD Anderson Cancer Center, 2004 - 2005

Member, Imaging Physics Search Committee, The University of Texas MD Anderson Cancer Center, 2003 - 2004

Member, Protocol Development Focus Group, The University of Texas MD Anderson Cancer Center, 2002 - 2004

Member, Oversight Panel for the Institutional Research Grants Committee, The University of Texas MD Anderson Cancer Center, 2002 - 2012

Member, Brain Tumor Center Translational Research Committee, The University of Texas MD Anderson Cancer Center, 2002 - 2012

Member, Brain Tumor Center Tissue Bank Focus Group, The University of Texas MD Anderson Cancer Center, 2002 - 2012

Member, Clinical Research Blue Ribbon Committee, The University of Texas MD Anderson Cancer Center, 2002 - 2003

Chair, Multidisciplinary Research Advisory Committee, The University of Texas MD Anderson Cancer Center, 2002 - 2014

Chair, Asia Task Force Committee, The University of Texas MD Anderson Cancer Center, 2002 - 2005

Member, Global Oncology China Steering Committee, The University of Texas MD Anderson Cancer Center, 2002 - 2009

Member, Institutional Research Executive Committee, The University of Texas MD Anderson Cancer Center, 2000 - 2016

Member, Brain and Spine Center Operations Committee, The University of Texas MD Anderson Cancer Center, 2000 - 2015

Member, Clinical Investigator Advisory Committee, The University of Texas MD Anderson Cancer Center, 2000 - 2003

Member, Ethical Principles for Use of Research Resources, The University of Texas MD Anderson Cancer Center, 2000 - 2002

Member, Clinical Faculty Review Committee, The University of Texas MD Anderson Cancer Center, 1999 - 2003

Co-Chair, Brain Tumor Center Executive Committee, The University of Texas MD Anderson Cancer Center, 1999 - 2015

Chair, Public Affairs Sub-committee, Faculty Celebration Committee, The University of Texas MD Anderson Cancer Center, 1999

Chair, Institutional Scientific Research Committee, The University of Texas MD Anderson Cancer Center, 1999 - 2003

Public Affairs, Sub-Committee, Faculty Celebration Committee, The University of Texas MD Anderson Cancer Center, 1999

Member, Search Committee for Head of Division of Pathology, The University of Texas MD Anderson Cancer Center, 1998

Member, Steering Committee on Cancer & Minorities, The University of Texas MD Anderson Cancer Center, 1998 - 2002

Member, Asia Business Development Task Force Committee, The University of Texas MD Anderson Cancer Center, 1998 - 2003

Member, Chief Academic Officer Search Advisory Committee, The University of Texas MD Anderson Cancer Center, 1997 - 1998

Member, Clinical Ethics Committee, The University of Texas MD Anderson Cancer Center, 1997 - 1998

Member, Institutional Product Development Committee, The University of Texas MD Anderson Cancer Center, 1995 - 1996

Member, Institutional Promotion and Tenure Task Force, The University of Texas MD Anderson Cancer Center, 1995 - 1999

Chairman, Faculty Classification Committee, The University of Texas MD Anderson Cancer Center, 1995 - 1996

Member, Clinical Research Committee, The University of Texas MD Anderson Cancer Center, 1994 - 1996

Member, Surveillance Committee, The University of Texas MD Anderson Cancer Center, 1994 - 1995

Member, Tissue Banking Committee, The University of Texas MD Anderson Cancer Center, 1993 - 1996

Member, Physicians Referral Service Executive Council, The University of Texas MD Anderson Cancer Center, 1993 - 1999

Member, PRS Research Committee, The University of Texas MD Anderson Cancer Center, 1993 - 1999

Member, Faculty Classification Committee, The University of Texas MD Anderson Cancer Center, 1993 - 1996

Chairman, Institutional Research Grant Committee, The University of Texas MD Anderson Cancer Center, 1992 - 1993

Member, PRS Fringe Benefit Committee, The University of Texas MD Anderson Cancer Center, 1991 - 1993

Member, Committee to Evaluate the Status of Minority and Women Faculty, Administrative Faculty and Administrative Staff, The University of Texas MD Anderson Cancer Center, 1991 - 1994

Member, Medical Practice Committee, The University of Texas MD Anderson Cancer Center, 1991 - 1994

Member, Faculty Senate, The University of Texas MD Anderson Cancer Center, 1991 - 1994

Member, Institutional Research Grant Committee, The University of Texas MD Anderson Cancer Center, 1990 - 1993

Member, Medical Records Committee, The University of Texas MD Anderson Cancer Center, 1989 - 1990

Member, Grievance Committee, The University of Texas MD Anderson Cancer Center, 1988 - 1990

Member, Promotion Committee, Division of Medicine, The University of Texas MD Anderson Cancer Center, 1987 - 1988

Member, Conduct of Care Committee, The University of Texas MD Anderson Cancer Center, 1987 - 1991

Member, Investigational Drug Committee, The University of Texas MD Anderson Cancer Center, 1985 - 1989

Member, Pharmacy Committee, The University of Texas MD Anderson Cancer Center, 1984 - 1989

Editorial Activities

Editorial Board Member, Neuro-Oncology, 2013 - Present

International Advisor, The Journal of Korean Neurosurgical Society, 2008 - Present

Editorial Board Member, Gene Therapy & Molecular Biology, 2007 - 2008

Editor-In-Chief, Neuro-Oncology, 2006 - 2013

Associate Editor, Neuro-Oncology, 2000 - 2006

Editorial Board, Cancer Therapy/Gene Therapy & Molecular Biology, 2000 - 2003

Associate Editor, Journal of Neuro-Oncology, 2000 - 2001

Editor, Cancer Therapy/Gene Therapy & Molecular Biology, 2000 - 2001

Editor, Journal of Neuro-Oncology, 2000 - 2006

Honors & Awards

2015	NBTS Founders Award
2015	Pritzher School of Medicine Alumni Distinguish Service Award, University of Chicago
2015	Lifetime Achievement Award, Society for Neuro Oncology
2014	John Mendelsohn Lifetime Scientific Achievement Award, UTMD Anderson Cancer Center
2013	Public Service Award, Society for Neuro Oncology
2012 - 2024	Top 1% Doctors in America, US News and World Report
2012	Takeo Hoshino Lecture, University of California, San Francisco
2012	Waun Ki Hong Team Science Award, UTMD Anderson Cancer Center
2006 - 2024	Who's Who in the South and Southwest
2005	ASCO's Expert Roster of Cancer Experts, American Society for Clinical Oncology
2005	Who's Who in America
2005 - 2007	Chair, Scientific Program Committee, Society for Neuro-Oncology
2005	Faculty Achievement Award in Clinical Research, UT M. D. Anderson Cancer Center
2002 - 2016	Margaret and Ben Love Chair in Clinical Cancer, The University of Texas MD Anderson Cancer Center
1999	Who's Who
1999 - 2003	NIH Clinical Oncology Study Section Member
1996 - 2002	Florence M. Thomas Professor of Cancer Research, The University of Texas MD Anderson Cancer Center
1993 - 2024	Who's Who Worldwide
1992 - 2024	Best Doctors in America 2013
1991 - 1995	NIH Path A Study Section Member
1979 - 1981	PHS National Research Service Award, Cancer Chemotherapy Training Grant
1975	Franklin McLean Research Award, University of Chicago
1971	Best Senior Award in Biochemistry, University of Minnesota

Professional Memberships

Ludwig Institute of Cancer Research

2017 - Present

Blue Ribbon Panel for National Cancer Moonshot Initiative (NCI/NIH)

2016 - Present

NCI Brain Malignancies Steering Committee

2010 - 2017

Journal of Korean Neurosurgical Society

2009 - Present

Goldhirsh Foundation Scientific Advisory Board

2005 - 2010

Radiation Therapy Oncology Committee

2001 - 2010

St. Jude Children's Research Hospital

2001

Who's Who

1999 - Present

Harris County Medical Society

1998 - Present

American Association for the Advancement of Science

1998 - Present

American Neurological Association

1998 - Present

Society for Neuro-Oncology

1994 - Present

American Academy of Neurology

1988 - Present

American Society of Clinical Oncology

1987 - Present

American Association for Cancer Research

1984 - Present

Texas Medical Association

1981 - Present

Selected Presentations & Talks

Local Presentations

2018. Progress in GBM research: GBM AGILE, a global adaptive platform trial. Conference. Progress in GBM research: GBM AGILE, a global adaptive platform trial. Houston, TX, US.
2015. Emil J Freireich Leukemia. Conference. Emil J Freireich Leukemia. Houston, TX, US.
2012. State of the Art Approach to Brain Tumor Therapy. Conference. State of the Art Approach to Brain Tumor Therapy. Houston, TX, US.
2008. MDACC Brain Tumor SPORE - Targeting PI3K Pathway in Malignant Gliomas. Conference. MDACC Brain Tumor SPORE - Targeting PI3K Pathway in Malignant Gliomas. Houston, TX, US.
2008. Targeted Molecular Therapy in Malignant Gliomas. Conference. Targeted Molecular Therapy in Malignant Gliomas. Houston, TX, US.
2008. Molecular determinants of glioblastoma subtypes. Conference. Molecular determinants of glioblastoma subtypes. Houston, TX, US.
2007. Brain Tumors. Conference. Brain Tumors. Houston, TX, US.
2007. Targeted therapies for malignant gliomas. Conference. Targeted therapies for malignant gliomas. Houston, TX, US.
2006. Personalized Targeted Therapy for Malignant Glioma. Conference. Personalized Targeted Therapy for Malignant Glioma. Houston, TX, US.
2006. Targeting the PI3K Pathway in Glioblastomas. Conference. Targeting the PI3K Pathway in Glioblastomas. Houston, TX, US.
2006. Signal Transduction Inhibitors. Conference. Signal Transduction Inhibitors. Houston, TX, US.
2006. EGFR vs PI3K Activities: Markers for Treatment Selection in Glioblastoma. Conference. EGFR vs PI3K Activities: Markers for Treatment Selection in Glioblastoma. Houston, TX, US.
2006. Targeted Therapies for Malignant Glioma; Session Chair & Moderator: Central Nervous System,. Conference. Targeted Therapies for Malignant Glioma; Session Chair & Moderator: Central Nervous System,. Houston, TX, US.
2005. Signal Transduction Inhibitors, Part II. Conference. Signal Transduction Inhibitors, Part II. Houston, TX, US.
2005. Targeting PI3 Kinase Pathway. Conference. Targeting PI3 Kinase Pathway. Houston, TX, US.
2005. Signal Transduction Inhibitors, Part I. Conference. Signal Transduction Inhibitors, Part I. Houston, TX, US.
2005. Signal Regulators of Tumor Cell Growth and Invasion: Potential Molecular Targets?. Conference. Signal Regulators of Tumor Cell Growth and Invasion: Potential Molecular Targets?. Houston, TX, US.
2004. Signal Transduction Inhibitors. Conference. Signal Transduction Inhibitors. Houston, TX, US.
2004. Basics of Chemotherapy. Conference. Basics of Chemotherapy. Houston, TX, US.
2004. CNS Malignancies. Conference. CNS Malignancies. Houston, TX, US.
2003. MMAC/PTEN in Brain Tumors. Conference. MMAC/PTEN in Brain Tumors. Houston, TX, US.
2003. Signal Transduction Inhibitors. Conference. Signal Transduction Inhibitors. Houston, TX, US.
2003. Where a Gene Won't Reach: Advances in Selectivity, Delivery, and Imaging of Viral-Based Cancer Gene Therapy. Conference. Where a Gene Won't Reach: Advances in Selectivity, Delivery, and Imaging of Viral-Based Cancer Gene Therapy. Houston, TX, US.
2003. Targeted Therapy in Malignant Gliomas. Conference. Targeted Therapy in Malignant Gliomas. Houston, TX, US.
2003. MMAC/PTEN Tumor Suppressor Gene in Human Brain Tumor. Conference. MMAC/PTEN Tumor Suppressor Gene in Human Brain Tumor. Houston, TX, US.
2003. Current Chemotherapy Options. Conference. Current Chemotherapy Options. Houston, TX, US.
2003. Signal Transduction Agents in Brain Tumor Therapy. Conference. Signal Transduction Agents in Brain Tumor Therapy. Houston, TX, US.
2002. Molecular and Genetic Therapies Against Brain Tumor Growth. Conference. Molecular and Genetic Therapies Against Brain Tumor Growth. Houston, TX, US.
2002. Principles of Brain Tumor Therapy. Conference. Principles of Brain Tumor Therapy. Houston, TX, US.
2002. Diagnosis and Treatment of Tumors of the Brain. Conference. Diagnosis and Treatment of Tumors of the Brain. Houston, TX, US.
2002. Glioblastoma: Molecular Targeted Therapy & Imaging; Cancer Center Support Grant Competitive Renewal. Conference. Glioblastoma: Molecular Targeted Therapy & Imaging; Cancer Center Support Grant Competitive Renewal. Houston, TX, US.
2001. Chemotherapy. Conference. Chemotherapy. Houston, TX, US.
2001. Conditionally Replicating Adenoviruses for Cancer Therapy. Conference. Conditionally Replicating Adenoviruses for Cancer Therapy. Houston, TX, US.
1999. Therapies for Malignant Brain Tumors in the New Millennium. Conference. Therapies for Malignant Brain Tumors in the New Millennium. Houston, TX, US.
1999. New Treatments Available. Conference. New Treatments Available. Houston, TX, US.
1998. Angiogenesis Clinical Trials in Brain Tumors. Conference. Angiogenesis Clinical Trials in Brain Tumors. Houston, TX, US.
1995. Science and Treatment: Chemotherapy. Conference. Science and Treatment: Chemotherapy. Houston, TX, US.
1993. Phase II and Phase III Studies for CNS Tumors. Conference. Phase II and Phase III Studies for CNS Tumors. Houston, TX, US.
1990. Proto-oncogenes and Growth Factors. Conference. Proto-oncogenes and Growth Factors. Houston, TX, US.
1987. Central Nervous System Malignancy. Conference. Central Nervous System Malignancy. Houston, TX, US.

Regional Presentations

2018. NCI Blue Ribbon Panel Listens: Submit Your Ideas for the National Cancer Moonshot Initiative. Conference. NCI Blue Ribbon Panel Listens: Submit Your Ideas for the National Cancer Moonshot Initiative. Chicago, TX, US.
2007. Phase II study of pegylated interferon Alfa-2b and temozolomide for the treatment of recurrent and progressive malignant gliomas. Conference. Phase II study of pegylated interferon Alfa-2b and temozolomide for the treatment of recurrent and progressive malignant gliomas. St Petersburg, FL, US.
2007. Glioblastoma - Molecular Progression and Therapy. Conference. Glioblastoma - Molecular Progression and Therapy. Salt Lake City, UT, US.
2006. Therapies in Clinical Trials: Today and Tomorrow. Conference. Therapies in Clinical Trials: Today and Tomorrow. Catalina, AZ, US.
2006. Mechanism-based Therapeutics. Conference. Mechanism-based Therapeutics. Cold Springs Harbor, NY, US.
2006. Brain Tumors. Conference. Brain Tumors. Austin, TX, US.
2006. Targeting the phosphatidylinositol 3-kinase pathway in human GBM. Conference. Targeting the phosphatidylinositol 3-kinase pathway in human GBM. Napa Valley, CA, US.
2005. Malignant Gliomas: An Overview. Conference. Malignant Gliomas: An Overview. Orlando, FL, US.
2003. Molecular Targeted Therapy in Malignant Gliomas. Conference. Molecular Targeted Therapy in Malignant Gliomas. Montgomery, TX, US.
2001. Temodar and Brain Tumors. Conference. Temodar and Brain Tumors. Albuquerque, NM, US.
2001. Future Trends in the Treatment of Brain Tumors. Conference. Future Trends in the Treatment of Brain Tumors. Padova, IT.
2000. Anaplastic Astrocytoma. Conference. Anaplastic Astrocytoma. Santa Fe, NM, US.
1997. Activity of Temodal in Anaplastic Astrocytoma at First Relapse. Conference. Activity of Temodal in Anaplastic Astrocytoma at First Relapse. New York, NY, US.
1997. Phase II Study of Temozolomide in the Treatment of Patients with Newly Diagnosed Anaplastic Astrocytoma. Conference. Phase II Study of Temozolomide in the Treatment of Patients with Newly Diagnosed Anaplastic Astrocytoma. San Francisco, CA, US.
1997. Temozolomide in AA: Quality of Life Issues. Conference. Temozolomide in AA: Quality of Life Issues. Denver, CO, US.
1996. Phase II Trials of Temozolomide in the Treatment of Patients with Glioblastoma Multiforme and Anaplastic Astrocytoma at First Relapse. Conference. Phase II Trials of Temozolomide in the Treatment of Patients with Glioblastoma Multiforme and Anaplastic Astrocytoma at First Relapse. Santa Fe, NM, US.
1996. A Phase II Study of Temozolomide in the Treatment of Patients with Newly Diagnosed, Supratentorial Malignant Glioma prior to Radiation Therapy. Conference. A Phase II Study of Temozolomide in the Treatment of Patients with Newly Diagnosed, Supratentorial Malignant Glioma prior to Radiation Therapy. Orlando, FL, US.
1995. Brain Tumor Biology/Specific Products: Angiogenic Growth Factors. Conference. Brain Tumor Biology/Specific Products: Angiogenic Growth Factors. Round Top, TX, US.
1993. EGF Receptor Mediated Growth Regulatory Mechanism in Human Glioblastoma-A Target for Antisense Approaches. Conference. EGF Receptor Mediated Growth Regulatory Mechanism in Human Glioblastoma-A Target for Antisense Approaches. Boston, MA, US.
1993. Temozolomide Clinical Pharmacoeconomics and Quality of Life. Conference. Temozolomide Clinical Pharmacoeconomics and Quality of Life. Short Hills, NJ, US.

National Presentations

2012. Targeting the PI3K/Akt/mTOR Axis. Conference. Targeting the PI3K/Akt/mTOR Axis. Washington, DC, US.
2011. The Challenge of Personalized Molecular Therapy for GBM. Conference. The Challenge of Personalized Molecular Therapy for GBM. Seoul.
2007. Novel Therapies in Neuroendocrine Tumors. Conference. American Society for Clinical Oncology. Chicago, IL, US.
2006. 1)Targeted Therapies in Malignant Gliomas, 2) Chemotherapy in Malignant Glioma: What is New?. Conference. Korean Brain Tumor Society/Korean Neurological Society. Seoul.
2006. 1) New strategies for management of malignant gliomas, 2) Temozolomide historical perspective. Conference. Temozolomide Symposium. Tokyo, US.
2006. Molecular Markers for Malignant Gliomas. Conference. 2006 ASCO Satellite Meeting. Atlanta, GA, US.
2006. Targeting the Phosphatidylilnositol 3-kinase Pathway in Human Glioma. Conference. Asilomar Brain Tumor Research Conference. Napa Valley, CA, US.
2005. Oncolytic Viruses. Conference. The Preuss Foundation Seminar, Oncolytic Viral Therapies for Brain Tumors. La Jolla, CA, US.
2005. Novel Therapies (preclinical experimental therapeutics). Conference. WFNO II / EANO VI Meeting. Edinburgh.
2003. Targeted Therapies for brain tumors. Conference. City of Hope 2nd Annual Brain Tumor Conference. Marina Del Rey, CA, US.
2003. “Controversies in Primary Brain Tumor Management", "Development of Biological Targeted Therapies for NST: Bench-Bedside". Conference. 8th Annual Meeting of the Society for Neuro-Oncology. Keystone, CO, US.
2003. Signal transduction inhibitors: Potential agents for malignant gliomas. Conference. 2nd Biennial Cleveland Clinic International Summit for Finding the Cure for Glioblastoma. Cleveland, OH, US.
2003. Signal transduction inhibitors in brain tumor therapy: Any hope? Co-Chair, "New Directions in Cancer: Organ Site Research from the Laboratory to the Clinic: Brain Cancer". Conference. AACR, 94th Annual Meeting. Washington, DC, US.
2003. A phase I trial of single-agent 787/ZK 222584 (PTK/ZK), An oral VEGFR tyrosine kinase inhibitor, in patients with recurrent Glioblastoma multiforme. Conference. ASCO, 39th Annual Meeting. Chicago, IL, US.
2003. Novel Signal Transduction Agents for Glioblastoma. Conference. American Radium Society 2003 Annual Meeting. Houston, TX, US.
2003. Recent Advances and Future Directions in Cell Biology & Clinical Research. Conference. The Fifth International Symposium on Anti-Angiogenic Agents. La Jolla, CA, US.
2002. A Phase I Trial of PTK787/ZK 222584 (PTK/ZK), A Novel Oral VEGF-R TK Inhibitor in Recurrent Glioblastoma” “Combination Treatment with Temozolomide in CNS Tumors. Conference. 38th Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, US.
2001. A RTOG Phase II Study of Conventional Radiation Therapy Plus Thalidomide Followed by the Thalidomide Post XRT for Supertentorial. Conference. ASCO. San Francisco, CA, US.
2000. New Frontiers in Therapy of Malignant Gliomas. Conference. AAN 52nd Annual Meeting. San Diego, CA, US.
1999. Delta-24 oncolytic adenovirus has anti-glioma effect in vivo + comparison between the delta 24 and dl1520 oncolytic adenoviruses in vitro and in vivo. Conference. Society for Neuro Oncology 4th Annual Meeting. Scottsdale, AZ, US.
1999. New Drug for Brain Tumor. Conference. AACR. Philadelphia, PA, US.
1998. Unknown. Conference. Third Annual Meeting of the Society for Neuro-Oncology. San Francisco, CA, US.
1998. Central Nervous System. Conference. 34th Annual ASCO Meeting. Los Angeles, CA, US.
1997. RMP-7 Phase III Malignant Glioma Study. Conference. Alkermes Expert Panel Meeting. Amsterdam, US.
1997. New Approaches in Bio-Chemotherapy for Malignant Brain Tumors. Conference. Biotherapy in Medicine Symposium. Seoul, US.
1997. Herpes Vector for Gene Therapy. Conference. NCI Meeting. Rockville, MD, US.
1997. Molecular Modulation of Vascular Endothelial Growth Factor (VEGF) Expression in Glioma Cells by Ribozymes. Conference. AAN Annual Meeting. Boston, MA, US.
1997. CNS Tumors: From Molecular to Clinical Diagnosis. Conference. AACR 88th Annual Meeting. San Diego, CA, US.
1997. Science and Treatment: Chemotherapy. Conference. 2nd Biennial Brain Tumor Patient & Family Conference. Houston, TX, US.
1997. Angiogenesis Strategies in Malignant Glioma. Conference. 40th Annual Clinical Conference: Cancer & the Central Nervous System. Houston, TX, US.
1996. Opportunities in Genes and Genetics. Conference. 1St Annual Society for Neuro-Oncology Meeting. Albuquerque, NM, US.
1996. Time to Tumor Progression as a Measure of Efficacy in Phase II Chemotherapy Trials for Recurrent Malignant Gliomas. Conference. 32nd Annual ASCO Meeting. Philadelphia, PA, US.
1995. 1)Molecular modulation of vascular endothelial growth factor(VEGF) in expression in Glioma Cells by Ribozyme 2)Gene therapy for Malignant Glioma with Adenoviral WT-P53 Vector. Conference. 11th International Conference on Brain Tumor Research and Therapy. Napa, CA, US.
1995. Phase II Study of rhIFN-b + cRA in Recurrent Gliomas. Conference. American Society for Clinical Oncology Annual Meeting. Los Angeles, CA, US.
1995. Growth Suppression of Human Glioma Cells by Restoration of Wild-Type p53 Gene Utilizing an Adenovirus Vector. Conference. 47th Annual American Academy of Neurology Meeting. Seattle, WA, US.
1995. 1)Chemotherapy Overview 2)Biologic Therapy 3)Moderator “Scientific Session II. Conference. 2nd Annual Symposium on Advances in Brain Tumor Management. Las Vegas, NV, US.
1994. A Phase II Study of rIFN-b +/- cRA in Recurrent Gliomas. Conference. Society for Biological Therapy Meeting. Napa, CA, US.
1994. All Trans-Retinoic Acid: A Phase II Radiation Therapy Oncology Group Study (RTOG-9113) in Patients with Recurrent Malignant Astrocytoma. Conference. American Society of Clinical Oncology Meeting. Dallas, TX, US.
1994. Modulation of EGFR/TGF-a Autocrine Growth Regulation in Human Glioma by Antisense Approaches - Potential Agents for Molecular Therapy. Conference. Sixth International Symposium on Pediatric Neuro-Oncology. Houston, TX, US.
1994. Inhibition of Growth and Epidermal Growth Factor Receptor Expression in Human Glioma Cells by Triple Helix Forming Oligonucleotides. Conference. American Association for Cancer Research Meeting. San Francisco, CA, US.
1993. Combination Chemotherapy with Carboplatin, 5-Fluorouracil (5FU) and Procarbazine (PCB) for Recurrent Malignant Gliomas. Conference. American Society of Clinical Oncology. Orlando, FL, US.
1993. Modulation of Transforming Growth Factor-Alpha (TGF-a) Autocrine Growth Regulation by Antisense Oligonucleotides in Glioma Cells. Conference. American Association for Cancer Research. Orlando, FL, US.
1993. Modulation of TGF-a Autocrine Growth Regulation in Glioma Cells by Antisense Oligonucleotides. Conference. American Academy of Neurology 44th Annual Meeting. New York, NY, US.
1992. Role in Biology of Primary Brain Tumors. Conference. Iowa-Midwest Neurologic Association. Iowa City, IA, US.
1992. 1)Combination Chemotherapy with Carboplatin, 5FU and Procarbazine for Recurrent Malignant Gliomas 2)Transforming Potential of Epidermal Growth Factor Receptor (EGF-R) and Transforming Growth Factor-a (TGF-?) in Human Glial Cells. Conference. American Academy of Neurology 44th Annual Meeting. San Diego, CA, US.
1992. Autocrine Growth Loop by EGFR and TGF-a in Human Malignant Gliomas. Conference. American Society for Neurochemistry. Houston, TX, US.
1991. Expression, Alteration, and Biological Activity of TGF-?. Conference. The Ninth International Conference on Brain Tumor Research and Therapy. Pacific Grove, CA, US.
1991. Growth Factors and Growth Factor Receptors in Brain Tumors. Conference. ASCO Education Symposium on Brain Tumors. Houston, TX, US.
1991. High Molecular Weight TGF-alpha in Human Gliomas. Conference. AACR Annual Meeting. Houston, TX, US.
1991. Session on Biology of Human Brain Tumors. Conference. Annual Meeting of American Academy of Neurology. Boston, MA, US.
1990. The Expression and Biological Activities of TGF-alpha and EGF-receptor in Malignant Brain Tumors. Conference. The 5th Annual Mid-America Molecular and Cellular Biology Colloquium. Ardmore, OK, US.
1990. Expression and Biological Activity of Transforming Growth Factor-alpha (TGF-a) in Human Gliomas. Conference. Annual Meeting of American Association for Cancer Research. Washington, US.
1989. Chemotherapy and Immunotherapy of Brain Tumors. Conference. 15th Annual Charles M. Barrett/American Cancer Society Cancer Symposium. Cincinnati, OH, US.
1989. Differential Expression of TGF-Alpha in Human Gliomas. Conference. Annual Meeting of American Association for Cancer Research. San Francisco, CA, US.
1989. AGF-Alpha & Autocrine Growth Regulation in Human Gliomas. Conference. 41st AAN Annual Meeting. Chicago, IL, US.
1988. Modulation of Growth and EGF-Receptor Activity by Retinoic Acid on Cultured Human Glioma Cells. Conference. Annual Meeting of American Association for Cancer Research. New Orleans, LA, US.
1988. Transformed Growth Factor Alpha and Epidermal Growth Factor Receptor in Human Glioma Cells Growth Regulation. Conference. Annual Meeting of American Academy of Neurology. Cincinnati, OH, US.
1987. Modulation of Growth and EGF-R Activities by Retinoic Acid on Human Glioma and Glial Cells. Conference. Annual Meeting of the American Association for Cancer Research. Atlanta, GA, US.
1987. Intravenous Recombinant Beta Interferon (IFN?Bser) in Patients with Malignant Gliomas. Conference. 37th Annual Meeting of American Academy of Neurology. New York, NY, US.
1986. Adjuvant Chemotherapy with BCNU and CDDP for Patients with Malignant Gliomas. Conference. 38th Annual Meeting of American Academy of Neurology. New Orleans, LA, US.
1986. Growth Inhibitory Activity and Mechanism of Recombinant Alpha and Beta Interferon Effect on Human Glioma Cells. Conference. Annual Meeting of American Association for Cancer Research. Los Angeles, CA, US.
1985. Analysis of Epidermal Growth Factor Receptor and Associated Glycoprotein on Human Glioma Cells In Vitro. Conference. 6th International Conference on Brain Tumor Research & Therapy. Asheville, NC, US.
1985. Differential Sensitivity of Glioma Cells to Recombinant Interferons. Conference. 37th Annual Meeting of American Academy of Neurology. Dallas, TX, US.
1983. In Vitro Chemosensitivity Testing for Human Malignant Gliomas. Conference. 5th Conference on Brain Tumor Research and Therapy. Monterey, CA, US.
1983. In Vitro Chemosensitivities of Human Glioma Cells to AZQ and Cisplatinum by three Different Assays. Conference. Annual Meeting of American Association for Cancer Research. San Diego, CA, US.
1983. Vitro Sensitivities of Human Glioma Cells to Dexamethasone and Cisplatinum. Conference. 35th Annual Meeting of American Academy of Neurology. San Diego, CA, US.
1983. Vimentin and GAFP in Human Brain Tumors; Vitro Sensitivities of Human Glioma Cells to Dexamethasone and Cisplatinum. Conference. 35th Annual Meeting of American Academy of Neurology. San Diego, CA, US.

International Presentations

2012. The Challenge of Personalized Therapy for GBM. Conference. The Challenge of Personalized Therapy for GBM. Beijing, CN.
2012. Molecular Therapy for GBM. Conference. Merck. Marseille, FR.
2012. Lessons from and future after RTOG-0525. Conference. Lessons from and future after RTOG-0525. Taipei, TW.
2012. Molecular Biology and Targeted Therapies in Neuro-Oncology. Conference. Molecular Biology and Targeted Therapies in Neuro-Oncology. Bangalore, IN.
2011. New Developments in the Management of Glioma and The Role of Chemotherapy in the Management of Glioma. Conference. New Developments in the Management of Glioma and The Role of Chemotherapy in the Management of Glioma. Suzhou, CN.
2010. Molecular and Lineage Characterization of Glioma Stem Cell Lines for Preclinical Modeling. Conference. Molecular and Lineage Characterization of Glioma Stem Cell Lines for Preclinical Modeling. Heidelberg, DE.
2010. Emerging Targets and Biomarkers for Treatment of Brain Cancer. Conference. Emerging Targets and Biomarkers for Treatment of Brain Cancer. Hong Kong, CN.
2010. Molecular Markers in Malignant Gliomas. Conference. Anniversary Special Lecture. Taiwan, HK.
2010. Continuous development of Delta-24 RGD for the treatment of gliomas. Conference. Annual Meeting. Travemunde, DE.
2010. "Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using sirna synthetic lethality screening". Conference. Asilomar. Hamburg, DE.
2010. Recent Advance in Neuro-Oncology Practice. Conference. Jin-Ling Neuro-Oncology Forum. Nanjing, CN.
2010. Targeted Therapies in Glioblastoma. Conference. Targeted Therapies in Glioblastoma. Toronto, CA.
2009. Anti-angiogenesis Therapy in Malignant Gliomas. Conference. Anti-angiogenesis Therapy in Malignant Gliomas. Yokohama, JP.
2008. Targeted Therapies in Malignant Gliomas. Conference. AINO. Rome, IT.
2008. Optimizing temozolomide treatment in high grade glioma. Conference. Schering Plough Satellite Symposium: Future Perspectives in Neuro-Oncology. Rome, IT.
2007. Future of Molecular Therapies in Malignant Glioma: The Future of Targeted Therapy. Conference. The 1st International Symposium on Brain Tumors. Heidelberg, DE.
2007. Temozolomide in treating brain tumor. Conference. Schering Plough Satellite Symposium. Beijing, CN.
2007. Personalized cancer therapy: Coming Soon. Conference. Chinese Society Clinical Oncology, HK.
2007. Role of chemotherapy in brain tumor. Conference. Chinese Society Clinical Oncology, HK.
2007. Role of chemotherapy in treating gliomas. Conference. Shanghai Neuro-Oncology Symposium. Shanghai, CN.
2007. D24-RGD: an oncolytic virus targeting the RB pathway. Conference. 2007 Asia Pacific Conference of Tumor Biology & Medicine. Beijing, CN.
2007. Role of chemotherapy in treating gliomas. Conference. Beijing Neuro-Oncology Symposium. Beijing, CN.
2007. Targeted therapies. Conference. Global Brain Tumor Advisory Board - Schering Plough. Rome, IT.
2007. Tumors of the Central Nervous System. Conference. 2nd International Congress of Biological Therapies in Oncology in Mexico. Cuernavaca, Morelos, MX.
2007. New trials on angiogenesis inhibiting agents. Conference. Perspectives in Central Nervous System Malignancies III. Warsaw, PL.
2007. Targeted Agents. Conference. Perspectives in Central Nervous System Malignancies III. Warsaw, PL.
2006. "Current Progress on Chemotherapy with Temodal for Brain Tumors" and "Molecular Markers for Malignant Gliomas". Conference. Chinese Society of Neuro-Oncology, 4th Chinese Conference on Oncology. Tianjin, CN.
2006. Targeting the PI3K Pathway in Malignant Glioma. Conference. 12th Biennial Canadian Neuro-Oncology Meeting. Toronto, CA.
2006. 1) Moderator Sess VII Ongoing Clin Trials & Emerging Treatment Opts 2) Co-Mod: Sess VIII Practical Mngmt Strategies:Case Studies 3) Lecture: Role of Chemotherapy for Brain Mets; Targeted Therapies for Malig Glioma, Chemo for Newly Diagnosed GBM. Conference. Perspectives in Central Nervous System Malignancies Meeting. Budapest, HU.
2006. Perspectives in Central Nervous System Malignancies II. Conference. Perspectives in Central Nervous System Malignancies II. Budapest, HU.
2005. Chemotherapy for Malignant Glioma: Cytotoxic and Targeted Therapies. Conference. Asian Society for Neuro-Oncology. Taipei, TW.
2005. New Treatments for High Grade Gliomas. Conference. Centro Oncologico M. D. Anderson International. Madrid, ES.
2005. Anti-EGFR and Anti-VEGFR Strategies: What Have We Learned from the First Trials?. Conference. Perspectives in Central Nervous System Malignancies Conference. Prague, CZ.
2005. Glioblastoma: State of the Art and Future Trends in the Adjuvant Setting", "Future Trials in Europe, Canada, and USA. Conference. 3rd International Conference on Future Trends in the Treatment of Brain Tumors. Padua, IT.
2005. Malignant Gliomas. Conference. Malignant Gliomas. Padua, IT.
2004. Target Markers and Validation. Conference. Society for Neuro-Oncology 9th Annual Meeting. Toronto, CA.
2004. 1)EGFR Inhibitors for Recurrent Glioblastoma 2)Targeting Angiogenesis in Malignant Gliomas 3)Chemotherapy for Newly Diagnosed Glioblastoma 4)Targeting PTEN/P13K Pathway in Malignant Glioma 5)Combination Therapies: What is the Best?. Conference. WFNS (World Federation of Neuro Surgeons) Tumor Section 2004 Meeting. Jaipur, IN.
2004. Targeted Therapy for Brain Tumors. Conference. AIIMS (All India Institute of Medicine): A sister institution of UT M. D. Anderson Cancer Center. Delhi, IN.
2004. Discussion of Brain Tumors Session (Chair). Conference. Schering Plough Brain Tumor Advisory Board. Brugge, BE.
2004. Introduction: Prognosis and Progress of CNS Malignancies. Conference. Temozolomide Global Investigators Meeting Schering Plough Corporation. Porto, PT.
2002. Extend the Benefits of Temozolomide Oral Therapy. Co-Chaired Satellite Symposium. Meet the Experts Session: "Targeted Therapy”. Conference. EANO V Conference (European Association Neuro-Oncology). Florence, IT.
2002. Overview of Single-Agent Temozolomide Use in Recurrent Malignant Glioma. Conference. Temozolomide Global Investigators Meeting, The Grimaldi Forum. Monte Carlo, MC.
2002. The future role of Temozolomide in Glioma. Conference. Temozolomide Global Investigators Meeting, The Grimaldi Forum. Monte Carlo, MC.
2001. Future Trends in the Treatment of Brain Tumors. Conference. Future Trends in the Treatment of Brain Tumors Meeting. Padova, IT.
2000. Advances in Molecular Biology gliomas with a Focus on Molecular Targets for Potential Therapy. Conference. 2000 Canadian Neuro Oncology Meeting. Vancouver, CA.
1999. Medical Therapeutic Options. Conference. International Neuro-Oncology Course. Sao Paolo, BR.
1999. Advances in Relation to Neuro Oncology and Future Therapies. Conference. Clinical Oncology Society Meeting. Melbourne, AU.
1999. A Combination of Temozolomide and Interferon-Alpha in recurrent Malignant Gliomas, A Phase II Study. Conference. The 13th International Conference on Brain Tumor Research and Therapy. Hokkaido, JP.
1999. Temozolomide: A New Drug for Malignant Gliomas. Conference. 1999 AmMed Group. Hong Kong, CN.
1999. Gene Therapy in Malignant Brain Tumors - From the Laboratory to the Clinic. Conference. 3rd Annual Terry Fox, Chang Gung Memorial Hospital International Cancer Symposium. Taipei, TW.
1998. 1)Advances in Treatment of Glioma, 2) Temodal in the Treatment of Anaplastic Astrocytoma, 3) Therapeutic Issues in Gliomas. Conference. 3rd Congress of the European Association for Neuro-Oncology. Versailles, FR.
1997. Phase II Trial of Topotecan as a Continuous Intravenous Infusion in Patients with High Grade Gliomas. Conference. ECCO 9 Conference. Hamburg, DE.
1997. Recent Advances in the Management of High-grade Glioma. Conference. ECCO 9 Conference. Hamburg, DE.
1997. A NCNSC Phase II Trial of Thalidomide, an Antiangiogenic Agent in Patients with Recurrent Malignant Gliomas. Conference. 12th International Conference on Brain Tumor Research and Therapy. Oxford, GB.
1996. Molecular Therapy. Conference. CNS Annual Meeting. Montreal, CA.
1996. Molecular Progression in Human Gliomas New Agents in Glioma Chemotherapy Gene Therapy for Brain Tumors. Conference. Asian Brain Tumor Seminar. Singapore, CN.
1996. New Approaches in Chemotherapy for Malignant Brain Tumors. Conference. 9th International Symposium for the Foundation of Promotion of Cancer Research. Tokyo, JP.
1995. 1)Modulation of VEGF and EGFR Expression by Recombinant IFN-? and Dexamethasone in Human Glioma Cells 2)Growth Suppression of Human Glioma Cells by Restoration of Wild-Type p53 Gene Utilizing an Adenovirus Vector. Conference. American Association for Cancer Research Meeting. Toronto, CA.
1993. 1)Initial Therapy and Treatment of Recurrent Gliomas 2)Modulation of EGFR/TGF-a Autocrine Growth Regulation in Human Glioma b Antisense Approaches. Conference. Tenth International Conference on Brain Tumour Research and Therapy. Stalheim, NO.
1992. Transforming Potential of Epidermal Growth Factor Receptor and Transforming Growth Factor-a Genes in Human Glial Cells. Conference. Fourth SCBA International Symposium and Workshop. Singapore, CN.
1989. TGF-alpha Expression and Biologic Activity in Human Gliomas. Conference. The Eighth Conference on Brain Tumor Research and Therapy. Zermatt, CH.
1989. 1)Biology of Malignant Brain Tumor: Hope for Future Clinical Advances 2)Immunotherapy: Update on Interferon/Interleukin-2". Conference. The Fourth Update in Neuro-Oncology Conference. Grand Cayman, KY.
1988. 1)In Vitro Chemotherapy Testing and its Clinical Application in Human Gliomas 2)Expression of EGF-R and TGF-??in Human Glioma Cells. Conference. Workshop on Neuro-Oncology of the German Society of Neurosurgery. Weilburg, DE.
1987. 1)Expression of EGF-R and TGF-beta in Human Glioma Cells 2)Intravenous Recombinant Beta Interferon in Recurrent Malignant Gliomas 3)Modulation of Growth and EGF-R Expression by Retinoic Acid on Cultured Human Glioma Cells. Conference. Seventh Conference on Brain Tumor Research and Therapy. Hakone, JP.
1985. Neuro-Oncology: A New Subspecialty of Neurology. Conference. Conference of the Association of Neurologists. Quebec City, CA.
1984. Tumor Angiogenesis Factor-Like Activity Detected in Glioma Cell Conditioned. Conference. 2nd International Symposium on Biology of Brain Tumor. London, GB.
1984. Tumor Heterogeneity as Related to Chemosensitivity Testing. Conference. Manssell Bequest Symposium on Neuro-Oncology. London, GB.
1982. Current Status of Treatment for Primary Malignant Brain Tumors. Conference. 9th Dr. Ena Thomas Memorial Lecture. Kingston, JM.

Formal Peers

2017. Glioma treatment: up-date and future direction and Clinical trial for glioma. Visiting, CN.
2016. From Molecular Landscape to Management of Malignant Gliomas. Invited. Columbus, OH, US.
2016. 21st International Conference on Brain Tumor Research. Invited, US.
2016. Molecular Landscape to Targeted Therapy in Malignant Gliomas. Visiting. Miami, FL, US.
2015. Molecular Landscape to Targeted Therapy in Malignant Gliomas. Invited. New York, NY, US.
2015. Lecture on CNS Tumor. Visiting, US.
2012. Progress and Challenges: Molecular Therapies for Glioblastoma. Visiting. San Francisco, CA, US.
2012. Advances in the Management of Brain Tumors. Visiting. Hong Kong, CN.
2011. The Challenge of Personalized Molecular Therapy for GBM. Visiting. Wake Forest, NC, US.
2011. Glioma Biology: Recent Advances at the Edge of Discovery - How to Apply This to the Clinical World. Invited. La Jolla, CA, US.
2010. Molecular Targeted Therapy in Malignant Gliomas. Invited. Lloyd Harbor, NY, US.
2010. Recent Advances in Neuro-Oncology Practice. Visiting. Nanjing, CN.
2009. Molecular Markers in Malignant Gliomas. Visiting. Stanford, CA, US.
2008. Case Presentation. Invited. Boston, MA, US.
2008. Glioblastoma Multiforme: The Multidisciplinary Approach to Treatment. Invited. Boston, MA, US.
2008. Molecular Targeted Therapies for Glioblastoma. Invited. Cold Springs Harbor, NY, US.
2008. Molecular prognostic profile for malignant gliomas. Invited. Shatin, HK.
2008. Targeting PI3 kinase pathway. Invited. Heidelberg, DE.
2008. Personalized Cancer Therapy: Coming Soon. Invited. Taichung, TW.
2007. Chemotherapeutics II. Invited. Boston, MA, US.
2007. Central nervous system malignancies. Invited. Houston, TX, US.
2007. Personalized Cancer Therapy: Coming Soon. Visiting. Shatin, HK.
2007. Targeting the I3K Pathway in Cancer and Malignant Glioma. Visiting. Shatin, HK.
2006. Bridging the Gap Between Scientific Promise and Clinical Practice. Invited. Worcester, MA, US.
2006. Session Chair: Central Nervous System. Session Moderator: Round Table. Lecturer: Targeted therapies for malignant glioma. Invited. Houston, TX, US.
2006. Session Chair & Lecturer: Biomarkers in Glioblastoma: Implication in Clinical Research & Practice, EGFR vs PI3K Activities: Markers for treatment selection in glioblastoma. Invited. Houston, TX, US.
2005. Chemotherapy of High Grade Gliomas. Invited. New York, NY, US.
2005. 1) Small Molecules & Monoclonal Antibody; 2) Immunotherapy/Stem Cell Therapy. Invited. Atlanta, GA, US.
2005. Novel Therapies for Malignant Glioma. Invited. Philadelphia, PA, US.
2004. PTEN Tumor Suppressor Gene in Human Cancers. Invited. Toronto, CA.
2004. MMAC/PTEN Tumor Suppressor Gene in Human Brain Tumor. Invited. Peoria, IL, US.
2003. MMAC/PTEN Tumor Suppressor Gene in Human Brain Tumor. Invited. Raleigh-Durham, NC, US.
2003. Relating Immunologic Advances to Brain Tumor Treatment. Invited. Woodstock, VT, US.
2003. Chemotherapy for Brain Metastasis. Invited. Moscow, RU.
2002. Targeted Therapy for Brain Tumors. Visiting. Guangzhou, CN.
2002. PTEN Alterations and Therapeutic Implication in Malignant Gliomas. Invited. San Francisco, CA, US.
2002. Targeted Therapies for Malignant Brain Tumors; Role of CTM in the Management of Cancers in Guangzhou, China. Visiting. Guangzhou, CN.
1999. Brain Tumor Treatments. Visiting. Taipei, TW.
1998. Molecular Progression in Malignant Brain Tumors. Invited. Houston, TX, US.
1997. Brain Tumor Therapies. Visiting. Seoul.
1996. Current Treatment for Malignant Brain Tumors. Invited. Houston, TX, US.
1996. Molecular Progression in Malignant Gliomas: Target for Molecular Modulation. Invited. New York, NY, US.
1995. Molecular Progression in Malignant Gliomas - Targets for Molecular Modulation. Invited. Little Rock, AR, US.
1994. 1)Biological Therapy for Malignant Gliomas (Neurology Grand Rounds & Moffitt Case Presentation USF College of Medicine) 2)Molecular Progression in Malignant Glioma. Invited. Tampa, FL, US.
1993. Biologic Brain Tumor Therapy. Invited. Marina del Rey, CA, US.
1993. Modulation of EGFR/TGF-a Autocrine Growth Regulation in Human Glioma by Antisense Approaches-Potential Agents for Molecular Therapy. Invited. Washington, US.
1993. Clinical Management of Malignant Gliomas-Present and Future. Invited. Corpus Christi, TX, US.
1992. Recent Advances in the Treatment of Primary Malignant Brain Tumors. Invited. Beaumont, TX, US.
1992. Growth Regulatory Mechanisms in Human Gliomas. Invited. Bethesda, MD, US.
1991. 1)Diagnosis and Treatment of Primary Brain Tumor 2)Neurotoxicities for Cancer Therapies. Invited. Orlando, FL, US.
1991. Potential Roles of Genes Altered on Chromosome 10 in Association with Human Gliomas. Invited. Keystone, CO, US.
1990. The Expression and Biological Activities of TGF-alpha and EGF-receptor in Malignant Brain Tumors. Invited. Boston, MA, US.
1990. Chemotherapy for Gliomas - The M.D. Anderson Experience. Invited. Long Island, NY, US.
1990. The Expression and Biological Activities of TGF-alpha and EGF-receptor in Malignant Brain Tumors. Invited. Los Angeles, CA, US.
1990. Treatment of Primary Malignant Gliomas: Current Status and Future Perspectives. Invited. Houston, TX, US.
1989. Biology of Malignant Brain Tumor: Hope for Future Clinical Advances. Invited. Cincinnati, OH, US.
1989. Effects of Chemotherapy on the Brain. Invited. Houston, TX, US.
1989. The Regulation of the Proto-Oncogene of EGF-Receptor in Human Glioma. Invited. Keystone, CO, US.
1987. Treatment of Malignant Gliomas. Invited. Nagoya, JP.
1987. Biological Activity of Recombinant Beta Interferon on Human Glioma. Invited. Chicago, IL, US.
1986. Oncogenes and Growth Factors Related to Human Gliomas. Invited. San Diego, CA, US.
1986. In Vitro Studies in Growth Regulations of Human Gliomas. Invited. Dallas, TX, US.
1986. Growth Inhibitory Mechanism of Recombinant Beta Interferon on Human Glioma Cells in Culture. Invited. Steamboat Springs, CO, US.
1986. 1)Medical Approach to Diagnosis of Brain Tumors 2)Chemotherapy for Primary Brain Tumors. Invited. El Paso, TX, US.

Less

Grant & Contract Support

Date:	2013 - 2018
Title:	SPORE in Brain Cancer
Funding Source:	NIH/NCI
Role:	Project Leader
ID:	P50 CA127001-06

Date:	2013 - 2018
Title:	Cancer Center Support (CORE) Grant
Funding Source:	NIH/NCI
Role:	Program Leader
ID:	2P30 CA 016672-38

Date:	2012 - 2014
Title:	Molecular Predictors of Response to Targeted Therapy in Glioblastoma: Preclinical Validation of Eli Lilly Compounds Targeting CDK4/6, SHH, FGFR, cMET, and p38-MAPK
Funding Source:	Eli Lilly Collaboration
Role:	Co-PI

Date:	2009 - 2012
Title:	Preclinical testing of HSP990 mono and combination therapy for gliomas
Funding Source:	Novartis Pharmaceuticals
Role:	PI
ID:	LS2009 00028451EB

Date:	2009 - 2010
Title:	Preclinical testing of BKM120 mono and combination therapy for gliomas
Funding Source:	Novartis Pharmaceuticals
Role:	PI
ID:	LS2008 00022948EB

Date:	2007 - 2013
Title:	Collaborative Ependymoma Research Network (CERN)
Funding Source:	Collaborative Medical Research Foundation
Role:	Co-I
ID:	CS2007-00021388EB

Date:	2007 - 2008
Title:	Identification of a compensatory molecular pathway
Funding Source:	Accelerate Brain Cancer Cure
Role:	PI

Date:	2006 - 2012
Title:	Deciphering synergistic combinatorial targets in glioblastoma
Funding Source:	NIH/NCI
Role:	PI
ID:	5 RO1 CA 123304-06

Date:	2006 - 2009
Title:	Smart Bomb Project
Funding Source:	Marcus Foundation
Role:	Project Leader
ID:	N/A

Date:	2006 - 2012
Title:	Evaluation of small molecule inhibitors of the PI3K/Akt pathway in glioma
Funding Source:	Accelerate Brain Cancer Cure Foundation
Role:	PI

Date:	2005 - 2007
Title:	Phase I sequential ascending dose trial of AP23573 in patients with progressive or recurrent malignant glioma
Funding Source:	Ariad Pharmaceuticals
Role:	Principal Investigator-MDACC
ID:	CS2005-00014349LE

Date:	2005 - 2006
Title:	Evaluation of small molecule inhibitors of the PI3K/Akt pathway in glioma
Funding Source:	Accelerate Brain Cancer Cure (ABC2)
Role:	PI

Date:	2004 - 2005
Title:	Phase I/II trial of CPT-11 and temozolomide
Funding Source:	Integrated Therapeutics Group Inc
Role:	PI
ID:	CS2004-00011195SP

Date:	2004 - 2008
Title:	NABTC Central Operation Grant - Data Management Core
Funding Source:	NIH/NCI
Role:	PI
ID:	UO1 CA 62399

Date:	2004 - 2008
Title:	Radiation Therapy Oncology Group
Funding Source:	NIH/NCI
Role:	PI
ID:	CA 21661

Date:	2003 - 2005
Title:	A Phase II, Multicenter Open-Label Trial of the Safety and Efficacy of Tarceva (erlotinib hydrochloride, OSI-774) in Patients With First Relapse of Grade IV Glioma (glioblastoma multiforme)
Funding Source:	Genentech, Inc
Role:	PI
ID:	CS2003-00009420AG

Date:	2003 - 2004
Title:	Novel PTEN/P13K pathway inhibitors for glioblastoma therapy
Funding Source:	Accelerate Brain Cancer Cure
Role:	PI
ID:	SR2003-00008818RM

Date:	2003 - 2005
Title:	Targeting the PTEN/PI3 kinase pathway in glioblastoma
Funding Source:	Golfers Against Cancer
Role:	PI
ID:	CBC 995047

Date:	2003 - 2006
Title:	Brain Cancer Network
Funding Source:	Accelerate Brain Cancer Cure
Role:	PI
ID:	SR2003-000088818RM

Date:	2002 - 2007
Title:	Conditional replicating adenovirus for glioma treatment
Funding Source:	NIH/NCI
Role:	Investigator
ID:	CA 090879

Date:	2002 - 2005
Title:	Bringing Oncolytic Virus Gene Therapy Against Malignant Glioma to the Clinic
Funding Source:	Golfers Against Cancer
Role:	PI
ID:	CBC 995034

Date:	2001 - 2004
Title:	A Phase IB, open-label, 2-arm dose escalation study of PTK787/ZK222584 in combination with single agent chemotherapy, either temozolomide (arm 1) or Lomustine (arm 2) in patients with glioblastoma multiforme (GBM)
Funding Source:	Novartis Pharmaceuticals Co
Role:	PI
ID:	CS01-343-01

Date:	2000 - 2008
Title:	Triple anti-angiogenic therapy for brain tumors
Funding Source:	NIH/NCI
Role:	PI
ID:	RO1 CA83127

Date:	1999 - 2008
Title:	Analysis of a 10Q Tumor suppressor Gene
Funding Source:	NIH/NCI
Role:	PI
ID:	RO1 CA56041

Date:	1999 - 2005
Title:	Phase IA, Open Label Dose Escalating Study of PTK787 Administered Orally in Patients with Glioblastoma Multiforme
Funding Source:	Novartis Pharmaceuticals Co
Role:	PI
ID:	ID98-317 (CS99-133A1)

Date:	1998 - 2003
Title:	Phase II evaluation of temodal and intron A for the treatment of recurrent and progressive malignant glioma
Funding Source:	Schering-Plough Research Institute
Role:	PI
ID:	CS99-005

Date:	1998 - 2002
Title:	A Phase III Randomized Study of SU101 versus Procarbazine for Patients with Glioblastoma Multiforme in First Relapse
Funding Source:	Sugen, Inc
Role:	PI
ID:	CS98-122

Date:	1998 - 2003
Title:	NABTC Clinical Center
Funding Source:	NCI
Role:	PI
ID:	U01 CA62412

Date:	1998 - 2008
Title:	NABTC Clinical Center
Funding Source:	NIH/NCI
Role:	Investigator
ID:	UO1 CA 62412

Date:	1996 - 2002
Title:	Gliomas: Biologic, Molecular & Genetic Studies
Funding Source:	NCI
Role:	Investigator
ID:	5P01 CA 55261

Date:	1995 - 2000
Title:	Modulation of Growth and Angiogenesis in Human Gliomas
Funding Source:	NCI
Role:	PI
ID:	R01 CA 51148

Date:	1995 - 1996
Title:	A Random, Double-Blind, Placebo-Controlled, Phase II Study of RMP-7 in Combination with Carboplatin Administered Intravenously for the Treatment of Recurrent Malignant Gliomas
Funding Source:	Alkermes, Inc
Role:	Co-PI
ID:	ALK01-017-04

Title:	Preclinical testing of DS7423 mono and combination therapy for glioblatoma
Funding Source:	NIH/NCI
Role:	Co-I

Selected Publications

Peer-Reviewed Articles

Chowdhury T, Tesileanu C, Kocakavuk E, Johnson KC, Lee J, Erson-Omay Z, Heo C, Aldape K, Amin SB, Anderson KJ, Ashley DM, Barnholtz-Sloan JS, Brat DJ, Brodbelt AR, Castro AV, Claus EB, Connelly JM, Costello J, Datta I, Elliott C, Finocchiaro G, French PJ, Gan HK, Garofano L, Ghospurkar PL, Golebiewska A, Gundla PS, Hermes B, Hong C, Hoogstrate Y, Horbinski C, Huse JT, Iavarone A, Karadag C, Khasraw M, Kouwenhoven MC, LaViolette PS, Li K, Lowman A, McCortney K, Moon H, Nader S, Nasrallah MP, Ng H, Ormond D, Padovan M, Paek SH, Poisson LM, Puri S, Shen E, Shwetal M, Sloan AE, Vallentgoed WR, Van Meir EG, Vaubel R, Wade T, Walenkamp AM, Watts C, Weiss T, Weller M, Wesseling P, Westcott K, Westerman B, Ye GY, Yung W, Consortium G, Varn FS, Verhaak RG. Tumor- initiating genetics and therapy drive divergent molecular evolution in IDH- mutant gliomas. bioRxiv, 2025. PMID: 40791422.
Spitzer, A, Johnson, KC, Nomura, M, Garofano, L, Nehar-Belaid, D, Darnell, NG, Greenwald, AC, Bussema, L, Oh, YT, Varn, FS, D’Angelo, F, Gritsch, S, Anderson, KJ, Migliozzi, S, Gonzalez Castro, LN, Chowdhury, T, Robine, N, Reeves, C, Park, JB, Lipsa, A, Hertel, F, Golebiewska, A, Niclou, SP, Nusrat, L, Kellet, S, Das, S, Moon, HE, Paek, SH, Bielle, F, Laurenge, A, Di Stefano, AL, Mathon, B, Picca, A, Sanson, M, Tanaka, S, Saito, N, Ashley, DM, Keir, ST, Ligon, KL, Huse, J, Yung, WA, Lasorella, A, Iavarone, A, Verhaak, R, Tirosh, I, Suvà, ML. Deciphering the longitudinal trajectories of glioblastoma ecosystems by integrative single-cell genomics. Nature Genetics 57(5):1168-1178, 2025. e-Pub 2025. PMID: 40346362.
Nomura, M, Spitzer, A, Johnson, KC, Garofano, L, Nehar-Belaid, D, Galili Darnell, N, Greenwald, AC, Bussema, L, Oh, YT, Varn, FS, D’Angelo, F, Gritsch, S, Anderson, KJ, Migliozzi, S, Gonzalez Castro, LN, ChowdhFury, T, Robine, N, Reeves, C, Park, JB, Lipsa, A, Hertel, F, Golebiewska, A, Niclou, SP, Nusrat, L, Kellet, S, Das, S, Moon, HE, Paek, SH, Bielle, F, Laurenge, A, Di Stefano, AL, Mathon, B, Picca, A, Sanson, M, Tanaka, S, Saito, N, Ashley, DM, Keir, ST, Ligon, KL, Huse, J, Yung, WA, Lasorella, A, Verhaak, R, Iavarone, A, Suvà, ML, Tirosh, I. The multilayered transcriptional architecture of glioblastoma ecosystems. Nature Genetics 57(5):1155-1167, 2025. e-Pub 2025. PMID: 40346361.
Zhao B, Cho CY, Ye L, Keal T, Mitchell T, Martin-Barrio I, Faraj CA, Unal M, Alsing J, Lawson NM, Kim ER, Chavez F, Rangel KM, Singh SK, McCarthy JH, Ashley DM, Yung W, Puduvalli V, Nir G, Weinberg JS, Wang L, Ligon KL, Genovese G, Loo PV, Futreal P, Huse JT, Dixon JR, Lang FF, Akdemir KC. Oncogenic drivers shape the tumor microenvironment in human gliomas. bioRxiv, 2025. PMID: 40475555.
Weathers S, Li X, Zhu H, Damania AV, Knafl M, McKinley B, Lin H, Harrison RA, Majd NK, O'Brien BJ, Penas-Prado M, Loghin M, Kamiya-Matsuoka C, Yung W, Solis Soto LM, Maru DM, Wistuba I, Parra Cuentas ER, Hernandez S, Futreal A, Wargo JA, Schulze K, Darbonne WC, Ajami NJ, Woodman SE, de Groot JF. Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trial. Nat Commun 16(1):3950, 2025. e-Pub 2025. PMID: 40289138.
Khan, S, Martinez-Ledesma, E, Dong, J, Mahalingam, R, Park, SY, Piao, Y, Koul, D, Balasubramaniyan, V, de Groot, JF, Yung, WA. Neuronal differentiation drives the antitumor activity of mitogen-activated protein kinase kinase (MEK) inhibition in glioblastoma. Neuro-Oncology Advances 5(1), 2023. e-Pub 2023. PMID: 38130900.
Liu I, Jiang L, Samuelsson ER, Salas SM, Beck A, Hack OA, Jeong D, Shaw ML, Englinger B, LaBelle J, Mire HM, Madlener S, Mayr L, Quezada MA, Trissal M, Panditharatna E, Ernst KJ, Vogelzang J, Gatesman TA, Halbert ME, Palova H, Pokorna P, Sterba J, Slaby O, Geyeregger R, Diaz A, Findlay IJ, Dun MD, Resnick A, Suvà ML, W Jones DT, Agnihotri S, Svedlund J, Koschmann C, Haberler C, Czech T, Slavc I, Cotter JA, Ligon KL, Alexandrescu S, Yung W, Arrillaga-Romany I, Gojo J, Monje M, Nilsson M, Filbin MG. The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location. Nat Genet 54(12):1881-1894, 2022. e-Pub 2022. PMID: 36471067.
Ding, J, Li, X, Khan, S, Zhang, C, Gao, F, Sen, S, Wasylishen, A, Zhao, Y, Lozano, G, Koul, D, Yung, WA. EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs. Neuro-oncology 24(10):1712-1725, 2022. e-Pub 2022. PMID: 35474131.
Noureen, N, Wu, S, Lv, Y, Yang, J, Yung, WA, Gelfond, J, Wang, X, Koul, D, Ludlow, A, Zheng, S. Integrated analysis of telomerase enzymatic activity unravels an association with cancer stemness and proliferation. Nature communications 12(1), 2021. e-Pub 2021. PMID: 33420056.
Lee, EQ, Selig, W, Meehan, C, Bacha, J, Barone, A, Bloomquist, E, Chang, SM, de Groot, JF, Galanis, E, Hassan, IA, Kalidas, C, Khasraw, M, Kvedar, JC, Lassman, AB, Puduvalli, VK, Sahebjam, S, Schwamm, LH, Tamir, S, Welch, M, Yung, WA, Zadeh, G, Arons, DF, Wen, PY. Report of national brain tumor society roundtable workshop on innovating brain tumor clinical trials. Neuro-oncology 23(8):1252-1260, 2021. e-Pub 2021. PMID: 33822177.
Wu S, Li X, Gao F, de Groot JF, Koul D, Yung WKA. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma. Neuro-Oncology 23(6):920-931, 2021. e-Pub 2021. PMID: 33433610.
Weathers SP, Rood-Breithaupt J, de Groot J, Thomas G, Manfrini M, Penas-Prado M, Puduvalli VK, Zwingelstein C, Yung WKA. Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma. Neurooncol Adv 3(1):vdab141, 2021. e-Pub 2021. PMID: 34693288.
Boxerman, JL, Quarles, CC, Hu, LS, Erickson, BJ, Gerstner, E, Smits, M, Kaufmann, TJ, Barboriak, DP, Huang, RH, Wick, W, Weller, M, Galanis, E, Kalpathy-Cramer, J, Shankar, LK, Jacobs, P, Chung, C, Van Den Bent, MJ, Chang, SM, Yung, WA, Cloughesy, TF, Wen, PY, Gilbert, MR, Rosen, BR, Ellingson, BM, Schmainda, KM. Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas. Neuro-oncology 22(9):1262-1275, 2020. e-Pub 2020. PMID: 32516388.
Puduvalli VK, Wu J, Yuan Y, Armstrong TS, Vera E, Wu J, Xu J, Giglio P, Colman H, Walbert T, Raizer J, Groves MD, Tran D, Iwamoto F, Avgeropoulos N, Paleologos N, Fink K, Peereboom D, Chamberlain M, Merrell R, Penas Prado M, Yung WKA, Gilbert MR. A Bayesian Adaptive Randomized Phase II Multicenter Trial of Bevacizumab with or without Vorinostat in Adults with Recurrent Glioblastoma. Neuro-Oncology 062(10):1505-1515, 2020. e-Pub 2020. PMID: 32166308.
Wu S, Gao F, Zheng S, Zhang C, Martinez-Ledesma E, Ezhilarasan R, Ding J, Li X, Feng N, Multani A, Sulman EP, Verhaak RG, de Groot JF, Heffernan TP, Yung WKA, Koul D. EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma. Clinical Cancer Research 26(6):1395-1407, 2020. e-Pub 2020. PMID: 31852834.
van den Bent M, Azaro A, De Vos F, Sepulveda J, Yung WKA, Wen PY, Lassman AB, Joerger M, Tabatabai G, Rodon J, Tiedt R, Zhao S, Kirsilae T, Cheng Y, Vicente S, Balbin OA, Zhang H, Wick W. A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma. Journal of Neuro-Oncology 146(1):79-89, 2020. e-Pub 2020. PMID: 31776899.
Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E, Anderson KJ, Abiola O, Aldape K, Alfaro KD, Alpar D, Amin SB, Ashley DM, Bandopadhayay P, Barnholtz-Sloan JS, Beroukhim R, Bock C, Brastianos PK, Brat DJ, Brodbelt AR, Bruns AF, Bulsara KR, Chakrabarty A, Chakravarti A, Chuang JH, Claus EB, Cochran, Connelly J, Costello JF, Finocchiaro G, Fletcher MN, French PJ, Gan HK, Gilbert MR, Gould PV, Grimmer MR, Iavarone A, Ismail A, Jenkinson MD, Khasraw M, Kim H, Kouwenhoven MCM, LaViolette PS, Li M, Lichter P, Ligon KL, Lowman AK, Malta TM, Mazor T, McDonald KL, Molinaro AM, Nam DH, Nayyar N, Ng HK, Ngan CY, Niclou SP, Niers JM, Noushmehr H, Noorbakhsh J, Ormond DR, Park CK, Poisson LM, Rabadan R, Radlwimmer B, Rao G, Reifenberger G, Sa JK, Schuster M, Shaw BL, Short SC, Smitt PAS, Sloan AE, Smits M, Suzuki H, Tabatabai G, Van Meir EG, Watts C, Weller M, Wesseling P, Westerman BA, Widhalm G, Woehrer A, Yung WKA, Zadeh G, Huse JT, De Groot JF, Stead LF, Verhaak RGW. GLASS Consortium. Longitudinal molecular trajectories of diffuse glioma in adults. Nature 576(7785):112-120, 2019. e-Pub 2019. PMID: 31748746.
de Groot J, Penas-Prado M, Alfaro-Munoz KD, Hunter K, Pei B, O'Brien BJ, Weathers SP, Loghin M, Kamiya Matsouka C, Yung WKA, Mandel J, Wu J, Yuan Y, Zhou S, Fuller GN, Huse J, Rao G, Weinberg JS, Prabhu SS, McCutcheon IE, Lang FF, Ferguson SD, Sawaya R, Colen R, Yadav SS, Blando J, Vence L, Allison J, Sharma P, Heimberger AB. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro-Oncology 185(4):539-549, 2019. e-Pub 2019. PMID: 31755915.
Ding J, Wu S, Zhang C, Garyali A, Martinez-Ledesma E, Gao F, Pokkulandra A, Li X, Bristow C, Carugo A, Koul D, Yung WA. BRCA1 identified as a modulator of temozolomide resistance in P53 wild-type GBM using a high-throughput shRNA-based synthetic lethality screening. American Journal of Cancer Research 9(11):2428-2441, 2019. e-Pub 2019. PMID: 31815044.
Li X, Martinez-Ledesma E, Zhang C, Gao F, Zheng S, Ding J, Wu S, Nguyen N, Clifford SC, Wen PY, Ligon KL, Yung WKA, Koul D. Tie2-FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in Glioblastoma. Cancer Research 79(19):5088-5101, 2019. e-Pub 2019. PMID: 31416846.
Harrison RA, Anderson MD, Cachia D, Kamiya-Matsuoka C, Weathers SS, O'Brien BJ, Penas-Prado M, Yung WKA, Wu J, Yuan Y, de Groot JF. Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center. European Journal of Cancer 112:83-93, 2019. e-Pub 2019. PMID: 30951926.
Zheng S, Alfaro-Munoz K, Wei W, Wang X, Wang F, Eterovic AK, Shaw KRM, Meric-Bernstam F, Fuller GN, Chen K, Verhaak RG, Mills GB, Yung WKA, Weathers SP, de Groot JF. Prospective Clinical Sequencing of Adult Glioma. Molecular Cancer Therapeutics(18(5)):991-1000, 2019. e-Pub 2019. PMID: 30926639.
Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, ZhaoJJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. Journal of Clinical Oncology 37(9):741-750, 2019. e-Pub 2019. PMID: 30715997.
Maraka, S, Groves, MD, Mammoser, AG, Melguizo-Gavilanes, I, Conrad, CA, Tremont, I, Loghin, ME, O'Brien, BJ, Puduvalli, VK, Sulman, EP, Hess, KR, Aldape, KD, Gilbert, MR, de Groot, JF, Yung, WA, Penas-Prado, M. Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. Cancer 125(3):424-433, 2019. e-Pub 2019. PMID: 30359477.
Aldape, KD, Amin, S, Ashley, DM, Barnholtz-Sloan, J, Bates, AJ, Beroukhim, R, Bock, C, Brat, DJ, Claus, EB, Costello, JF, de Groot, JF, Finocchiaro, G, French, PJ, Gan, HK, Griffith, B, Herold-Mende, C, Horbinski, C, Iavarone, A, Kalkanis, SN, Karabatsou, K, Kim, H, Kouwenhoven, MC, McDonald, KL, Miletic, H, Nam, DH, Ng, H, Niclou, SP, Noushmehr, H, Ryan Ormond, D, Poisson, LM, Reifenberger, G, Roncaroli, F, Sa, JK, Sillevis Smitt, PA, Smits, M, Souza, C, Tabatabai, G, Van Meir, EG, Verhaak, R, Watts, C, Wesseling, P, Wöhrer, A, Yung, WA, Jungk, C, Hau, AC, van Dyck, E, Westerman, BA, Yin, J, Abiola, O, Zeps, N, Grimmond, SM, Buckland, M, Khasraw, M, Sulman, EP, Muscat, AM, Stead, L. Glioma through the looking GLASS. Neuro-oncology 20(7):873-884, 2018. e-Pub 2018. PMID: 29432615.
Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya R, Weinberg JS, Prabhu SS, Rao G, Fuller GN, Aldape KD, Gumin J, Vence LM, Wistuba I, Rodriguez-Canales J, Villalobos PA, Dirven CMF, Tejada S, Valle RD, Alonso MM, Ewald B, Peterkin JJ, Tufaro F, Fueyo J. Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. J Clin Oncol 36(14):1419-1427, 2018. e-Pub 2018. PMID: 29432077.
Ali AN, Zhang P, Yung WKA, Chen Y, Movsas B, Urtasun RC, Jones CU, Choi KN, Michalski JM, Fischbach AJ, Markoe AM, Schultz CJ, Penas-Prado M, Garg MK, Hartford AC, Kim HE, Won M, Jr CW. NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. Journal of Neuro-Oncology 137(1):39-47, 2018. e-Pub 2018. PMID: 29404979.
Alexander BM, Ba S, Berger MS, Berry DA, Cavenee WK, Chang SM, Cloughesy TF, Jiang T, Khasraw M, Li W, Mittman R, Poste GH, Wen PY, Yung WKA, Barker AD. GBM AGILE Network. Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. Clinical Cancer Research 24(4):737-743, 2018. e-Pub 2018. PMID: 28814435.
Alexander BM, Ba S, Berger MS, Berry DA, Cavenee WK, Chang SM, Cloughesy TF, Jiang T, Khasraw M, Li W, Mittman R, Poste GH, Wen PY, Yung WKA, Barker AD. Adaptive Global Innovative Learning Environment for Glioblastoma:. GBM AGILE Network, 2018. e-Pub 2017. PMID: 28814435.
Wu S, Wang S, Gao F, Li L, Zheng S, Yung WKA, Koul D. Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma. Neuro Oncology 20(1):78-91, 2018. e-Pub 2018. PMID: 29016926.
Nghiemphu PL, Ebiana VA, Wen P, Gilbert M, Abrey LE, Lieberman F, DeAngelis LM, Robins HI, Yung WKA, Chang S, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados M, Kuhn J, Cloughesy TF. Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. Journal of Neuro-Oncology 136(1):79-86, 2018. e-Pub 2018. PMID: 28988377.
Ong DST, Hu B, Ho YW, Sauvé CG, Bristow CA, Wang Q, Multani AS, Chen P, Nezi L, Jiang S, Gorman CE, Monasterio MM, Koul D, Marchesini M, Colla S, Jin EJ, Sulman EP, Spring DJ, Yung WA, Verhaak RGW, Chin L, Wang YA, DePinho RA. PAF promotes stemness and radioresistance of glioma stem cells. Proc Natl Acad Sci USA 114(43):E9086-E9095, 2017. e-Pub 2017. PMID: 29073105.
Wang Y, Wu S, Zheng S, Wang S, Wali A, Ezhilarasan R, Sulman EP, Koul D, Alfred Yung WK. APOBEC3G acts as a therapeutic target in mesenchymal gliomas by sensitizing cells to radiation-induced cell death. Oncotarget 8(33):54285-54296, 2017. e-Pub 2017. PMID: 28903341.
Nayak, L, de Groot, JF, Wefel, JS, Cloughesy, TF, Lieberman, F, Chang, SM, Omuro, A, Drappatz, J, Batchelor, TT, DeAngelis, LM, Gilbert, MR, Aldape, KD, Yung, WA, Fisher, JD, Ye, X, Chen, A, Grossman, SA, Prados, M, Wen, PY. Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. Journal of neuro-oncology 132(1):181-188, 2017. e-Pub 2017. PMID: 28116649.
Koul D, Wang S, Wu S, Saito N, Zheng S, Gao F, Kaul I, Setoguchi M, Nakayama K, Koyama K, Shiose Y, Sulman EP, Hirota Y, Yung WKA. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma. Oncotarget, 2017. e-Pub 2017. PMID: 28423515.
Weathers SP, Han X, Liu DD, Conrad CA, Gilbert MR, Loghin ME, O'Brien BJ, Penas-Prado M, Puduvalli VK, Tremont-Lukats I, Colen RR, Yung WKA, de Groot JF. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. Neurooncol, 2016. e-Pub 2016. PMID: 27406589.
Wu, S, Wang, S, Zheng, S, Verhaak, R, Koul, D, Yung, WA. MSK1-Mediated βb-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma. Molecular cancer therapeutics 15(7):1656-1668, 2016. e-Pub 2016. PMID: 27196759.
Wu S, Wang S, Zheng S, Verhaak R, Koul D, Yung WK. MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma. Mol Cancer Ther, 2016. e-Pub 2016.
Cortes-Santiago N, Hossain MB, Gabrusiewicz K, Fan X, Gumin J, Marini FC, Alonso MM, Lang F, Yung WK, Fueyo J, Gomez-Manzano C. Soluble Tie2 overrides the heightened invasion induced by anti-angiogenesis therapies in gliomas. Oncotarget, 2016. e-Pub 2016. PMID: 26910374.
Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF, Berger MS, Poste GH, Khasraw M, Ba S, Jiang T, Mikkelson T, Yung WK, de Groot JF, Fine H, Cantley LC, Mellinghoff IK, Mitchell DA, Okada H, Heimberger AB. Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology, 2016. e-Pub 2016. PMID: 27471611.
Raizer JJ, Giglio P, Hu J, Groves M, Merrell R, Conrad C, Phuphanich S, Puduvalli VK, Loghin M, Paleologos N, Yuan Y, Liu D, Rademaker A, Yung WK, Vaillant B, Rudnick J, Chamberlain M, Vick N, Grimm S, Tremont-Lukats IW, De Groot J, Aldape K, Gilbert MR. Brain Tumor Trials Collaborative. A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. J Neurooncol, 2016. e-Pub 2016. PMID: 26476729.
Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, Rao AA, Grifford M, Cherniack AD, Zhang H, Poisson L, Jr CC, Tirapelli DP, Rao A, Mikkelsen T, Lau CC, Yung WK, Rabadan R, Huse J, Brat DJ, Lehman NL, Barnholtz-Sloan JS, Zheng S, Hess K, Rao G, Meyerson M, Beroukhim R, Cooper L, Akbani R, Wrensch M, Haussler D, Aldape KD, Laird PW, Gutmann DH, Network TR, Noushmehr H, Iavarone A, Verhaak RG. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell, 2016. e-Pub 2016. PMID: 26824661.
Wu S, Wang S, Zheng S, Verhaak R, Koul D, Yung WK. MSK1-Mediated beta-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma. Mol Cancer Ther(15 (7)):1656-1668, 2016. e-Pub 2016.
Liu Q, Liu Y, Li W, Wang X, Sawaya R, Lang FF, Yung WK, Chen K, Fuller GN, Zhang W. Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma. Acta Neuropathol 130(4):587-97, 2015. e-Pub 2015. PMID: 26323991.
Kim SJ, Lee HJ, Kim MS, Choi HJ, He J, Wu Q, Aldape K, Weinberg JS, Yung WK, Conrad CA, Langley RR, Lehembre F, Regenass U, Fidler IJ. Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice. Clin Cancer Res 21(20):4630-41, 2015. e-Pub 2015. PMID: 26106074.
Research Network CGA, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, Cherniack AD, Akbani R, Huse JT, Ciriello G, Poisson LM, Barnholtz-Sloan JS, Berger MS, Brennan C, Colen RR, Colman H, Flanders AE, Giannini C, Grifford M, Iavarone A, Jain R, Joseph I, Kim J, Kasaian K, Mikkelsen T, Murray BA, O'Neill BP, Pachter L, Parsons DW, Sougnez C, Sulman EP, Vandenberg SR, Van Meir EG, von Deimling A, Zhang H, Crain D, Lau K, Mallery D, Morris S, Paulauskis J, Penny R, Shelton T, Sherman M, Yena P, Black A, Bowen J, Dicostanzo K, Gastier-Foster J, Leraas KM, Lichtenberg TM, Pierson CR, Ramirez NC, Taylor C, Weaver S, Wise L, Zmuda E, Davidsen T, Demchok JA, Eley G, Ferguson ML, Hutter CM, Mills Shaw KR, Ozenberger BA, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Ayala B, Baboud J, Chudamani S, Jensen MA, Liu J, Pihl T, Raman R, Wan Y, Wu Y, Ally A, Auman JT, Balasundaram M, Balu S, Baylin SB, Beroukhim R, Bootwalla MS, Bowlby R, Bristow CA, Brooks D, Butterfield Y, Carlsen R, Carter S, Chin L, Chu A, Chuah E, Cibulskis K, Clarke A, Coetzee SG, Dhalla N, Fennell T, Fisher S, Gabriel S, Getz G, Gibbs R, Guin R, Hadjipanayis A, Hayes DN, Hinoue T, Hoadley K, Holt RA, Hoyle AP, Jefferys SR, Jones S, Jones CD, Kucherlapati R, Lai PH, Lander E, Lee S, Lichtenstein L, Ma Y, Maglinte DT, Mahadeshwar HS, Marra MA, Mayo M, Meng S, Meyerson ML, Mieczkowski PA, Moore RA, Mose LE, Mungall AJ, Pantazi A, Parfenov M, Park PJ, Parker JS, Perou CM, Protopopov A, Ren X, Roach J, Sabedot TS, Schein J, Schumacher SE, Seidman JG, Seth S, Shen H, Simons JV, Sipahimalani P, Soloway MG, Song X, Sun H, Tabak B, Tam A, Tan D, Tang J, Thiessen N, Triche T, Van Den Berg DJ, Veluvolu U, Waring S, Weisenberger DJ, Wilkerson MD, Wong T, Wu J, Xi L, Xu AW, Yang L, Zack TI, Zhang J, Aksoy BA, Arachchi H, Benz C, Bernard B, Carlin D, Cho J, DiCara D, Frazer S, Fuller GN, Gao J. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med 372(26):2481-98, 2015. e-Pub 2015. PMID: 26061751.
Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, Cherniack AD, Akbani R, Huse JT, Ciriello G, Poisson LM, Barnholtz-Sloan JS, Berger MS, Brennan C, Colen RR, Colman H, Flanders AE, Giannini C, Grifford M, Iavarone A, Jain R, Joseph I, Kim J, Kasaian K, Mikkelsen T, Murray BA, O'Neill BP, Pachter L, Parsons DW, Sougnez C, Sulman EP, Vandenberg SR, Van Meir EG, von Deimling A, Zhang H, Crain D, Lau K, Mallery D, Morris S, Paulauskis J, Penny R, Shelton T, Sherman M, Yena P, Black A, Bowen J, Dicostanzo K, Gastier-Foster J, Leraas KM, Lichtenberg TM, Pierson CR, Ramirez NC, Taylor C, Weaver S, Wise L, Zmuda E, Davidsen T, Demchok JA, Eley G, Ferguson ML, Hutter CM, Mills Shaw KR, Ozenberger BA, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Ayala B, Baboud J, Chudamani S, Jensen MA, Liu J, Pihl T, Raman R, Wan Y, Wu Y, Ally A, Auman JT, Balasundaram M, Balu S, Baylin SB, Beroukhim R, Bootwalla MS, Bowlby R, Bristow CA, Brooks D, Butterfield Y, Carlsen R, Carter S, Chin L, Chu A, Chuah E, Cibulskis K, Clarke A, Coetzee SG, Dhalla N, Fennell T, Fisher S, Gabriel S, Getz G, Gibbs R, Guin R, Hadjipanayis A, Hayes DN, Hinoue T, Hoadley K, Holt RA, Hoyle AP, Jefferys SR, Jones S, Jones CD, Kucherlapati R, Lai PH, Lander E, Lee S, Lichtenstein L, Ma Y, Maglinte DT, Mahadeshwar HS, Marra MA, Mayo M, Meng S, Meyerson ML, Mieczkowski PA, Moore RA, Mose LE, Mungall AJ, Pantazi A, Parfenov M, Park PJ, Parker JS, Perou CM, Protopopov A, Ren X, Roach J, Sabedot TS, Schein J, Schumacher SE, Seidman JG, Seth S, Shen H, Simons JV, Sipahimalani P, Soloway MG, Song X, Sun H, Tabak B, Tam A, Tan D, Tang J, Thiessen N, Jr TT, Van Den Berg DJ, Veluvolu U, Waring S, Weisenberger DJ, Wilkerson MD, Wong T, Wu J, Xi L, Xu AW, Yang L, Zack TI, Zhang J, Aksoy BA, Arachchi H, Benz C, Bernard B, Carlin D, Cho J, DiCara D, Frazer S, Fuller GN, Gao J, Gehlenborg N, Haussler D, Heima. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med, 2015. e-Pub 2015. PMID: 26061751.
Turner KM, Sun Y, Ji P, Granberg KJ, Bernard B, Hu L, Cogdell DE, Zhou X, Yli-Harja O, Nykter M, Shmulevich I, Yung WK, Fuller GN, Zhang W. Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression. Proc Natl Acad Sci U S A 112(11):3421-6, 2015. e-Pub 2015. PMID: 25737557.
Pachella LA, Kamiya-Matsuoka C, Lee EL, Olar A, Yung WK. Supratentorial extraventricular anaplastic ependymoma with extracranial metastasis. J Clin Neurosci 22(3):605-7, 2015. e-Pub 2015. PMID: 25455735.
Turner KM, Sun Y, Ji P, Granberg KJ, Bernard B, Hu L, Cogdell DE, Zhou X, Yli-Harja O, Nykter M, Shmulevich I, Yung WK, Fuller GN, Zhang W. Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression. Proc Natl Acad Sci U S A, 2015. e-Pub 2015. PMID: 25737557.
Penas-Prado M, Hess KR, Fisch MJ, Lagrone LW, Groves MD, Levin VA, De Groot JF, Puduvalli VK, Colman H, Volas-Redd G, Giglio P, Conrad CA, Salacz ME, Floyd JD, Loghin ME, Hsu SH, Gonzalez J, Chang EL, Woo SY, Mahajan A, Aldape KD, Yung WK, Gilbert MR, Program MD, Trials Collaborative BT. Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol 17(2):266-73, 2015. e-Pub 2015. PMID: 25239666.
Mandel, JJ, Yust-Katz, S, Cachia, D, Wu, J, Liu, D, de Groot, JF, Yung, WA, Gilbert, MR. Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution. Journal of neuro-oncology 120(3):597-605, 2014. e-Pub 2014. PMID: 25168214.
Koul D, Yao J, Wang S, Yuan Y, Sulman E, Lang F, Yung W, Colman H. Erratum: Retraction: Novel HSP90 Inhibitor NVP-HSP990 targets cell-cycle regulators to ablate olig 2-positive glioma tumor-initiating cells. Cancer Research 74(22):6731-6732, 2014. e-Pub 2014.
Mandel, J J, Yust-Katz, S, Cachia, D, Wu, J, Liu, D, Groot D, J F, Yung, A W K, Gilbert, M R. Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution. Journal of Neuro-Oncology 120(3):597-605, 2014. e-Pub 2014.
Andersson, U, Wibom, C, Cederquist, K, Aradottir, S, Borg, Å, Armstrong, G, Shete, S, Lau, CC, Bainbridge, M, Claus, EB, Barnholtz-Sloan, J, Lai, R, Il'yasova, D, Houlston, R, Schildkraut, J, Reiner, AS, Olson, SH, Guan, X, Lachance, DH, Wrensch, M, Davis, FG, Merrell, R, Johansen, C, Sadetzki, S, Bondy, ML, Melin, B, Adatto, P, Morice, F, Payen, S, McQuinn, L, Mcgaha, R, Guerra, S, Paith, L, Roth, K, Zeng, D, Zhang, H, Yung, WA, Aldape, KD, Gilbert, M, Weinberger, J, Colman, H, Conrad, CA, de Groot, JF, Forman, A, Groves, MD, Levin, V, Loghin, ME, Puduvalli, VK, Sawaya, RE, Heimberger, AB, Lang Jr, FF, Levine, NB, Tolentino, L, Saunders, KC, Thach, TT, Iacono, DD, Sloan, AE, Gerson, SL, Selman, WR, Bambakidis, N, Hart, D, Miller, J, Hoffer, A, Cohen, ML, Rogers, LR, Nock, CJ, Wolinsky, Y, Devine, K, Fulop, J, Barrett, W, Shimmel, K, Ostrom, QT, Barnett, GH, Rosenfeld, SS, Vogelbaum, MA, Weil, RJ, Ahluwalia, MS, Peereboom, D, Staugaitis, SM, Schilero, C, Brewer, C, Smolenski, K, McGraw, M, Naska, T, Ram, Z, Blumenthal, DT, Bokstein, F, Umansky, F, Zaaroor, M, Cohen, A, Tzuk-Shina, T, Voldby, B, Laursen, R, Andersen, C, Brennum, J, Henriksen, MB, Marzouk, M, Davis, ME, Boland, E, Smith, MT, Eze, O, Way, M, Lada, P, Miedzianowski, N, Frechette, M, Paleologos, NA, Byström, G, Svedberg, E, Huggert, S, Kimdal, M, Sandstrom̈, M, Brännström, N, Hayat, A, Tihan, T, Zheng, S, Berger, M, Butowski, N, Chang, SM, Clarke, J, Prados, M, Rice, T, Sison, JD, Kivett, V, Duo, X, Hansen, HM, Hsuang, G, Lamela, R, Ramos, C, Patoka, J, Wagenman, K, Zhou, M, Klein, AP, McGee, N, Pfefferle, J, Wilson, C, Morris, P, Hughes, M, Britt-Williams, M, Foft, J, Madsen, J, Polony, C, McCarthy, B, Zahora, C, Villano, JL, Engelhard, H, Chanock, SK, Collins, P, Elston, RC, Kleihues, P, Kruchko, C, Petersen, GM, Plon, SE, Thompson, PA, Scheurer, ME, Liu, Y, Yu, R, Gilbert, MR, Weinberg, J, Hosking, FJ, Robertson, LB, Papaemmanuil, E, McKean-Cowdin, R, Yechezkel, GH, Bruchim, RS, Aslanov, L, Kosteljanetz, M, Broholm, H, Schubert, E, DeAngelis, LM, Yang, P, Rynearson, AL, Henriksson, R, Wiencke, JK, Wiemels, JL, McCoy, L, McCarthy, B. Germline rearrangements in families with strong family history of glioma and malignant melanoma colon, and breast cancer. Neuro-oncology 16(10):1333-1340, 2014. e-Pub 2014. PMID: 24723567.
Desai S, Ding M, Wang B, Lu Z, Zhao Q, Shaw K, Yung WK, Weinstein JN, Tan M, Yao J. Tissue-specific isoform switch and DNA hypomethylation of the pyruvate kinase PKM gene in human cancers. Oncotarget 5(18):8202-10, 2014. e-Pub 2014. PMID: 24077665.
Hamza MA, Mandel JJ, Conrad CA, Gilbert MR, Yung WK, Puduvalli VK, DeGroot JF. Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. J Neurooncol 119(1):135-40, 2014. e-Pub 2014. PMID: 24803001.
Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D, Aldape K, Hunter T, Yung W, Lu Z. Erratum: PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 158(5):1210, 2014. e-Pub 2014.
Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D, Aldape K, Hunter T, Yung W, Lu Z. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 150(4):685-696, 2014. e-Pub 2014. PMID: 28917293.
Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, Wright JJ, Dancey J, Aldape KD, Prados MD, Ligon KL. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol 16(4):567-78, 2014. e-Pub 2014. PMID: 24470557.
Yao J, Caballero OL, Yung WK, Weinstein JN, Riggins GJ, Strausberg RL, Zhao Q. Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers. Cancer Immunol Res 2(4):371-9, 2014. e-Pub 2014. PMID: 24764584.
Peng Z, Maxwell D, Sun D, Ying Y, Schuber PT, Bhanu Prasad BA, Gelovani J, Yung WK, Bornmann WG. Design and Synthesis of an Inositol Phosphate Analog Based on Computational Docking Studies. Tetrahedron 70(4):984-990, 2014. e-Pub 2014. PMID: 25110363.
Saito N, Fu J, Zheng S, Yao J, Wang S, Liu DD, Yuan Y, Sulman EP, Lang FF, Colman H, Verhaak RG, Yung WK, Koul D. A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor initiating cells. Stem Cells 32(1):301-12, 2014. e-Pub 2014. PMID: 24038660.
Liu Q, Turner KM, Yung W, Chen K, Zhang W. Role of AKT signaling in DNA repair and clinical response to cancer therapy. Neuro-Oncology 16(10):1313-1323, 2014. e-Pub 2014.
Guan X, Vengoechea J, Zheng S, Sloan AE, Chen Y, Brat DJ, O'Neill BP, de Groot J, Yust-Katz S, Yung WK, Cohen ML, Aldape KD, Rosenfeld S, Verhaak RG, Barnholtz-Sloan JS. Molecular subtypes of glioblastoma are relevant to lower grade glioma. PLoS One 9(3):e91216, 2014. e-Pub 2014. PMID: 24614622.
Desai S, Ding M, Wang B, Lu Z, Zhao Q, Shaw K, Yung W, Weinstein JN, Tan M, Yao J. Tissue-specific isoform switch and DNA hypomethylation of the pyruvate kinase PKM gene in human cancers. Oncotarget 5(18):8202-8210, 2014. e-Pub 2014.
Hamza MA, Mandel JJ, Conrad CA, Gilbert MR, Yung W, Puduvalli VK, DeGroot JF. Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. Journal of Neuro-Oncology 119(1):135-140, 2014. e-Pub 2014.
Jiang H, Clise-Dwyer K, Ruisaard KE, Fan X, Tian W, Gumin J, Lamfers ML, Kleijn A, Lang FF, Yung WK, Vence LM, Gomez-Manzano C, Fueyo J. Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model. PLoS One 9(5):e97407, 2014. e-Pub 2014. PMID: 24827739.
Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O'Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L, Network TR. The somatic genomic landscape of glioblastoma. Cell 155(2):462-77, 2013. e-Pub 2013. PMID: 24120142.
Weinstein JN, Collisson EA, Mills GB, Mills Shaw KR, Ozenberger BA, Ellrott K, Sander C, Stuart JM, Chang K, Creighton CJ, Davis C, Donehower L, Drummond J, Wheeler D, Ally A, Balasundaram M, Birol I, N Butterfield YS, Chu A, Chuah E, E Chun HJ, Dhalla N, Guin R, Hirst M, Hirst C, Holt RA, M Jones SJ, Lee D, Li HI, Marra MA, Mayo M, Moore RA, Mungall AJ, Robertson A, Schein JE, Sipahimalani P, Tam A, Thiessen N, Varhol RJ, Beroukhim R, Bhatt AS, Brooks AN, Cherniack AD, Freeman SS, Gabriel SB, Helman E, Jung J, Meyerson M, Ojesina AI, Pedamallu CS, Saksena G, Schumacher SE, Tabak B, Zack T, Lander ES, Bristow CA, Hadjipanayis A, Haseley P, Kucherlapati R, Lee S, Lee E, Luquette LJ, Mahadeshwar HS, Pantazi A, Parfenov M, Park PJ, Protopopov A, Ren X, Santoso N, Seidman J, Seth S, Song X, Tang J, Xi R, Xu AW, Yang L, Zeng D, Auman J, Balu S, Buda E, Fan C, Hoadley KA, Jones CD, Meng S, Mieczkowski PA, Parker JS, Perou CM, Roach J, Shi Y, Silva GO, Tan D, Veluvolu U, Waring S, Wilkerson MD, Wu J, Zhao W, Bodenheimer T, Hayes D, Hoyle AP, Jeffreys SR, Mose LE, Simons JV, Soloway MG, Baylin SB, Berman BP, Bootwalla MS, Danilova L, Herman JG, Hinoue T, Laird PW, Rhie SK, Shen H, Triche T, Weisenberger DJ, Scott. The cancer genome atlas pan-cancer analysis project. Nature Genetics 45(10):1113-1120, 2013. e-Pub 2013.
Anderson MD, Theeler BJ, Penas-Prado M, Groves MD, Yung WK. Bevacizumab use in disseminated choroid plexus papilloma. J Neurooncol 114(2):251-3, 2013. e-Pub 2013. PMID: 23761024.
Zhang C, Moore LM, Li X, Yung WK, Zhang W. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. Neuro Oncol 15(9):1114-26, 2013. e-Pub 2013. PMID: 23877318.
Yust-Katz S, Liu D, Yuan Y, Liu V, Kang S, Groves M, Puduvalli V, Levin V, Conrad C, Colman H, Hsu S, Yung WK, Gilbert MR. Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma. Cancer 119(15):2747-53, 2013. e-Pub 2013. PMID: 23633392.
Weller M, Yung WK. Angiogenesis inhibition for glioblastoma at the edge: beyond AVAGlio and RTOG 0825. Neuro Oncol 15(8):971, 2013. e-Pub 2013. PMID: 23864129.
Alexander BM, Wen PY, Trippa L, Reardon DA, Yung WK, Parmigiani G, Berry DA. Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2. Neuro Oncol 15(8):972-8, 2013. e-Pub 2013. PMID: 23857706.
Zheng S, Fu J, Vegesna R, Mao Y, Heathcock LE, Torres-Garcia W, Ezhilarasan R, Wang S, McKenna A, Chin L, Brennan CW, Yung WK, Weinstein JN, Aldape KD, Sulman EP, Chen K, Koul D, Verhaak RG. A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. Genes Dev 27(13):1462-72, 2013. e-Pub 2013. PMID: 23796897.
Kim YW, Koul D, Kim SH, Lucio-Eterovic AK, Freire PR, Yao J, Wang J, Almeida JS, Aldape K, Yung WK. Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis. Neuro Oncol 15(7):829-39, 2013. e-Pub 2013. PMID: 23502430.
Shonka N, Piao Y, Gilbert M, Yung A, Chang S, DeAngelis LM, Lassman AB, Liu J, Cloughesy T, Robins HI, Lloyd R, Chen A, Prados M, Wen PY, Heymach J, de Groot J. Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept. Target Oncol 8(2):117-25, 2013. e-Pub 2013. PMID: 23345034.
Fu J, Koul D, Yao J, Wang S, Yuan Y, Colman H, Sulman EP, Lang FF, Yung WK. Novel HSP90 inhibitor NVP-HSP990 targets cell cycle regulators to ablate Olig2-positive glioma tumor initiating cells. Cancer Res 73(10):3062-74, 2013. e-Pub 2013. PMID: 23492364.
Zhao Q, Caballero OL, Davis ID, Jonasch E, Tamboli P, Yung WK, Weinstein JN, research network KSFT, Strausberg RL, Yao J. Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas. Clin Cancer Res 19(9):2460-72, 2013. e-Pub 2013. PMID: 23444225.
Yung WK. From GWAS risk foci to glioma molecular subclass. Neuro Oncol 15(5):513-4, 2013. e-Pub 2013. PMID: 23620433.
Alexander BM, Wang M, Yung WK, Fine HA, Donahue BA, Tremont IW, Richards RS, Kerlin KJ, Hartford AC, Curran WJ, Mehta MP. A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806). J Neurooncol 111(1):33-9, 2013. e-Pub 2013. PMID: 23086432.
Yung W. Neuro-oncology: Past milestones and the journey ahead. Neuro-Oncology 15(11):1453-1454, 2013. e-Pub 2013.
Yung W. Neuro-oncology. Neuro-Oncology 15(12):1591-1594, 2013. e-Pub 2013.
Lee EQ, Kuhn J, Lamborn KR, Abrey L, DeAngelis LM, Lieberman F, Robins HI, Chang SM, Yung WK, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados MD, Cloughesy TF, Gilbert MR, Wen PY. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro Oncol 14(12):1511-8, 2012. e-Pub 2012. PMID: 23099651.
Lee EQ, Puduvalli VK, Reid JM, Kuhn JG, Lamborn KR, Cloughesy TF, Chang SM, Drappatz J, Yung WK, Gilbert MR, Robins HI, Lieberman FS, Lassman AB, McGovern RM, Xu J, Desideri S, Ye X, Ames MM, Espinoza-Delgado I, Prados MD, Wen PY. Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03. Clin Cancer Res 18(21):6032-9, 2012. e-Pub 2012. PMID: 22923449.
Theeler BJ, Yung WK, Fuller GN, De Groot JF. Moving toward molecular classification of diffuse gliomas in adults. Neurology 79(18):1917-26, 2012. e-Pub 2012. PMID: 23109653.
Yung WK. New impact factor reflects increased quality. Neuro Oncol 14(9):1115, 2012. e-Pub 2012. PMID: 22910299.
Giglio P, Dhamne M, Hess KR, Gilbert MR, Groves MD, Levin VA, Kang SL, Ictech SE, Liu V, Colman H, Conrad CA, Loghin M, de Groot J, Yung WK, Puduvalli VK. Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer 118(14):3599-606, 2012. e-Pub 2012. PMID: 22086614.
Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu P, Xue X, Ellingson BM, Schiff D, Aregawi D, Cha S, Puduvalli VK, Wu J, Yung WK, Young GS, Vredenburgh J, Barboriak D, Abrey LE, Mikkelsen T, Jain R, Paleologos NA, Rn PL, Prados M, Goldin J, Wen PY, Cloughesy T. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol, 2012. e-Pub 2012. PMID: 22426926.
Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu P, Xue X, Ellingson BM, Schiff D, Aregawi D, Cha S, Puduvalli VK, Wu J, A Yung WK, Young GS, Vredenburgh J, Barboriak D, Abrey LE, Mikkelsen T, Jain R, Paleologos NA, Rn PL, Prados M, Goldin J, Wen PY, Cloughesy T. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: A multi-center study. Journal of Neuro-Oncology 108(3):491-498, 2012. e-Pub 2012.
Reardon DA, Conrad CA, Cloughesy T, Prados MD, Friedman HS, Aldape KD, Mischel P, Xia J, DiLea C, Huang J, Mietlowski W, Dugan M, Chen W, Yung WK. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemother Pharmacol 69(6):1507-18, 2012. e-Pub 2012. PMID: 22392572.
Sai K, Wang S, Balasubramaniyan V, Conrad C, Lang FF, Aldape K, Szymanski S, Fokt I, Dasgupta A, Madden T, Guan S, Chen Z, Alfred Yung WK, Priebe W, Colman H. Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway. J Neurooncol 107(3):487-501, 2012. e-Pub 2012. PMID: 22249692.
Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, Pedraza A, Brennan CW, Heguy A, Liau LM, Lieberman F, Yung WK, Gilbert MR, Reardon DA, Drappatz J, Wen PY, Lamborn KR, Chang SM, Prados MD, Fine HA, Horvath S, Wu N, Lassman AB, DeAngelis LM, Yong WH, Kuhn JG, Mischel PS, Mehta MP, Cloughesy TF, Mellinghoff IK. Differential Sensitivity of Glioma- versus Lung Cancer-Specific EGFR Mutations to EGFR Kinase Inhibitors. Cancer Discov 2(5):458-471, 2012. e-Pub 2012. PMID: 22588883.
Reardon DA, Wen PY, Alfred Yung WK, Berk L, Narasimhan N, Turner CD, Clackson T, Rivera VM, Vogelbaum MA. Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial. Cancer Chemother Pharmacol 69(4):849-60, 2012. e-Pub 2012. PMID: 22037923.
Koul D, Fu J, Shen R, LaFortune TA, Wang S, Tiao N, Kim YW, Liu JL, Ramnarian D, Yuan Y, Garcia-Echevrria C, Maira SM, Yung WK. Antitumor activity of NVP-BKM120- a selective pan class 1 PI3 Kinase inhibitor showed differential forms of cell death based on P53 status of glioma cells. Clin Cancer Res 18(1):184-95, 2012. e-Pub 2012. PMID: 22065080.
Yung W. A year of continued growth and success. Neuro-Oncology 14(1):1-2, 2012. e-Pub 2012.
Yung WK. A year of continued growth and success. Neuro Oncol 14(1):1-2, 2012. e-Pub 2012. PMID: 22200986.
Reardon DA, Cloughesy T, Rich J, Alfred Yung WK, Yung L, DiLea C, Huang J, Dugan M, Mietlowski W, Maes A, Conrad C. Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma. Cancer Chemother Pharmacol 69(1):281-7, 2012. e-Pub 2012. PMID: 21984222.
Yao J, Zhao Q, Yuan Y, Zhang L, Liu X, Yung WK, Weinstein JN. Identification of Common Prognostic Gene Expression Signatures with Biological Meanings from Microarray Gene Expression Datasets. PLoS One 7(9):e45894, 2012. e-Pub 2012. PMID: 23029298.
Gomez-Manzano C, Jiang H, Alonso M, Yung WK, Fueyo J. Gene therapy. Handb Clin Neurol 104:331-8, 2012. e-Pub 2012. PMID: 22230451.
Zhang N, Wei P, Gong A, Chiu WT, Lee HT, Colman H, Huang H, Xue J, Liu M, Wang Y, Sawaya R, Xie K, Yung WK, Medema RH, He X, Huang S. FoxM1 Promotes ß-Catenin Nuclear Localization and Controls Wnt Target-Gene Expression and Glioma Tumorigenesis. Cancer Cell 20(4):427-42, 2011. e-Pub 2011. PMID: 22014570.
Clarke JL, Ennis MM, Yung WK, Chang SM, Wen PY, Cloughesy TF, Deangelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Lamborn KR, Prados MD, Tumor Consortium NAB. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?. Neuro Oncol 13(10):1118-24, 2011. e-Pub 2011. PMID: 21813511.
Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, Boulos N, Wright K, Johnson RA, Poppleton H, Mohankumar KM, Féau C, Phoenix T, Gibson P, Zhu L, Tong Y, Eden C, Ellison DW, Priebe W, Koul D, Yung WK, Gajjar A, Stewart CF, Guy RK, Gilbertson RJ. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell 20(3):384-99, 2011. e-Pub 2011. PMID: 21907928.
Siker ML, Wang M, Porter K, Nelson DF, Curran WJ, Michalski JM, Souhami L, Chakravarti A, Yung WK, Delrowe J, Coughlin CT, Mehta MP. Age as an independent prognostic factor in patients with glioblastoma: a radiation therapy oncology group and American College of Surgeons National Cancer Data Base comparison. J Neurooncol 104(1):351-6, 2011. e-Pub 2011. PMID: 21221714.
de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, DeAngelis L, Camphausen K, Chen A, Yung WK, Prados M, Wen PY, Heymach JV. Myeloid Biomarkers Associated with Glioblastoma Response to Anti-Vascular Endothelial Growth Factor Therapy with Aflibercept. Clin Cancer Res 17(14):4872-81, 2011. e-Pub 2011. PMID: 21632852.
de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, Mehta MP, Lassman AB, Deangelis LM, Yung WK, Chen A, Prados MD, Wen PY. Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study. J Clin Oncol 29(19):2689-95, 2011. e-Pub 2011. PMID: 21606416.
Guan S, Shen R, Lafortune T, Tiao N, Houghton P, Yung WK, Koul D. Establishment and characterization of clinically relevant models of ependymoma: a true challenge for targeted therapy. Neuro Oncol 13(7):748-58, 2011. e-Pub 2011. PMID: 21653596.
Research Network CGA. Integrated genomic analyses of ovarian carcinoma. Nature 474(7353):609-615, 2011. e-Pub 2011. PMID: 21720365.
Wefel JS, Cloughesy T, Zazzali JL, Zheng M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 13(6):660-8, 2011. e-Pub 2011. PMID: 21558074.
Iwamoto FM, Lamborn KR, Kuhn JG, Wen PY, Yung WK, Gilbert MR, Chang SM, Lieberman FS, Prados MD, Fine HA. A phase I/II trial of the histone deacetylase inhibitor, romidepsin, for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol 13(5):509-16, 2011. e-Pub 2011. PMID: 21377994.
Lawrence YR, Wang M, Dicker AP, Andrews D, Curran WJ, Michalski JM, Souhami L, Yung WK, Mehta M. Early toxicity predicts long-term survival in high-grade glioma. Br J Cancer 104(9):1365-71, 2011. e-Pub 2011. PMID: 21487410.
Kim YW, Liu TJ, Koul D, Tiao N, Feroze AH, Wang J, Powis G, Yung WK. Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM. Neuro Oncol 13(4):367-75, 2011. e-Pub 2011. PMID: 21430111.
Walbert T, Gilbert MR, Groves MD, Puduvalli VK, Yung WK, Conrad CA, Bobustuc GC, Colman H, Hsu SH, Bekele BN, Qiao W, Levin VA. Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma. J Neurooncol 102(2):273-80, 2011. e-Pub 2011. PMID: 20652724.
Gwak HS, Shingu T, Chumbalkar V, Hwang YH, DeJournett R, Latha K, Koul D, Alfred Yung WK, Powis G, Farrell NP, Bögler O. Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma. Int J Cancer 128(4):787-96, 2011. e-Pub 2011. PMID: 20473884.
Liu JL, Mao Z, Gallick GE, Yung WK. AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor. Neuro Oncol 13(2):184-94, 2011. e-Pub 2011. PMID: 21123367.
Prados M, Cloughesy T, Samant M, Fang L, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 13(1):143-51, 2011. e-Pub 2011. PMID: 21084434.
Yung W. Reflections on a successful 2010. Neuro-Oncology 13(1):1-2, 2011. e-Pub 2011.
Gilbert MR, Gonzalez J, Hunter K, Hess K, Giglio P, Chang E, Puduvalli V, Groves MD, Colman H, Conrad C, Levin V, Woo S, Mahajan A, de Groot J, Yung WK. A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. Neuro Oncol 12(11):1167-72, 2010. e-Pub 2010. PMID: 20729242.
Yung WK, Vredenburgh JJ, Cloughesy TF, Nghiemphu P, Klencke B, Gilbert MR, Reardon DA, Prados MD. Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro Oncol 12(10):1061-70, 2010. e-Pub 2010. PMID: 20615922.
Koul D, Shen R, Kim YW, Kondo Y, Lu Y, Bankson J, Ronen SM, Kirkpatrick DL, Powis G, Yung WK. Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol 12(6):559-69, 2010. e-Pub 2010. PMID: 20156803.
Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KD, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD, Tumor Consortium NAB. A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol 12(1):87-94, 2010. e-Pub 2010. PMID: 20150371.
Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD, Lieberman F, Wen PY. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol 96(2):211-7, 2010. e-Pub 2010. PMID: 19562255.
Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KA, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD, Tumor Consortium NAB. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol 12(1):95-103, 2010. e-Pub 2010. PMID: 20150372.
Vredenburgh JJ, Cloughesy T, Samant M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Das A, Friedman HS. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist 15(12):1329-34, 2010. e-Pub 2010. PMID: 21147867.
Zhou YH, Hess KR, Raj VR, Yu L, Liu L, Yung AW, Linskey ME. Establishment of prognostic models for astrocytic and oligodendroglial brain tumors with standardized quantification of marker gene expression and clinical variables. Biomark Insights 5:153-68, 2010. e-Pub 2010. PMID: 21234290.
Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733-40, 2009. e-Pub 2009. PMID: 19720927.
Groves MD, Hess KR, Puduvalli VK, Colman H, Conrad CA, Gilbert MR, Weinberg J, Cristofanilli M, Yung WK, Liu TJ. Biomarkers of Disease: Cerebrospinal fluid Vascular Endothelial Growth factor (VEGF) and Stromal cell derived factor (SDF-1) levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol 94(2):229-34, 2009. e-Pub 2009. PMID: 19267183.
Groves MD, Puduvalli VK, Gilbert MR, Levin VA, Conrad CA, Liu VH, Hunter K, Meyers C, Hess KR, Alfred Yung WK. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme. Br J Cancer 101(4):615-20, 2009. e-Pub 2009. PMID: 19672263.
Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, Maira SM, Garcia-Echevrria C, Yung WK. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther 8(8):2204-10, 2009. e-Pub 2009. PMID: 19671762.
Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD. Phase II study of imatinib mesylate (Gleevec(R)) for recurrent meningiomas (North American Brain Tumor Consortium Study 01-08). Neuro Oncol 11(6):853-60, 2009. e-Pub 2009. PMID: 19293394.
Powis G, Ihle NT, Yung WK. Inhibiting PI-3-K for glioma therapy. Cell Cycle 8(3):335, 2009. e-Pub 2009. PMID: 19164951.
Gomez-Manzano C, Holash J, Fueyo J, Xu J, Conrad CA, Aldape KD, de Groot JF, Bekele BN, Yung WK. VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol 10(6):940-5, 2008. e-Pub 2008. PMID: 18708344.
de Groot JF, Gilbert MR, Aldape K, Hess KR, Hanna TA, Ictech S, Groves MD, Conrad C, Colman H, Puduvalli VK, Levin V, Yung WK. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neurooncol 90(1):89-97, 2008. e-Pub 2008. PMID: 18581057.
[Yung WK] CGARN. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216):1061-8, 2008. e-Pub 2008. PMID: 18772890.
Prados MD, Yung WKA, Wen PY, Junck L, Cloughesy T, Fink K, Chang S, Robins HI, Dancey J, Kuhn J. Phase I trial of gefitinib and temozolomide in patients with malignant gliomas: A North American Brain Tumor Consortium Study. Cancer Chemother Pharmacol 61((6)):1059-1067, 2008. e-Pub 2008. PMID: 17694310.
Knisely JP, Berkey B, Chakravarti A, Yung AW, Curran WJ, Jr, Robins HI, Movsas B, Brachman DG, Henderson RH, Mehta MP. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). Int J Radiation Oncol Biol Phys 17((1)):79-86, 2008. e-Pub 2008.
Corn BW, Moughan J, Knisely JP, Fox SW, Chakravarti A, Yung WK, Jr CW, Robins HI, Brachman DG, Henderson RH, Mehta MP, Movsas B. Prospective evaluation of quality of life and neurocognitive effects in patients with multiple brain metastases receiving whole-brain radiotherapy with or without thalidomide on Radiation Therapy Oncology (RTOG) Trial 0118. Int J Radiat Oncol Biol Phys 71((1)):71-8, 2008. e-Pub 2008. PMID: 18164829.
Groves MD, Glantz MJ, Chamberlain MC, Baumgartner KE, Conrad CA, Hsu S, Wefel JS, Gilbert MR, Ictech S, Hunter KU, Forman AD, Puduvalli VK, Colman H, Hess KR, Yung WK. A multicenter Phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol 10(2):208-215, 2008. e-Pub 2008. PMID: 18316473.
Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Hibberts J, Peterson PM, Prados MD, Tumor Consortium NAB. Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10(2):162-170, 2008. e-Pub 2008. PMID: 18356283.
Puduvalli VK, Giglio P, Groves MD, Hess KR, Gilbert MR, Mahankali S, Jackson EF, Levin VA, Conrad CA, Hsu SH, Colman H, de Groot JF, Ritterhouse MG, Ictech SE, Yung WK. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol 10(2):216-222, 2008. e-Pub 2008. PMID: 18314417.
deGroot JF, Piao Y, Lu L, Gn F, Yung WK. Knockdown of GluR1 expression by RNA interference inhigits glioma proliferation. J Neurooncol 88(2):121-33, 2008. e-Pub 2008. PMID: 18317690.
Freire P, Vilela M, Deus H, Kim YW, Koul D, Colman H, Aldape KD, Bogler O, Yung WK, Coombes K, Mills GB, Vasconcelos AT, Almeida JS. Exploratory analysis of the copy number alterations in glioblastoma multiforme. PLoS One 3(12):e4076, 2008. e-Pub 2008. PMID: 19115005.
Loghin M, Prados M, Wen P, Junck L, Lieberman F, Fine H, Fink K, Mehta M, Kuhn J, Lamborn K, Chang S, Cloughesy T, DeAngelis L, Robins HI, Aldape K, Yung, WKA. Phase I study of Temozolomide and Irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium study. Clin Cancer Res 13((23)):7133-7138, 2007. e-Pub 2007. PMID: 18056194.
Alonso M, Gomez-Manzano C, Bekele BN, Yung WKA, Fueyo-Margareto J. Adenovirus-based strategies overcome temozolomide resistance by silencing the 06-methylguanine-DNA methyltransferase promotor. Cancer Res 67((24)):11499-504, 2007. e-Pub 2007. PMID: 18089777.
Scheurer ME, Etzel CJ, Liu M, El-Zein R, Airewele GE, Malmer B, Aldape KD, Weinberg JS, Yung WK, Bondy MI. Aggregation of cancer in first-degree relatives of patients with glioma. Cancer Epidemiol Biomarkers Prev 16((11)):2491-5, 2007. e-Pub 2007. PMID: 18006942.
Jing R, Choi W, Khan A Hess K, Gerner EW, Jr CR, Yung WK, Hamilton SR, Zhang W. Activation of polyamine catabolism by N1, N11-diethylnorspermine leads to cell death in glioblastoma. Int J Oncol 31((2)):431-40, 2007. e-Pub 2007. PMID: 17611701.
Alonso MM, Gomez-Manzano C, Jiang H, Bekele NB, Piao Y, Yung WK, Alemany R, Fueyo J. Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo. Cancer Gene Ther 14(8):756-61, 2007. e-Pub 2007. PMID: 17557108.
Olson MV, Johnson DG, Jiang H, Xu J, Alonso MM, Aldape KD, Fuller GN, BEkele BN, Yung WK, Gomez-Manzano C, Fueyo J. Transgenic E2F1 expression in the mouse brain induces a human-like bimodal pattern of tumors. Cancer Res 67((9)):4005-09, 2007. e-Pub 2007. PMID: 17483310.
Grewal J, Dellinger CA, Yung WK. Fatal reactivation of Hepatitis B with temozolomide. N Engl J Med 356(15)(15):1591-92, 2007. e-Pub 2007. PMID: 17429098.
Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, Deangelis LM, Hess KR, Lamborn KR, Prados MD, Yung WK. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol 81(3)(3):271-7, 2007. e-Pub 2007. PMID: 17031561.
Xia D, Srinivas H, Ahn YH, Sethi G, Sheng X, Yung WK, Xia Q, Chiao PJ, Kim H, Brown PH, Wistuba, II, Aggarwal BB, Kurie JM. Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NFkappaB-dependent pathway. J Biol Chem 282(6)(6):3507-19, 2007. e-Pub 2007. PMID: 17158870.
Koul D, Shen R, Shishodia S, Takada Y, Bhat KP, Reddy SA, Aggarwal BB, Yung WK. PTEN down regulates AP-1 and targets c-fos in human glioma cells Via PI3-kinase/Akt pathway. Mol Cell Biochem 300(1-2)(1-2):77-87, 2007. e-Pub 2007. PMID: 17235455.
Xia Y, Wang J, Liu TJ, Yung WK, Hunter T, Lu Z. c-Jun downregulation by HDAC3-dependent transcriptional repression promotes osmotic stress-induced cell apoptosis. Mol Cell 25(2)(2):219-32, 2007. e-Pub 2007. PMID: 17244530.
Lustig RA, Sieferheld W, Berkey B, Yung AW, Scarantino C, Movsas B, Jones CU, Simpson JR, Fishbach J, Jr CW. Imaging response in malignant glioma, RTOG 90-06. Am J Clin Oncol 30(1):32-37, 2007. e-Pub 2007.
Liu TJ, LaFortune T, Honda T, Ohmori O, Hatakeyama S, Meyer T, deGroot J, Yung WKA. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther 6(4)(4):1357-67, 2007. e-Pub 2007. PMID: 17431114.
Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, McDonald JM, Yung WK, Colman H, Woo SY, Heimberger AB, Suki D, Prado M, Chang SM, FGnd B, Buckner JC, James CD, Aldape K. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 1:25(16)(16):2288-2294, 2007. e-Pub 2007. PMID: 17538175.
Liu JL, Mao Z, LaFortune TA, Alonso MM, Gallick GE, Fueyo J, Yung WK. Cell cycle-dependent nuclear export of phosphatase and tensin homologue tumor suppressor is regulated by the phosphoinositide-3-kinase signaling cascade. Cancer Res 67:(22):11054-63, 2007. e-Pub 2007. PMID: 18006852.
Jiang H, Olson MV, Medrano DR, Lee OH, Xu J, Piao Y, Alonso MM, Gomez-Manzano C, Hung MC, Yung WK, Fueyo J. A novel CRM1-dependent nuclear export signal in adenoviral E1A protein regulated by phosphorylation. FASEB J 20(14)(14):2603-5, 2006. e-Pub 2006. PMID: 17065226.
Colman H, Berkey BA, Maor MH, Groves MD, Schultz CJ, Vermeulen S, Nelson DF, Mehta MP, Yung WK. Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblastoma: results of RTOG 9710. Int J Radiat Oncol Biol Phys 66(3)(3):818-24, 2006. e-Pub 2006. PMID: 16887285.
Koul D, Takada Y, Shen R, Aggarwal BB, Yung WK. PTEN enhances TNF-induced apoptosis through modulation of nuclear factor-kappaB signaling pathway in human glioma cells. Biochem Biophys Res Commun 350(2)(2):463-71, 2006. e-Pub 2006. PMID: 17011514.
Groves MD, Puduvalli VK, Conrad CA, Gilbert MR, Yung WK, Jaeckle K, Liu V, Hess KR, Aldape KD, Levin VA. Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. J Neurooncol 80(1):83-90, 2006. e-Pub 2006. PMID: 16639492.
Mayes DA, Hu Y, Teng Y, Siegel E, Wu X, Panda K, Tan F, Yung WK, Zhou YH. PAX6 suppresses the invasiveness of glioblastoma cells and the expression of the matrix metalloproteinase-2 gene. Cancer Res 66(20)(20):9809-17, 2006. e-Pub 2006. PMID: 17047041.
Cloughesy TF, Wen PY, Robins HI, Chang SM, Groves MD, Fink KL, Junck L, Schiff D, Abrey L, Gilbert MR, Lieberman F, Kuhn J, DeAngelis LM, Mehta M, Raizer JJ, Yung WK, Aldape K, Wright J, Lamborn KR, Prados MD. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 24(22)(22):3651-6, 2006. e-Pub 2006. PMID: 16877733.
Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, Junck L, Schiff D, Lieberman F, Fine HA, Mehta M, Robins HI, DeAngelis LM, Groves MD, Puduvalli VK, Levin V, Conrad C, Maher EA, Aldape K, Hayes M, Letvak L, Egorin MJ, Capdeville R, Kaplan R, Murgo AJ, Stiles C, Prados MD. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 12(16)(16):4899-907, 2006. e-Pub 2006. PMID: 16914578.
Pelloski CE, Lin E, Zhang L, Yung WK, Colman H, Liu JL, Woo SY, Heimberger AB, Suki D, Prados M, Chang S, Barker FG, rd, Fuller GN, Aldape KD. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res 12(13)(13):3935-41, 2006. e-Pub 2006. PMID: 16818690.
Lee OH, Fueyo J, Xu J, Yung WK, Lemoine MG, Lang FF, Bekele BN, Zhou X, Alonso MA, Aldape KD, Fuller GN, Gomez-Manzano C. Sustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growth. Neoplasia 8(5)(5):419-28, 2006. e-Pub 2006. PMID: 16790091.
Levin VA, Giglio P, Puduvalli VK, Jochec J, Groves MD, Yung WK, Hess K. Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme. J Neurooncol 78(1):85-90, 2006. e-Pub 2006. PMID: 16391896.
Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, Hess K, Kuhn J, Kuhn J. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol 8(2):189-93, 2006. e-Pub 2006. PMID: 16533878.
Levin VA, Phuphanich S, Yung WKA, Forsyth PA, Maestro RD, Perry JR, Gn F, Elliot M, Baillet M. Randomized, double-blind, placebo controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J Neurooncol 78(3)(3):295-302, 2006. e-Pub 2006. PMID: 16636750.
Armstrong TS, Cohen MZ, Hess KR, Manning R, Lee ELT, Tamayo G, Baumgartner K, Min SJ, Yung A, Gilbert M. Complementary and alternative medicine use and quality of life in patients with primary brain tumors. J of Pain and Symptom Management 43(2):148-54, 2006. e-Pub 2006.
Alonso MM, Fueyo J, Yung WK, Gomez-Manzano C. E2F1 and telomerase: Alliance on the dark side. Cell Cycle 5(9):930-35, 2006. e-Pub 2006.
Koul D, Shen R, Bergh S, Sheng X, Shishodia S, LaFortune T, Liu Y, deGroot J, Mills GB, Yung WK. Inhibition of Akt survival pathway by a small molecule inhibitor in human glioblastoma. Mol Cancer Ther 5(3)(3):637-44, 2006. e-Pub 2006. PMID: 16546978.
Prados MD, Lamborn K, Yung WKA, Jaeckle K Rogbins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K Hess K Kuhn J. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium Study. Neuro-Oncology 8:189-93, 2006. e-Pub 2006.
Gomez-Manzano C, Alonso MM, gWKA Y, McCormick F, Curiel DT, lang FF, Jian HH, Bekele BN, Zhou X, Fueyo J. Delta-24 increases the expression and activity of topoisomerase I and enhances the anti-glioma effect of irinotecan. Clin Cancer Res 12(2)(2):566-62, 2006. e-Pub 2006. PMID: 16428500.
Levin VA, Giglio P, Puduvalli VK, Jochec J, Groves MD, Yung WKA, Hess K. Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma. J of Neuro-Oncology 78(1):85-90, 2005. e-Pub 2005.
Conrad C, Miller CR, Ji Y, Gomez-Manzano C, Bharara S, McMurray JS, Lang FF, Wong F, Sawaya R, Yung WK, Fueyo J. Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Ther 12(3)(3):284-94, 2005. e-Pub 2005. PMID: 15650766.
Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, Griffin C, Ozburn N, Chen M, Pan E, Koul D, Yung WK, Feuerstein BG, Aldape KD. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res 65(5):1678-86, 2005. e-Pub 2005. PMID: 15753362.
Unni E, Koul D, Yung WK, Sinha R. Se-methylselenocysteine inhibits phosphatidylinositol 3-kinase activity of mouse mammary epithelial tumor cells in vitro. Breast Cancer Res 7(5):R699-707, 2005. e-Pub 2005. PMID: 16168115.
Koul D, Shen R, Bergh S, Liu Y, deGroot JF, Tj L, Mills GB, Yung WK. Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. Mol Cancer Ther 4(11):1681-1688, 2005. e-Pub 2005. PMID: 16275989.
Cloughesy T, Kuhn J Robins HI, Abrey L, Wen P, Fink K, Lieberman FS, Mehta M, Change S, Yung A, DeAngelis L, Schiff D, Junck L, Groves M, Paquette S, Wright J, Lamborn K, Sebti SM, Prados M. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium Study. J of Clin Oncology 23(27):6647-56, 2005. e-Pub 2005.
Jiang H, Gomez-Manzano C, Alemany R, Medrano D, Alonso M, Bekele BN, Lin E, Conrad CC, Yung WK, Fueyo J. Comparative effect of oncolytic adenoviruses with E1A-55 kDa or E1B-55 kDa deletions in malignant gliomas. Neoplasia 7(1):48-56, 2005. e-Pub 2005. PMID: 15720816.
McDonald D, Kiebert G, Prados M, Yung A, Olson J. Benefit of Temozolomide compared to Procarbazine in treatment of glioblastoma multiforme at first relapse: Effect on neurological functioning, performance status and health related quality of life. Cancer Investigation 23(2):138-144, 2005. e-Pub 2005.
Alonso MM, Fueyo J, Shay JW, Aldape KW, Jiang H, Lee OH, Johnson DG, Xiu J, Kondo Y, Kanzawa T, Kyo S Bekele BN, Zhou X, Nigro J, McDonald JM, Yung WK, Gomez-Manzano C. Expression of transcription factor E2F1 and telomerase in glioblastomas: Mechanistic linkage and prognostic significance. J Natl Cancer Inst 97(21)(21):1589-1600, 2005. e-Pub 2005. PMID: 16264179.
Y-H Z, Wu X, Tan F, Shi YX, Glass T, Liu TJ, Wathen K, Hess KR, Gumin J, Lang F, Yung WK. PAX6 suppresses growth of human glioblastoma cells. J Neurooncol 71(3)(3):223-29, 2005. e-Pub 2005. PMID: 15735909.
Zhou YH, Hess KR, Liu L, Linskey ME, Yung WK. Modeling prognosis for patients with malignant astrocytic gliomas: Quantifying the expression of multiple genetic markers and clinical variables. Neuro Oncol 7(4)(4):485-94, 2005. e-Pub 2005. PMID: 16212813.
de Groot JF, Liu TJ, Fuller G, Yung WK. The excitatory amino acid transporter-2 induces apoptosis and decreases glioma growth in vitro and in vivo. Cancer Res 65(5)(5):1934-40, 2005. e-Pub 2005. PMID: 15753393.
Liu JL, Sheng X, Hortobagyi ZK, Mao Z, Gallick GE, Yung WK. Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation. Mol Cell Biol 25(14)(14):6211-24, 2005. e-Pub 2005. PMID: 15988030.
Lassman AB, Rossi MR, Razier JR, Abrey LE, Lieberman FS, Grefe CN, Lamborn K, Pao W, Shih AH, Kuhn JB, Wilson R, Nowark NJ, Cowell JK, DeAngelis LM, Wen P, Gilbert MR, Chang S, Yung WA, Prados M, Holland EC. Molecular study of malignant gliomas treated with epidermal growth factor inhibitors: Tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Ca Research 11(21):7841-50, 2005. e-Pub 2005.
Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, Griffin C, Ozburn N, Chen M Pan E, Koul D, Yung WKA, Feuerstein BG, Aldape KD. Integrated array-comparative genomic hybridization and expression array profiels identify clinically relevant molecular subtypes of glioblastoma. Cancer Research 65(5):1678-86, 2005. e-Pub 2005.
Jiang H, Alemany R Gomez-Manzano C, Medrano DR, Lemoine MG, Olson MV, Alonso MM, Lee O, Conrad CA, Yung WKA, Fueyo J. Downmodulation of E1A protein expression as a novel strategy to design cancer selective adenoviruses. Neoplasia 7(8):723-29, 2005. e-Pub 2005. PMID: 16207474.
Puduvalli VK, Yung WK, Hess KR, Kuhn JG, Groves MD, Levin VA, Zwiebel J, Chang SM, Cloughesy TF, Junck L, Wen P, Lieberman F, Conrad CA, Gilbert MR, Meyers CA, Liu V, Mehta MP, Nicholas MK, Prados M. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol 22(21)(21):4282-9, 2004. e-Pub 2004. PMID: 15514370.
Wang LE, Bondy ML, Shen H, El-Zein R, Aldape K, Cao Y, Puduvalli V, Levin VA, Yung WK, Wei Q. Polymorphisms of DNA repair genes and risk of glioma. Cancer Res 64(16):5560-3, 2004. e-Pub 2004. PMID: 15313891.
See SJ, Levin VA, Yung WK, Hess KR, Groves MD. 13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme. Neuro Oncol 6(3)(3):253-8, 2004. e-Pub 2004. PMID: 15279718.
Okcu MF, Selvan M, Wang LE, Stout L, Erana R, Airewele G, Adatto P, Hess K, Ali-Osman F, Groves M, Yung AW, Levin VA, Wei Q, Bondy M. Glutathione S-transferase polymorphisms and survival in primary malignant glioma. Clin Cancer Res 10(8):2618-25, 2004. e-Pub 2004. PMID: 15102663.
Gomez-Manzano C, Balague C, Alemany R, Lemoine MG, Mitlianga P, Jiang H, Khan A, Alonso M, Lang FF, Conrad CA, Liu TJ, Bekele BN, Yung WK, Fueyo J. A novel E1A-E1B mutant adenovirus induces glioma regression in vivo. Oncogene 23(10)(10):1821-8, 2004. e-Pub 2004. PMID: 15014451.
Cerrato JA, Khan T, Koul D, Lang FF, Conrad CA, Yung WK, Liu TJ. Differential activation of the Fas/CD95 pathway by Ad-p53 in human gliomas. Int J Oncol 24(2)(2):409-17, 2004. e-Pub 2004. PMID: 14719118.
Gomez-Manzano C, Yung WK, Alemany R, Fueyo J. Genetically modified adenoviruses against gliomas: From bench to bedside. Neurology 63(3):418-26, 2004. e-Pub 2004. PMID: 15304571.
Prados MD, Yung WK, Fine HA, Greenberg HS, Junck L, Chang SM, Nicholas MK, Robins HI, Mehta MP, Fink KL, Jaeckle KA, Kuhn J, Hess KR, Schold SC, Jr. Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. Neuro Oncol 6(1)(1):33-7, 2004. e-Pub 2004. PMID: 14769138.
Yung, WK. Current therapies for glioblastoma. Clin Adv Hematol Oncol 2(9)(9):527-73, 2004. e-Pub 2004. PMID: 16163238.
Gomez-Manzano C, Yung WKA, Alemany R, Fueyo J. Genetically modified adenoviruses against gliomas: From bench to bedside. Neurology 63:418-426, 2004. e-Pub 2004.
Chang SM, Prados MD, Yung WK, Fine H, Junck L, Greenberg H, Hi R, Mehta M, Fink KL, Jaeckle KA, Kuhn J, Hess K, Schold C. Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and Temozolomide for newly diagnosed anaplastic glioma: A North American Brain Tumor Consortium Trial. Cancer 100(8)(8):1712-16, 2004. e-Pub 2004. PMID: 15073861.
Wen P, Yung WKA, Lamborn K, Peng, B, Dahia P, Abrey, L, Raiser J, Cloughesy T, Fink K, Gilbert M, Chang, S, Junck L, Schiff D, Lieberman F, Fine H, Mehta M, Robins JI, DeAngelis LM, Hess K, Groves M, Puduvalli VK, Levin V, Conrad C, Kuhn J, Maher E, Hayes M, Silberman S, Letvak L, Capdeville R, Kaplan R, Murgo A, Stiles C, Prados MD. Phase I/II study of Imatinib Mesylate (ST1571) for patients with recurrent malignant gliomas (NABTC 98-08). Society for Neuro-Oncology Ninth Annual Meeting (SNO), Toronto Ontario, Canada. Neuro-Oncology 6(1):385, 2004. e-Pub 2004.
Groves MD, Liu TJ, Hess KR, Forman AD, Hsu SH, Gilbert MR, Colman H, Puduvalli VK, Conrad CA, Yung WKA. Cerebrospinal fluid VEGF levels as a biomarker of neoplastic meningitis. Society for Neuro-Oncology Ninth Annual Meeting (SNO), Toronto Ontario, Canada. Neuro-Oncology 6:352, 2004. e-Pub 2004.
Gilbert M, Hess K, Gaupp P, Groves M, Puduvalli V, Levin V, Conrad C, Colman H, Hsu S, DePorre P, Yung WKA. A Phase I study of Temozolomide (TMZ) and the farnesyltransferase inhibitor (FTI), Tipifarnib (Zarnestra, R115777) in recurrent glioblastoma: A dose and schedule intensive regimen. Society for Neuro-Oncology Ninth Annual Meeting (SNO), Toronto Ontario, Canada, November 18–21, 2004. Neuro-Oncology 6:375, 2004. e-Pub 2004.
Prados MD, Yung WK, Jaeckle KA, Robins HI, Mehta MP, Fine HA, Wen PY, Cloughesy TF, Chang SM, Nicholas MK, Schiff D, Greenberg HS, Junck L, Fink KL, Hess KR, Kuhn J. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol 6(1)(1):44-54, 2004. e-Pub 2004. PMID: 14769140.
Lu Y, Yu Q, Liu JH, Zhang J, Wang H, Koul D, McMurray JS, Fang X, Yung WK, Siminovitch KA, Mills GB. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem 278(41)(41):40057-66, 2003. e-Pub 2003. PMID: 12869565.
Dabaja BS, McLaughlin P, Ha CS, Pro B, Meyers CA, Seabrooke LF, Wilder RB, Kyritsis AP, Preti HA, Yung WK, Levin V, Cabanillas F, Cox JD. Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy. Cancer 98(5)(5):1021-28, 2003. e-Pub 2003. PMID: 12942571.
Zhou YH, Tan F, Hess KR, Yung WK. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res 9(9):3369-75, 2003. e-Pub 2003. PMID: 12960124.
Lang FF, Bruner JM, Fuller GN, Aldape K, Prados MD, Chang S, Berger MS, McDermott MW, Kunwar SM, Junck LR, Chandler W, Zwiebel JA, Kaplan RS, Yung WK. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 21(13)(13):2508-18, 2003. e-Pub 2003. PMID: 12839017.
Jaeckle KA, Hess KR, Yung WK, Greenberg H, Fine H, Schiff D, Pollack IF, Kuhn J, Fink K, Mehta M, Cloughesy T, Nicholas MK, Chang S, Prados M. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 21(12)(12):2305-11, 2003. e-Pub 2003. PMID: 12805331.
Fueyo J, Alemany R, Gomez-Manzano C, Fuller GN, Khan A, Conrad CA, Liu TJ, Jiang H, Lemoine MG, Suzuki K, Sawaya R, Curiel DT, Yung WK, Lang FF. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 95(9)(9):652-60, 2003. e-Pub 2003. PMID: 12734316.
Levin VA, Hess KR, Choucair A, Flynn PJ, Jaeckle KA, Kyritsis AP, Yung WK, Prados MD, Bruner JM, Ictech S, Gleason MJ, Kim HW. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 9(3):981-90, 2003. e-Pub 2003. PMID: 12631596.
Puduvalli VK, Hashmi M, McAllister LD, Levin VA, Hess KR, Prados M, Jaeckle KA, Yung WK, Buys SS, Bruner JM, Townsend JJ, Davis R, Sawaya R, Kyritsis AP. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival. Oncology 65(3)(3):259-66, 2003. e-Pub 2003. PMID: 14657600.
Gomez-Manzano C, Fueyo J, Jiang H, Glass TL, Lee HY, Hu M, Liu JL, Jasti SL, Liu TJ, Conrad CA, Yung WK. Mechanisms underlying PTEN regulation of vascular endothelial growth factor and angiogenesis. Ann Neurol 53(1)(1):109-17, 2003. e-Pub 2003. PMID: 12509854.
Zhou YH, Zheng JB, Gu X, Saunders GF, Yung WK. Novel PAX6 binding sites in the human genome and the role of repetitive elements in the evolution of gene regulation. Genome Res 12(11)(11):1716-22, 2002. e-Pub 2002. PMID: 12421758.
Lang FF, Gilbert MR, Puduvalli VK, Weinberg J, Levin VA, Yung WK, Sawaya R, Fuller GN, Conrad CA. Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies. Neuro Oncol 4(4)(4):268-77, 2002. e-Pub 2002. PMID: 12356357.
Koul D, Shen R, Garyali A, Ke LD, Liu TJ, Yung WK. MMAC/PTEN tumor suppressor gene regulates vascular endothelial growth factor-mediated angiogenesis in prostate cancer. Int J Oncol 21(15)(3):469-75, 2002. e-Pub 2002. PMID: 12168088.
Levin VA, Yung WK, Bruner J, Kyritsis A, Leeds N, Gleason MJ, Hess KR, Meyers CA, Ictech SA, Chang E, Maor MH. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys 53(1):58-66, 2002. e-Pub 2002. PMID: 12007942.
Robins HI, Chang SM, Prados MD, Yung WK, Hess K, Schiff D, Greenberg H, Fink K, Nicolas K, Kuhn JG, Cloughesy T, Junck L, Mehta M. A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study. Neuro Oncol 4(2)(2):109-14, 2002. e-Pub 2002. PMID: 11916502.
Koul D, Jasser SA, Lu Y, Davies MA, Shen R, Shi Y, Mills GB, Yung WK. Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Oncogene 21(15)(15):2357-64, 2002. e-Pub 2002. PMID: 11948419.
Sheng X, Koul D, Liu JL, Liu TJ, Yung WK. Promoter analysis of tumor suppressor gene PTEN: identification of minimum promoter region. Biochem Biophys Res Commun 292(2)(2):422-6, 2002. e-Pub 2002. PMID: 11906179.
Groves MD, Puduvalli VK, Hess KR, Jaeckle KA, Peterson P, Yung WK, Levin VA. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 20(5)(5):1383-88, 2002. e-Pub 2002. PMID: 11870183.
Ke LD, Shi YX, Yung WK. VEGF(121), VEGF(165) overexpression enhances tumorigenicity in U251 MG but not in NG-1 glioma cells. Cancer Res 62(6):1854-61, 2002. e-Pub 2002. PMID: 11912165.
Kunschner LJ, Fine H, Hess K, Jaeckle K, Kyritsis AP, Yung WK. CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980. Cancer Invest 20(7 & 8)(7-8):948-54, 2002. e-Pub 2002. PMID: 12449727.
Liu JL, Sheng X, Koul D, Yung WKA. Cell cycle-dependent subcellular localization of PTEN/MMAC tumor suppressor is regulated by PI3K signaling cascades. Neuro-Oncology 4(4):315, 2002. e-Pub 2002.
Koul D, Parthasarathy R, Shen R, Davies MA, Jasser SA, Chintala SK, Rao JS, Sun Y, Benvenisite EN, Liu TJ, Yung WK. Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN. Oncogene 20(46):6669-78, 2001. e-Pub 2001. PMID: 11709701.
Gomez-Manzano C, Mitlianga P, Fueyo J, Lee HY, Hu M, Spurgers KB, Glass TL, Koul D, Liu TJ, McDonnell TJ, Yung WK. Transfer of E2F-1 to human glioma cells results in transcriptional up-regulation of Bcl-2. Cancer Res 61(18)(18):6693-97, 2001. e-Pub 2001. PMID: 11559537.
Mohanam S, Jasti SL, Kondraganti SR, Chandrasekar N, Kin Y, Fuller GN, Lakka SS, Kyritsis AP, Dinh DH, Olivero WC, Gujrati M, Yung WK, Rao JS. Stable transfection of urokinase-type plasminogen activator antisense construct modulates invasion of human glioblastoma cells. Clin Cancer Res 7(8)(8):2519-26, 2001. e-Pub 2001. PMID: 11489835.
Wang ML, Yung WK, Royce ME, Schomer DF, Theriault RL. Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. Am J Clin Oncol 24(4)(4):421-24, 2001. e-Pub 2001. PMID: 11474279.
Gomez-Manzano C, Lemoine MG, Hu M, He J, Mitlianga P, Liu TJ, Yung AW, Fueyo J, Groves MD. Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU. Int J Oncol 19:359-65, 2001. e-Pub 2001. PMID: 11445852.
Mohanam S, Jasti SL, Kondraganti SR, Chandrasekar N, Lakka SS, Kin Y, Fuller GN, Yung AW, Kyritsis AP, Dinh DH, Olivero WC, Gujrati M, Ali-Osman F, Rao JS. Down-regulation of cathepsin B expression impairs the invasive and tumorigenic potential of human glioblastoma cells. Oncogene 20:3665-73, 2001. e-Pub 2001. PMID: 11439329.
Im SA, Kim JS, Gomez-Manzano C, Fueyo J, Liu TJ, Cho MS, Seong CM, Lee SN, Hong YK, Yung WK. Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF. Br J Cancer 84(9)(9):1252-7, 2001. e-Pub 2001. PMID: 11336478.
Cerrato JA, Yung WK, Liu TJ. Introduction of mutant p53 into a wild-type p53-expressing glioma cell line confers sensitivity to Ad-p53-induced apoptosis. Neuro Oncol 3(2)(2):113-22, 2001. e-Pub 2001. PMID: 11296482.
Lakka SS, Rajagopal R, Rajan MK, Mohan PM, Adachi Y, Dinh DH, Olivero WC, Gujrati M, Ali-Osman F, Roth JA, Yung WK, Kyritsis AP, Rao JS. Adenovirus-mediated antisense urokinase-type plasminogen activator receptor gene transfer reduces tumor cell invasion and metastasis in non-small cell lung cancer cell lines. Clin Cancer Res 7(4)(4):1087-93, 2001. e-Pub 2001. PMID: 11309361.
Koul D, Yao Y, Abbruzzese JL, Yung WK, Reddy SA. Tumor suppressor MMAC/PTEN inhibits cytokine-induced NFkappaB activation without interfering with the IkappaB degradation pathway. J Biol Chem 276(14)(14):11402-408, 2001. e-Pub 2001. PMID: 11278366.
Mitlianga PG, Kyritsis AP, Gomez-Manzano C, Lemoine MG, Hu M, Liu TJ, Yung WK, Fueyo J. Co-expression of E2F-2 enhances the p53 anti-cancer effect in human glioma cells. Int J Oncol 18(2)(2):343-47, 2001. e-Pub 2001. PMID: 11172602.
Kunschner, Kuttesch J, Hess K, Yung, WKA. Survival and recurrence factors in adult medulloblastoma: The M.D. Anderson Cancer Center experience from 1978 to 1998. Neuro Oncol 3(3)(3):167-173, 2001. e-Pub 2001. PMID: 11465397.
Mehta M, Yung WK, Bullard D, Barger G, Choucair A, Gillin M, Grossman S, Guha A, Hammond ME, Michalski J, Prados M, Provins S, Scott C, Zamorano L. Radiation Therapy Oncology Group. Research Plan 2002-2006. Brain Tumor Committee. Int J Radiat Oncol Biol Phys 51(3 Supplement 2)(3 Suppl 2):11-8, 2001. e-Pub 2001. PMID: 11641010.
Ajani J, Ettinger D, Kelsen DP, Hudis C, Kudelka A, Langer C, Pienta K, Safran H, Vokes EE, Yung WK. Radiation Therapy Oncology Group. Research Plan 2002-2006. Medical Oncology Committee. Int J Radiat Oncol Biol Phys 51(3 Supplement 2)(3 Suppl 2):88-91, 2001. e-Pub 2001. PMID: 11641021.
Chandrasekar N, Jasti S, Yung AWK, Ali-Osman F, Dinh DH, Olivero WC, Gujrati, M, Mohanam S. Modulation of endothelial cell morphogenesis in vitro by MMP-9 during glial-endothelial cell interactions. Clin and Experi Metastasis 18(4):337-42, 2001. e-Pub 2001.
Levin VA, Uhm JH, Jaeckle KA, Choucair A, Flynn PJ, Yung WKA PJ, Prados MD, Bruner JM, Chang SM, Kyritsis AP, Gleason MJ, Hess KR. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res 6(10):3878-84, 2000. e-Pub 2000. PMID: 11051233.
Osoba D, Brada M, Prados MD, Yung WK. Effect of disease burden on health-related quality of life in patients with malignant gliomas. Neuro Oncol 2(4)(4):221-8, 2000. e-Pub 2000. PMID: 11265231.
Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83(5)(5):588-93, 2000. e-Pub 2000. PMID: 10944597.
Osoba D, Brada M, Yung WK, Prados MD. Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur J Cancer 36(14)(14):1788-95, 2000. e-Pub 2000. PMID: 10974627.
Hong YK, Chung DS, Joe YA, Yang YJ, Kim KM, Park YS, Yung WK, Kang JK. Efficient inhibition of in vivo human malignant glioma growth and angiogenesis by interferon-beta treatment at early stage of tumor development. Clin Cancer Res 6(8)(8):3354-60, 2000. e-Pub 2000. PMID: 10955823.
Glass TL, Liu TJ, Yung WK. Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336. Neuro Oncol 2(3)(3):151-8, 2000. e-Pub 2000. PMID: 11302335.
Hong YK, Joe YA, Yang YJ, Lee KS, Son BC, Jeun SS, Chung DS, Cho KK, Park CK, Kim MC, Kim HK, Yung WK, Kang JK. Potentials and limitations of adenovirus-p53 gene therapy for brain tumors. J Korean Med Sci 15(3)(3):315-22, 2000. e-Pub 2000. PMID: 10895975.
Ke LD, Shi YX, Im SA, Chen X, Yung WK. The relevance of cell proliferation, vascular endothelial growth factor, and basic fibroblast growth factor production to angiogenesis and tumorigenicity in human glioma cell lines. Clin Cancer Res 6(6):2562-72, 2000. e-Pub 2000. PMID: 10873113.
Brada M, Yung WK. Clinical trial end points in malignant glioma: need for effective trial design strategy. Semin Oncol 27 (3 Supplement)(3 Suppl 6):11-9, 2000. e-Pub 2000. PMID: 10866345.
Osoba D, Brada M, Yung WK, Prados M. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol 18(7)(7):1481-91, 2000. e-Pub 2000. PMID: 10735896.
Ke LD, Chen Z, Yung WK. A reliability test of standard-based quantitative PCR: exogenous vs endogenous standards. Mol Cell Probes 14(2)(2):127-35, 2000. e-Pub 2000. PMID: 10799275.
Meyers CA, Hess KR, Yung WK, Levin VA. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 18(3)(3):646-50, 2000. e-Pub 2000. PMID: 10653880.
Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18(4):708-15, 2000. e-Pub 2000. PMID: 10673511.
Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, Shi YX, Levin VA, Yung WK, Kyritsis AP. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19(1)(1):2-12, 2000. e-Pub 2000. PMID: 10644974.
Lakka SS, Jasti SL, Kyritsis AP, Yung WK, Ali-Osman F, Nicolson GL, Rao JS. Regulation of MMP-9 (type IV collagenase) production and invasiveness in gliomas by the extracellular signal-regulated kinase and jun amino-terminal kinase signaling cascades. Clin Exp Metastasis 18(93)(3):245-52, 2000. e-Pub 2000. PMID: 11315098.
Huai, Bondy ML, Langford LA, Hess KR, Delclos GL, Uw X, Chan W, Pershouse MA, Yung WKA, Steck PA. Allelic deletion analysis of MMAC/PTEN and DMBT1 loci in gliomas: Relationship to prognostic significance. Clin Cancer Research 4:2447-2454, 2000. e-Pub 2000.
Fine HA, Figg WD, Jaeckle KA, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK. A Phase II trial of the anti-angiogenic agent, thalidomide, in patients with recurrent high grade gliomas. J Clin Oncology 18(4):708-15, 2000. e-Pub 2000.
Levin VA, Uhm JH, Jaeckle KA, Choucair A, Flynn PJ, Yung WKA, Prados MD, Bruner JM, Chang SM, Kyritsis AP, Gleason MJ, Hess KR. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N’-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res 6(10):3878-3884, 2000. e-Pub 2000.
Yung WK. BUdR radiosensitization in anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 45(5):1105-6, 1999. e-Pub 1999. PMID: 10613300.
Chintala SK, Kyritsis AP, Mohan PM, Mohanam S, Sawaya R, Gokslan Z, Yung WK, Steck P, Uhm JH, Aggarwal BB, Rao JS. Altered actin cytoskeleton and inhibition of matrix metalloproteinase expression by vanadate and phenylarsine oxide, inhibitors of phosphotyrosine phosphatases: modulation of migration and invasion of human malignant glioma cells. Mol Carcinog 26(4):274-85, 1999. e-Pub 1999. PMID: 10569804.
Hess KR, Wong ET, Jaeckle KA, Kyritsis AP, Levin VA, Prados MD, Yung WK. Response and progression in recurrent malignant glioma. Neuro-Oncol 1(4):282-8, 1999. e-Pub 1999. PMID: 11550320.
Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17(9):2762-71, 1999. e-Pub 1999. PMID: 10561351.
Fuller GN, Rhee CH, Hess KR, Caskey LS, Wang R, Bruner JM, Yung WK, Zhang W. Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Cancer Res 59(17):4228-32, 1999. e-Pub 1999. PMID: 10485462.
Groves MD, Maor MH, Meyers C, Kyritsis AP, Jaeckle KA, Yung WK, Sawaya RE, Hess K, Bruner JM, Peterson P, Levin VA. A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 45(1):127-35, 1999. e-Pub 1999. PMID: 10477016.
Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17(8):2572-8, 1999. e-Pub 1999. PMID: 10561324.
Tang P, Jasser SA, Sung JC, Shi Y, Steck PA, Yung WK. Transforming growth factor-alpha antisense vectors can inhibit glioma cell growth. J Neurooncol 43(2):127-35, 1999. e-Pub 1999. PMID: 10533724.
Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ, McConkey D, Yung WK, Steck PA. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res 59(11):2551-6, 1999. e-Pub 1999. PMID: 10363971.
Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML, Hess KR, Myers JN, Hong YK, Yung WK, Steck PA. Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res 59(8):1820-4, 1999. e-Pub 1999. PMID: 10213484.
Rhee CH, Ruan S, Chen S, Chenchik A, Levin VA, Yung AW, Fuller GN, Zhang W. Characterization of cellular pathways involved in glioblastoma response to the chemotherapeutic agent 1, 3-bis(2-chloroethyl)-1-nitrosourea (BCNU) by gene expression profiling. Oncol Rep 6:393-401, 1999. e-Pub 1999. PMID: 10023010.
Steck PA, Lin H, Langford LA, Jasser SA, Koul D, Yung WK, Pershouse MA. Functional and molecular analyses of 10q deletions in human gliomas. Genes Chromosomes Cancer 24(2):135-43, 1999. e-Pub 1999. PMID: 9885980.
Im SA, Gomez-Manzano C, Fueyo J, Liu TJ, Ke LD, Kim JS, Lee HY, Steck PA, Kyritsis AP, Yung WK. Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res 59(4):895-900, 1999. e-Pub 1999. PMID: 10029081.
Uhm Yung WK. Neurologic Complications of Cancer Therapy. Curr Treat Options Neurol 5(1):428-437, 1999. e-Pub 1999.
Gomez-Manzano Yung WKA. Gene Therapy for Gliomas. BioMedicina 2, 1999. e-Pub 1999.
Gomez-Manzano C, Fueyo J, Alameda F, Kyritsis AP, Yung WKA. Gene therapy for gliomas: p53 and E2f1 proteins and the target of apoptosis. Bioorganic & Medicinal Chemistry Letters 3:81-85, 1999. e-Pub 1999.
Davies MA, Lu Y, Sano T, Fang X, Tang P, LaPushin R, Koul D, Bookstein R, Stokoe D, Yung WK, Mills GB, Steck PA. Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res 58(23):5285-90, 1998. e-Pub 1998. PMID: 9850049.
Sigurdson AJ, Bondy ML, Hess KR, Toms SA, Kyritsis AP, Gu J, Wang LE, Wang X, Adatto P, Bruner JL, Yung WK, Levin VA, Wei Q. Gamma-ray mutagen sensitivity and survival in patients with glioma. Clin Cancer Res 4(12):3031-5, 1998. e-Pub 1998. PMID: 9865917.
Ke LD, Adler-Storthz K, Clayman GL, Yung AW, Chen Z. Differential expression of epidermal growth factor receptor in human head and neck cancers. Head Neck 20:320-7, 1998. e-Pub 1998. PMID: 9588705.
Lang FF, Yung WK, Raju U, Libunao F, Terry NH, Tofilon PJ. Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene. J Neurosurg 89(1):125-32, 1998. e-Pub 1998. PMID: 9647183.
Ke LD, Fueyo J, Chen X, Steck PA, Shi YX, Im SA, Yung WK. A novel approach to glioma gene therapy: down-regulation of the vascular endothelial growth factor in glioma cells using ribozymes. Int J Oncol 12(6):1391-6, 1998. e-Pub 1998. PMID: 9592205.
Fueyo J, Gomez-Manzano C, Yung WK, Liu TJ, Alemany R, McDonnell TJ, Shi X, Rao JS, Levin VA, Kyritsis AP. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat Med 4:685-90, 1998. e-Pub 1998. PMID: 9623977.
Fueyo J, Gomez-Manzano C, Yung WK, Liu TJ, Alemany R, Bruner JM, Chintala SK, Rao JS, Levin VA, Kyritsis AP. Suppression of human glioma growth by adenovirus-mediated Rb gene transfer. Neurology 50:1307-15, 1998. e-Pub 1998. PMID: 9595979.
Hess KR, Wong ET, Yung WK. Assessing response to chemotherapy in malignant glioma: the role of steroids. Neurology 50(4):1197-1198, 1998. e-Pub 1998. PMID: 9566439.
Ligon AH, Pershouse MA, Jasser S, Hong YK, Yung WK, Steck PA. Differentially expressed gene products in glioblastoma cells suppressed for tumorigenicity. J Neurovirol 4(2):217-26, 1998. e-Pub 1998. PMID: 9584958.
Fueyo J, Gomez-Manzano C, Puduvalli VK, Martin-Duque P, Perez-Soler R, Levin VA, Yung WK, Kyritsis AP. Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: implications for therapy. Int J Oncol 12(3):665-9, 1998. e-Pub 1998. PMID: 9472109.
Wong ET, Jackson EF, Hess KR, Schomer DF, Hazle JD, Kyritsis AP, Jaeckle KA, Yung WK, Levin VA, Leeds NE. Correlation between dynamic MRI and outcome in patients with malignant gliomas. Neurology 50(3):777-81, 1998. e-Pub 1998. PMID: 9521274.
Fueyo J, Gomez-Manzano C, Yung WKA, Liu TJ, Alemany R, Bruner J, Levin VA, Kyritsis AP. Adenovirus-mediated Rb gene transfer suppresses human glioma growth. Neurology 50(5):1307-15, 1998. e-Pub 1998.
Huai L, Bondy ML, Langford LA, Hess KR, Delclos GL, Uw X, Chan W, Pershouse MA, Yung WKA, Steck PA. Allelic deletion analysis of mMAC/PTEN and DMBT1 loci in gliomas: Relationship to prognostic significance. Clin Ca Research 4(10):2447-2454, 1998. e-Pub 1998.
Puduvalli VP, Yung WKA. New frontiers in the therapy of malignant gliomas: Trends in experimental medicine and therapeutics. Forum 8:261-69, 1998. e-Pub 1998.
Fueyo, Gomez-Manzano C, Mitlianga P, Lagos G, Yung WKA, Kyritsis AP. p16/Rb/E2F-1 Pathway in Gliomas: from Function to Therapy. Biotech Lab International 3:22-23, 1998. e-Pub 1998.
Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, Swedlund B, Hansen KL, Vinson VL, Gumpper KL, Ellis L, El-Naggar A, Frazier M, Jasser S, Langford LA, Lee J, Mills GB, Pershouse MA, Pollack RE, Tornos C, Troncoso P, Yung WK, Fujii G, Berson A, Bookstein R, Bolen JB< Tavtigian SV, Steck PA. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 57(23):5221-5, 1997. e-Pub 1997. PMID: 9393738.
Pershouse MA, Ligon AH, Pereira-Smith OM, Killary AM, Yung WK, Steck PA. Suppression of transformed phenotype and tumorigenicity after transfer of chromosome 4 into U251 human glioma cells. Genes Chromosomes Cancer 20(3):260-7, 1997. e-Pub 1997. PMID: 9365833.
Chintala SK, Fueyo J, Gomez-Manzano C, Venkaiah B, Bjerkvig R, Yung WK, Sawaya R, Kyritsis AP, Rao JS. Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro. Oncogene 15(17):2049-57, 1997. e-Pub 1997. PMID: 9366522.
Osoba D, Aaronson NK, Muller M, Sneeuw K, Hsu MA, Yung WK, Brada M, Newlands E. Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma. J Neurooncol 34(3):263-78, 1997. e-Pub 1997. PMID: 9258818.
Kaba SE, Kyritsis AP, Conrad C, Gleason MJ, Newman R, Levin VA, Yung WK. The treatment of recurrent cerebral gliomas with all-trans-retinoic acid (tretinoin). J Neurooncol 34(2):145-51, 1997. e-Pub 1997. PMID: 9210061.
Gomez-Manzano C, Fueyo J, Kyritsis AP, McDonnell TJ, Steck PA, Levin VA, Yung WK. Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J Natl Cancer Inst 89(14):1036-44, 1997. e-Pub 1997. PMID: 9230885.
Sneeuw KC, Aaronson NK, Osoba D, Muller MJ, Hsu MA, Yung WK, Brada M, Newlands ES. The use of significant others as proxy raters of the quality of life of patients with brain cancer. Med Care 35(5):490-506, 1997. e-Pub 1997. PMID: 9140337.
Wei Q, Bondy ML, Mao L, Gaun Y, Cheng L, Cunningham J, Fan Y, Bruner JM, Yung WK, Levin VA, Kyritsis AP. Reduced expression of mismatch repair genes measured by multiplex reverse transcription-polymerase chain reaction in human gliomas. Cancer Res 57(9):1673-7, 1997. e-Pub 1997. PMID: 9135006.
Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15(4):356-62, 1997. e-Pub 1997. PMID: 9090379.
Kaba SE, Kyritsis AP, Hess K, Yung WK, Mercier R, Dakhil S, Jaeckle KA, Levin VA. TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. J Clin Oncol 15(3):1063-70, 1997. e-Pub 1997. PMID: 9060546.
Ligon AH, Pershouse MA, Jasser SA, Yung WK, Steck PA. Identification of a novel gene product, RIG, that is down-regulated in human glioblastoma. Oncogene 14(9):1075-81, 1997. e-Pub 1997. PMID: 9070656.
Pershouse MA, El-Naggar AK, Hurr K, Lin H, Yung WK, Steck PA. Deletion mapping of chromosome 4 in head and neck squamous cell carcinoma. Oncogene 14(3):369-73, 1997. e-Pub 1997. PMID: 9018123.
Yung W. A Phase II Radiation Therapy Oncology Group study (RTOG 91-13) in patients with recurrent malignant astrocytoma. J of Neuro-Oncology 34(2):193-200, 1997. e-Pub 1997.
Phuphanich S, Scott C, Fischbach AJ, Langer C, Yung WKA. All trans-retinoic acid A phase II Radiation Therapy Oncology Grop Study (RTOG 91-13) in patients with recurrent malignant astrocytoma. Journal of Neuro-Oncology 34(92):193-200, 1997. e-Pub 1997.
Kaba SE, DeMonte F, Bruner JM, Kyritsis AP, Jaeckle KA, Levin V, Yung WKA. The treatment of recurrent unresectable and malignant meningiomas with interferon-alpha-2b. Neurosurgery 40(2):271-75, 1997. e-Pub 1997.
Chin LS, Yung WKA, Raffel C. Two primitive neuroectodermal tumor cell lines require an activated insulin-like growth factor I receptor for growth in vitro. Neurosurgery 39(6):1183-90, 1997. e-Pub 1997.
Fueyo, Gomez-Manzano C, Bruner JM, Saito Y, Zhang B, Zhang W, Levin VA, Yung WKA, Kyritsis AP. Hypomethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas. Oncogene 13(8):1615-1619, 1997. e-Pub 1997.
Yung WK, Kyritsis AP, Gleason MJ, Levin VA. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. Clin Cancer Res 2(12):1931-5, 1996. e-Pub 1996. PMID: 9816151.
Kyritsis AP, Yung WK, Jaeckle KA, Bruner J, Gleason MJ, Ictech SE, Flowers A, Levin VA. Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. Neurosurgery 39(5):921-6, 1996. e-Pub 1996. PMID: 8905746.
Kaba SE, Langford LA, Yung WK, Kyritsis AP. Resolution of recurrent malignant ganglioglioma after treatment with cis-retinoic acid. J Neurooncol 30(1):55-60, 1996. e-Pub 1996. PMID: 8865003.
Rao JS, Sawaya R, Gokaslan ZL, Yung WK, Goldstein GW, Laterra J. Modulation of serine proteinases and metalloproteinases during morphogenic glial-endothelial interactions. J Neurochem 66(4):1657-64, 1996. e-Pub 1996. PMID: 8627323.
Osoba D, Aaronson NK, Muller M, Sneeuw K, Hsu MA, Yung WK, Brada M, Newlands E. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res 5(1):139-50, 1996. e-Pub 1996. PMID: 8901377.
Gomez-Manzano C, Fueyo J, Kyritsis AP, Steck PA, Roth JA, McDonnell TJ, Steck KD, Levin VA, Yung WK. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res 56(4):694-9, 1996. e-Pub 1996. PMID: 8630997.
Fueyo J, Gomez-Manzano C, Yung WK, Clayman GL, Liu TJ, Bruner J, Levin VA, Kyritsis AP. Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene 12(1):103-10, 1996. e-Pub 1996.
Kyritsis AP, Bondy ML, Hess KR, Cunningham JE, Zhu D, Amos CJ, Yung WK, Levin VA, Bruner JM. Prognostic significance of p53 immunoreactivity in patients with glioma. Clin Cancer Res 1(12):1617-22, 1995. e-Pub 1995. PMID: 9815964.
Fueyo J, Gomez-Manzano C, Yung WK, Zhang W, Lee PS, Majumder S, Perhouse M, Levin VA, Kyritsis AP. A frequent polymorphism in exon 1 of the p16/CDKN2 gene. Mol Cell Probes 9(6):465-6, 1995. e-Pub 1995. PMID: 8808318.
Levin VA, Maor MH, Thall PF, Yung WK, Bruner J, Sawaya R, Kyritsis AP, Leeds N, Woo S, Rodriguez L, et al. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 33(2):357-64, 1995. e-Pub 1995. PMID: 7673023.
Korkmaz M, Kim EE, Wong FC, Podoloff DA, Haynie TP, Yung A. In-111 DTPA Ommayagrams in leptomeningeal carcinomatosis. Clin Nucl Med 20(7):610-2, 1995. e-Pub 1995. PMID: 7554663.
Steck PA, Ligon AH, Cheong P, Yung WK, Pershouse MA. Two tumor suppressive loci on chromosome 10 involved in human glioblastomas. Genes Chromosomes Cancer 12(4):255-61, 1995. e-Pub 1995. PMID: 7539279.
Van Tassel P, Bruner JM, Maor MH, Leeds NE, Gleason MJ, Yung WK, Levin VA. MR of toxic effects of accelerated fractionation radiation therapy and carboplatin chemotherapy for malignant gliomas. AJNR Am J Neuroradiol 16(4):715-26, 1995. e-Pub 1995. PMID: 7611028.
Pershouse MA, Stubblefield E, Hadi A, Killary AM, Yung WK, Steck PA. Analysis of the functional role of chromosome 10 loss in human glioblastomas. Cancer Res 53(20):5043-50, 1993. e-Pub 1993. PMID: 8104691.
Janus TJ, Kim EE, Tilbury R, Bruner JM, Yung WK. Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Ann Neurol 33(5):540-8, 1993. e-Pub 1993. PMID: 8498831.
Kyritsis AP, Levin VA, Yung WK, Leeds NE. Imaging patterns of multifocal gliomas. Eur J Radiol 16(3):163-70, 1993. e-Pub 1993. PMID: 8389708.
Meyers CA, Yung WK. Delayed neurotoxicity of intraventricular interleukin-2: a case report. J Neurooncol 15(3):265-7, 1993. e-Pub 1993. PMID: 8360712.
Kyritsis AP, Yung WK, Bruner J, Gleason MJ, Levin VA. The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery 32(3):365-70; discussion 371, 1993. e-Pub 1993. PMID: 8455760.
Steck PA, Bruner J, Pershouse MA, Hadi A, Conrad CA, Yung WKA, Saya H. Molecular, genetic, and biologic aspects of primary brain tumors. The Cancer Bulletin 45:296-302, 1993. e-Pub 1993.
Levin VA, Prados MD, Yung WK, Gleason MJ, Ictech S, Malec M. Treatment of recurrent gliomas with eflornithine. J Natl Cancer Inst 84(18):1432-7, 1992. e-Pub 1992. PMID: 1380989.
Kyritsis AP, Yung WK, Leeds NE, Bruner J, Gleason MJ, Levin VA. Multifocal cerebral gliomas associated with secondary malignancies. Lancet 339(8803):1229-30, 1992. e-Pub 1992. PMID: 1349958.
Kim EE, Chung SK, Haynie TP, Kim CG, Cho BJ, Podoloff DA, Tilbury RS, Yang DJ, Yung WK, Moser RP, Jr, et al. Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET. Radiographics 12(2):269-79, 1992. e-Pub 1992. PMID: 1561416.
Yung WK, Janus TJ, Maor M, Feun LG. Adjuvant chemotherapy with carmustine and cisplatin for patients with malignant gliomas. J Neurooncol 12:131-5, 1992. e-Pub 1992. PMID: 1560258.
Yung WK, Prados M, Levin VA, Fetell MR, Bennett J, Mahaley MS, Salcman M, Etcubanas E. Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study. J Clin Oncol 9(11):1945-9, 1991. e-Pub 1991. PMID: 1658242.
Yung WK, Mechtler L, Gleason MJ. Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol 9(5):860-4, 1991. e-Pub 1991. PMID: 1849986.
Garden AS, Maor MH, Yung WK, Bruner JM, Woo SY, Moser RP, Lee YY. Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas. Radiother Oncol 20(2):99-110, 1991. e-Pub 1991. PMID: 1851573.
Feun, Savaraj N, Lee YY, Landy H, Martinez-Prieto J, Charnsangavej C, Post JD, Lee KF, Wallace S, Bowen B, Kochan P, Yung WKA. A pilot clinical and pharmacokinetic study of intracarotid cisplatin and bleomycin. Selective Cancer Therapeutics 7:29-36, 1991. e-Pub 1991.
Newton LK, Yung WK, Pettigrew LC, Steck PA. Growth regulatory activities of endothelial extracellular matrix: mediation by transforming growth factor-beta. Exp Cell Res 190(1):127-32, 1990. e-Pub 1990. PMID: 2387324.
Yung WK, Zhang X, Steck PA, Hung MC. Differential amplification of the TGF-alpha gene in human gliomas. Cancer Commun 2(6):201-5, 1990. e-Pub 1990. PMID: 2165797.
Rosenblum MG, Yung WK, Kelleher PJ, Ruzicka F, Steck PA, Borden EC. Growth inhibitory effects of interferon-beta but not interferon-alpha on human glioma cells: correlation of receptor binding, 2',5'-oligoadenylate synthetase and protein kinase activity. J Interferon Res 10(2):141-51, 1990. e-Pub 1990. PMID: 2140395.
Steck PA, Hadi A, Lotan R, Yung WK. Inhibition of epidermal growth factor receptor activity by retinoic acid in glioma cells. J Cell Biochem 42(1):83-94, 1990. e-Pub 1990. PMID: 2307713.
Yung WK, Castellanos AM, Van Tassel P, Moser RP, Marcus SG. A pilot study of recombinant interferon beta (IFN-beta ser) in patients with recurrent glioma. J Neurooncol 9(1):29-34, 1990. e-Pub 1990. PMID: 2082958.
Yung WK, Lotan R, Lee P, Lotan D, Steck PA. Modulation of growth and epidermal growth factor receptor activity by retinoic acid in human glioma cells. Cancer Res 49(4):1014-9, 1989. e-Pub 1989. PMID: 2912547.
Maria BL, Steck PA, Yung WK, Milici A, Bruner JM, Pathak S, Becker FF. The modulation of astrocytic differentiation in cells derived from a medulloblastoma surgical specimen. J Neurooncol 7(4):329-38, 1989. e-Pub 1989. PMID: 2555453.
Yung WK, Harris MI, Bruner JM, Feun LG. Intravenous BCNU and AZQ in patients with recurrent malignant gliomas. J Neurooncol 7(3):237-40, 1989. e-Pub 1989. PMID: 2795118.
Steck PA, Moser RP, Bruner JM, Liang L, Freidman AN, Hwang TL, Yung WK. Altered expression and distribution of heparan sulfate proteoglycans in human gliomas. Cancer Res 49(8):2096-103, 1989. e-Pub 1989. PMID: 2522816.
Frappaz D, Singletary SE, Spitzer G, Yung A. Enhancement of growth of primary metastatic fresh human tumors of the nervous system by epidermal growth factor in serum-free short term culture. Neurosurgery 23:355-9, 1988. e-Pub 1988. PMID: 3265764.
McLaughlin P, Velasquez WS, Redman JR, Yung WK, Hagemeister FB, Rodriguez MA, Cabanillas F. Chemotherapy with dexamethasone, high-dose cytarabine, and cisplatin for parenchymal brain lymphoma. J Natl Cancer Inst 80(17):1408-12, 1988. e-Pub 1988. PMID: 3172268.
Steck PA, Lee P, Hung MC, Yung WK. Expression of an altered epidermal growth factor receptor by human glioblastoma cells. Cancer Res 48(19):5433-9, 1988. e-Pub 1988. PMID: 3416300.
Iwata K, Yung WK, Fields WS. In vitro effects of ACNU, BCNU, CDDP, and bleomycin on human glioma cells. Neurol Med Chir (Tokyo) 28(10):965-9, 1988. e-Pub 1988. PMID: 2462685.
Castellanos AM, Glass JP, Yung WK. Regional nerve injury after intra-arterial chemotherapy. Neurology 37(5):834-7, 1987. e-Pub 1987. PMID: 3033546.
Steck PA, Cheong PH, Nakajima M, Yung WK, Moser RP, Nicolson GL. Altered expression of glycosaminoglycans in metastatic 13762NF rat mamma adenocarcinoma cells. Biochemistry 26(4):1020-8, 1987. e-Pub 1987. PMID: 3567153.
Feun LG, Lee YY, Yung WK, Savaraj N, Wallace S. Intracarotid VP-16 in malignant brain tumors. J Neurooncol 4(4):397-401, 1987. e-Pub 1987. PMID: 3572470.
Yung WK, Steck PA, Kelleher PJ, Moser RP, Rosenblum MG. Growth inhibitory effect of recombinant alpha and beta interferon on human glioma cells. J Neurooncol 5(4):323-30, 1987. e-Pub 1987. PMID: 2964515.
Feun LG, Lee YY, Yung WK, Charnsangavej C, Savaraj N, Tang RA, Wallace S. Phase II trial of intracarotid BCNU and cisplatin in primary malignant brain tumors. Cancer Drug Deliv 3(2):147-56, 1986. e-Pub 1986. PMID: 3708537.
Steck PA, Gallick GE, Maxwell SA, Kloetzer WS, Arlinghaus RB, Moser RP, Gutterman JU, Yung WK. Expression of epidermal growth factor receptor and associated glycoprotein on cultured human brain tumor cells. J Cell Biochem 32(1):1-10, 1986. e-Pub 1986. PMID: 3533968.
Fainstein V, Leavens M, Moser C, Bray R, Obbens E, Yung WK, Glass P, Mansell PW. Brain and meningeal biopsy in patients with acquired immunodeficiency syndrome. Tex Med 82(1):40-5, 1986. e-Pub 1986. PMID: 3003948.
Hwang TL, Yung WK, Lee YY, Borit A, Fields WS. High dose Ara-C related leukoencephalopathy. J Neurooncol 3(4):335-9, 1986. e-Pub 1986. PMID: 3457103.
Hromas RA, Yung WK. Anguidine potentiates cis-platinum in human brain tumor cells. J Neurooncol 3(4):343-8, 1986. e-Pub 1986. PMID: 3958780.
Hwang TL, Yung WK, Estey EH, Fields WS. Central nervous system toxicity with high-dose Ara-C. Neurology 35(10):1475-9, 1985. e-Pub 1985. PMID: 4033929.
Feun LG, Yung WK, Stewart DJ, Savaraj N, Bodey GP. Phase II trial of mitogauzone in malignant primary brain tumors. Cancer Treat Rep 69(3):329-30, 1985. e-Pub 1985. PMID: 3978660.
Yung WK, Luna M, Borit A. Vimentin and glial fibrillary acidic protein in human brain tumors. J Neurooncol 3(1):35-8, 1985. e-Pub 1985. PMID: 3889231.
Feun LG, Wallace S, Stewart DJ, Chuang VP, Yung WK, Leavens ME, Burgess MA, Savaraj N, Benjamin RS, Young SE, Tang RA, Handel S, Mavligit G, Fields WS. Intracarotid infusion of cis-diamminedichloroplatinum in the treatment of recurrent malignant brain tumors. Cancer 54(5):794-9, 1984. e-Pub 1984. PMID: 6331626.
Feun LG, Wallace S, Yung WK, Lee YY, Leavens ME, Moser R, Savaraj N, Burgess MA, Plager C, Benjamin RS, tang RA, Mavligit GM, Fields WS. Phase-I trial of intracarotid BCNU and cisplatin in patients with malignant intracerebral tumors. Cancer Drug Deliv 1(3):239-45, 1984. e-Pub 1984. PMID: 6544123.
Feun LG, Yung WK, Leavens ME, Burgess MA, Obbens EA, Bedikian AY, Savaraj N, Stewart DJ, Benjamin RS, Fields WS, et al. A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors. J Neurooncol 2(1):13-7, 1984. e-Pub 1984. PMID: 6088722.
Wang E, Cairncross JG, Yung WK, Garber EA, Liem RK. An intermediate filament-associated protein, p50, recognized by monoclonal antibodies. J Cell Biol 97:1507-14, 1983. e-Pub 1983. PMID: 6355121.
Yung WK, Tepper SJ, Young DF. Diffuse bone marrow metastasis by glioblastoma: premortem diagnosis by peroxidase-antiperoxidase staining for glial fibrillary acidic protein. Ann Neurol 14(5):581-5, 1983. e-Pub 1983. PMID: 6316836.
Feun LG, Stewart DJ, Maor M, Leavens M, Savaraj N, Burgess MA, Yung WK, Benjamin RS. A pilot study of cis-diamminedichloroplatinum and radiation therapy in patients with high grade astrocytomas. J Neurooncol 1(2):109-13, 1983. e-Pub 1983. PMID: 6088710.
Yung WK, Shapiro JR, Shapiro WR. Heterogeneous chemosensitivities of subpopulations of human glioma cells in culture. Cancer Res 42(3):992-8, 1982. e-Pub 1982. PMID: 7199383.
Shapiro WR, Yung WA, Basler GA, Shapiro JR. Heterogeneous response to chemotherapy of human gliomas grown in nude mice and as clones in vitro. Cancer Treat Rep 65 Suppl 2:55-9, 1981. e-Pub 1981. PMID: 7346147.
Shapiro JR, Yung WK, Shapiro WR. Isolation, karyotype, and clonal growth of heterogeneous subpopulations of human malignant gliomas. Cancer Res 41(6):2349-59, 1981. e-Pub 1981. PMID: 7016313.
Yung WA, Horten BC, Shapiro WR. Meningeal gliomatosis: a review of 12 cases. Ann Neurol 8:605-8, 1980. e-Pub 1980. PMID: 6260012.
Yung WK, Steward W, Marks JE, Griem ML, Mullan JF. Glioblastoma multiforme: treatment with radiation and triiodothyronine. Int J Radiat Oncol Biol Phys 1(7):645-50, 1976. e-Pub 1976. PMID: 185171.
Yung WK, Blank NK, Vick NA. Glioblastoma. Induction of a reproducible autochonous tumor in rats with murine sarcoma virus. Neurology 26(1):76-83, 1976. e-Pub 1976. PMID: 174026.
Maruyama Y, Gedgaudes RK, Lee TC, Yung WK. DNA synthesis in fast- and slow-growing C57BL ascites tumors. Cancer Res 34(10):2580-4, 1974. e-Pub 1974. PMID: 4412879.

Invited Articles

Majd NK, Yap TA, Koul D, Balasubramaniyan V, Li X, Khan S, Gandy KS, Yung WKA, de Groot JF. The promise of DNA damage response inhibitors for the treatment of glioblastoma. Neurooncol Adv 3(1), 2021. e-Pub 2021. PMID: 33738447.
Ou A, Yung WKA, Majd N. Molecular Mechanisms of Treatment Resistance in Glioblastoma. Int J Mol Sci 22(1):1-24, 2020. e-Pub 2020. PMID: 33396284.
Gomez-Manzano C, Yung WKA, Alemany R, Fueyo J. Invited Review: Cancer-selective replication-competent adenoviruses as novel therapies for malignant brain tumors. Neurology, 2004. e-Pub 2004.
Caskey LS, Fuller GN, Bruner JM, Yung WK, Sawaya RE, Holland EC, Zhang W. Toward a molecular classification of the gliomas: histopathology, molecular genetics, and gene expression profiling. Histol Histopathol 15(3):971-81, 2000. e-Pub 2000. PMID: 10963139.
Caskey LS, Fuller GN, Bruner JM, Yung WK, Sawaya RE, Holland EC, Zhang W. Toward a molecular classification of the gliomas: histopathology, molecular genetics, and gene expression profiling. Histol Histopathol 15:971-81, 2000. e-Pub 2000. PMID: 10963139.
Koul D, Davies MA, Steck PA, Yung WKA. MMAC/PTEN: The progression tumor suppressor gene. Recent Research Development in Cancer:271-281, 2000. e-Pub 2000.
Puduvalli VK, Yung AW. New frontiers in therapy of malignant gliomas. Forum (Genova) 8(3):261-69, 1998. e-Pub 1998. PMID: 9755291.
Uhm JH, Yung WKA. Biological response modifiers: The role of interferons and retinoids in the treatment of malignant brain tumors. CNS Drugs 10(1):1-82, 1998. e-Pub 1998.
Conrad CA, Milosavljevic VP, Yung WK. Advances in chemotherapy for brain tumors. Neurol Clin 13(4):795-812, 1995. e-Pub 1995. PMID: 8583997.
Yung WK. Molecular biology, genetics, and central nervous system neoplasms. Commentary. Curr Opin Neurol 7(6):475-76, 1994. e-Pub 1994. PMID: 7866577.
Yung WKA. Neoplasms. Section Editor. Current Opinion in Neurology 7:476-505, 1994. e-Pub 1994.
Kim EE, Wong FCL, Wong WHG, Tilbury R, Podoloff DA, Haynie TP, Leeds NE, Yung WKA, Sawaya R. Positron-emission tomography in clinical neuro-oncology. Neuroimaging Clinics of North America 3(4):1-8, 1993. e-Pub 1993.
Yung WKA. Chemotherapy for malignant brain tumors. Cancer Bulletin 45:357-61, 1993. e-Pub 1993.
Steck PA, Bruner JM, Pershouse MA, Hadi A, Conrad CA, Yung WKA, and Saya H. Molecular genetic and biological aspects of primary brain tumors. Cancer Bulletin, 1993. e-Pub 1993.
Moser RP, Johnson ML, Yung WKA. Metastatic brain cancer in patients with no known primary site. Cancer Bulletin 41:173-78, 1989. e-Pub 1989.
Yung WKA. Pitfalls and controversies in diagnosis and treatment (consultant). J Medical Consultation, 1988. e-Pub 1988.
Steck PA, Gallick GE, Hwant TL, Yung WKA. Altered expression of cell surface glycoproteins as markers for brain tumors. Cancer Bulletin 38:10-14, 1986. e-Pub 1986.
Yung WKA, Moser RP. Heterogeneity and chemosensitivity of cellular DNA in human gliomas. Cancer Bulletin 39:7-10, 1986. e-Pub 1986.
Martinez Prieto JN, Yung WKA, Feun LG, and Lee YY. Toxicity of intracarotid chemotherapy for patients with malignant brain tumors. Cancer Bulletin 38:49-52, 1986. e-Pub 1986.
Yung WK, Hwang TL, Martinez-Prieto J, Lee YY, Feun LG. Neurotoxicity of high-dose Ara-C and intracarotid chemotherapy. Prog Exp Tumor Res 29:183-9, 1985. e-Pub 1985. PMID: 4070631.
Feun LG, Lee YY, Wallace S, Charn C, Savaraj N, Carrasco CH, Gianturco C, and Yung WKA. New Drugs and New Delivery Techniques. Progress in Experimental Tumor Research 29:131-39, 1985. e-Pub 1985.
Nishioka K, Yap HY, Yap BS, Fritsche HA, Patenia D, and Yung WKA. Cerebrospinal fluid (CSF) polyamines as markers of meningeal metastasis. Polyamines: Basic and Clinical Aspects, A Satellite Symposium of the Third International Congress on Cell Biology:383-390, 1984. e-Pub 1984.

Review Articles

Majd, NK, Yap, TA, Yung, WA, de Groot, JF. The promise of poly(Adp-ribose) polymerase (parp) inhibitors in gliomas. Journal of Immunotherapy and Precision Oncology 3(4):157-164, 2020. e-Pub 2020. PMID: 35665372.
Jaffee, EM, Dang, CV, Agus, DB, Alexander, BM, Anderson, KC, Ashworth, A, Barker, A, Bastani, R, Bhatia, S, Bluestone, JA, Brawley, OW, Butte, AJ, Coit, D, Davidson, NE, Davis, M, DePinho, RA, Diasio, RB, Draetta, G, Frazier, AL, Futreal, A, Gambhir, SS, Ganz, PA, Garraway, LA, Gerson, SL, Gupta, S, Heath, JR, Hoffman, RI, Hudis, C, Hughes-Halbert, C, Ibrahim, R, Jadvar, H, Kavanagh, B, Kittles, RA, Le, Q, Lippman, SM, Mankoff, DA, Mardis, ER, Mayer, DK, McMasters, KM, Meropol, NJ, Mitchell, BS, Naredi, P, Ornish, D, Pawlik, TM, Peppercorn, J, Pomper, MG, Raghavan, D, Ritchie, CS, Schwarz, SW, Sullivan, R, Wahl, RL, Wolchok, JD, Wong, SL, Yung, WA. Future cancer research priorities in the USA. The lancet oncology 18(11):e653-e706, 2017. e-Pub 2017. PMID: 29208398.
Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, Nelson SJ, Gerstner E, Alexander B, Goldmacher G, Wick W, Vogelbaum M, Weller M, Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, Pope WB, Yang D, Chung C, Knopp MV, Cha S, van den Bent MJ, Chang S, Yung WK, Cloughesy TF, Wen PY, Gilbert MR, Steering Committee JBTDDCIS. Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering Committee. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol 17(9):1188-98, 2015. e-Pub 2015. PMID: 26250565.
Alexander BM, Galanis E, Yung WK, Ballman KV, Boyett JM, Cloughesy TF, Degroot JF, Huse JT, Mann B, Mason W, Mellinghoff IK, Mikkelsen T, Mischel PS, O'Neill BP, Prados MD, Sarkaria JN, Tawab-Amiri A, Trippa L, Ye X, Ligon KL, Berry DA, Wen PY. Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group. Neuro Oncol 17(2):180-8, 2015. e-Pub 2015. PMID: 25165194.
Wen PY, Cloughesy TF, Ellingson BM, Reardon DA, Fine HA, Abrey L, Ballman K, Bendszuz M, Buckner J, Chang SM, Prados MD, Pope WB, Gregory Sorensen A, van den Bent M, Yung WK. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro Oncol 16(suppl 7):vii36-vii47, 2014. e-Pub 2014. PMID: 25313237.
Wen PY, Lee EQ, Reardon DA, Ligon KL, Alfred Yung WK. Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol 14(7):819-29, 2012. e-Pub 2012. PMID: 22619466.
Wick W, Weller M, Weiler M, Batchelor T, Yung AW, Platten M. Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro Oncol 13(6):566-79, 2011. e-Pub 2011. PMID: 21636705.
Fueyo J, Gomez-Manzano C, Yung WK. Advances in translational research in neuro-oncology. Arch Neurol 68(3):303-8, 2011. e-Pub 2011. PMID: 21059986.
de Groot JF, Yung WK. Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas. Cancer J 14(5):279-85, 2008. e-Pub 2008. PMID: 18836331.
Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Wen PY, Fine HA, Mehta MP, DeAngelis LM, Lieberman FS, Cloughesy TF, Robins HI, Abrey LE, Prados MD, Tumor Consortium NAB. Neuro-Oncology clinical trial design for targeted therapies -- Lessons learned from the North American Brain Tumor Consortium. Neuro Oncol 10(4):631-642, 2008. e-Pub 2008. PMID: 18559968.
Alonso MM, Fueyo J, Yung WK, Gomez-Manzano C. E2F1 and telomerase: alliance in the dark side. Cell Cycle 5(9):930-5, 2006. e-Pub 2006. PMID: 16628012.
Reardon DA, Friedman HS, Powell JB, Jr, Gilbert M, Yung WK. Irinotecan: promising activity in the treatment of malignant glioma. Oncology (Williston Park) 17(5 Supplement)(5 Suppl 5):9-14, 2003. e-Pub 2003. PMID: 12800600.
Fuller GN, Hess KR, Rhee CH, Yung WK, Sawaya RA, Bruner JM, Zhang W. Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets. Brain Pathol 12(1):108-16, 2002. e-Pub 2002. PMID: 11771519.
Yung WK. Future directions for temozolomide therapy. Semin Oncol 28(4 Supplement 13)(4 Suppl 13):43-6, 2001. e-Pub 2001. PMID: 11550138.
Fueyo J, Gomez-Manzano C, Liu TJ, Yung WK. Delivery of cell cycle genes to block astrocytoma growth. J Neurooncol 51(3)(3):277-87, 2001. e-Pub 2001. PMID: 11407598.
Yung WK. Temozolomide in malignant gliomas. Semin Oncol 27 (3 Supplement)(3 Suppl 6):27-34, 2000. e-Pub 2000. PMID: 10866347.
Lang FF, Yung WK, Sawaya R, Tofilon PJ. Adenovirus-mediated p53 gene therapy for human gliomas. Neurosurgery 45(5):1093-104, 1999. e-Pub 1999. PMID: 10549925.
Alemany R, Gomez-Manzano C, Balague C, Yung WK, Curiel DT, Kyritsis AP, Fueyo J. Gene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses. Exp Cell Res 252(1):1-12, 1999. e-Pub 1999. PMID: 10502394.
Fueyo J, Gomez-Manzano C, Yung WK, Kyritsis AP. Targeting in gene therapy for gliomas. Arch Neurol 56(4):445-8, 1999. e-Pub 1999. PMID: 10199333.
Gomez-Manzano C, Fueyo J, Alameda F, Kyritsis AP, Yung WK. Gene therapy for gliomas: p53 and E2F-1 proteins and the target of apoptosis. Int J Mol Med 3(1):81-5, 1999. e-Pub 1999. PMID: 9864390.
Fueyo J, Gomez-Manzano C, Yung WK, Kyritsis AP. The functional role of tumor suppressor genes in gliomas: clues for future therapeutic strategies. Neurology 51:1250-5, 1998. e-Pub 1998. PMID: 9818841.
Tang P, Steck PA, Yung WK. The autocrine loop of TGF-alpha/EGFR and brain tumors. J Neurooncol 35(3):303-14, 1997. e-Pub 1997. PMID: 9440027.
Yung WK. New approaches to molecular therapy of brain tumors. Curr Opin Neurol 7(6):501-5, 1994. e-Pub 1994. PMID: 7866580.
Yung WK. New approaches in brain tumor therapy using gene transfer and antisense oligonucleotides. Curr Opin Oncol 6(3):235-9, 1994. e-Pub 1994. PMID: 8080851.
Yung WK. Chemotherapy for malignant brain tumors. Curr Opin Oncol 2(4):673-8, 1990. e-Pub 1990. PMID: 2095876.
Yung WK. In vitro chemosensitivity testing and its clinical application in human gliomas. Neurosurg Rev 12(3):197-203, 1989. e-Pub 1989. PMID: 2682352.

Editorials

Chang S, Yung WK. New neuro-oncology practice journal to launch in 2014. Neuro Oncol 15(10):1277, 2013. PMID: 24057884.
Yung WK. Higher impact, wider influence. Neuro Oncol 15(9):1113, 2013. PMID: 23966014.
Yung WK. Year brings higher impact factor, more submissions for Neuro-Oncology. Neuro Oncol 15(1):1-3, 2013. PMID: 23284031.
Yung WK. The value of cell line validation. Neuro Oncol 14(6):675, 2012. PMID: 22669103.
Yung WK. New impact factor number reflects sustained and enhanced growth. Neuro Oncol 13(9):925, 2011. PMID: 21852428.
Yung WK. Reflections on a successful 2010. Neuro Oncol 13(1):1-2, 2011. PMID: 21193689.
Yung WK. The problem with cell phones...or maybe not. Neuro Oncol 12(11):1087, 2010. PMID: 20966155.
Yung WK. Impact Factor number reflects sustained high quality. Neuro Oncol 12(9):893, 2010. PMID: 20720000.
Yung WK. Journal to shift practice on obtaining conflict of interest declarations. Neuro Oncol 12(7):619-20, 2010. PMID: 22156772.
Yung WK. Quality of Life: A Fertile Field for Inquiry. Neuro Oncol 11(3):241, 2009. PMID: 19403802.
Yung WK. To publish or not to publish... Neuro Oncol 11(1):1, 2009. PMID: 19106331.
Yung WK. Moving toward the next steps in angiogenesis therapy?. Neuro Oncol 10(6):939, 2008. PMID: 18981258.
Yung, WKA. Impact factor grows, thanks to hard-working reviewers. Neuro-Oncology 10:539, 2008.
Yung WKA. Value of meetings is far from abstract. Neuro-Oncology 10:235, 2008.
Yung WKA. "Review"-ing our new opportunities for "Rapid Report"-ing. Neuro-Oncology 10:111, 2008. PMID: 18326687.
Yung WK. Carrying Neuro-Oncology to a world that needs knowledge. Neuro Oncol 10(1):1, 2008. PMID: 18184773.
Yung WK, James CD. Mapping the future of Neuro-Oncology. Neuro Oncol 9(1)(1):1-2, 2007. PMID: 17170381.
Yung WK, James CD. Focusing in, broadening our reach. Neuro-Oncology 9(2):81, 2007.
Bigner DD, Yung WKA, James CD, Cohen SA. Neuro-Oncology impact factor for 2005. Neuro-Oncology 8:289, 2006.
Yung WKA. BudR radiosensitization in anaplastic astrocytoma. J Rad Oncol, 1999.

Abstracts

Fu J, Koul D, Yao J, Wang S, Gumin J, Shen R, Vaillant B, Colman H, Lang FF, Aldape K, Yung WK. Molecular and lineage analysis of Glioblastoma Stem Cells identifieds clinically relevant models of glioblastoma, 2011. e-Pub 2011.
Colman H, Conrad C A, Sai K, Wang S, Popoff S, Aldape K, Lang F, Fokt I, Madden T L, Yung W K, Preibe W. WP1193 Inhibits JAK2/STAT3 Pathway, blocks self-renewal and induces apoptosis in glioblastoma cancer stem cells Proceeding of the American Association of Cancer Research, Denver, CO 4/09, 2009. e-Pub 2009.
Cloughesy TF, Prados MD, Wen PY, Mikkelsen T, Abrey LE, Schiff D, Yung WK, Maoxia Z, Dimery I, Friedman HS. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clinical Oncol Abstract #2010b:226, 2008. e-Pub 2008.
Colman H, Sai K, Wang S, Popoff S, Aldape KD, Lang FF, Conrad CA, Madden T, Yung A, Priebe W. Effect of small molecule inhibitor of the JAK2/STAT3 pathway on self-renewal of glioblastoma stem cells. Proceedings of the American Society for Clinical Oncology Abstract #2003, 2008. e-Pub 2008.
deGroot JF, Wen PY, Lamborn K, Chang S, Cloughesy TF, Chen AP, DeAngelis LM, Mehta MP, Gilbert MR, Yung WK, Prados MD. Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601. Proceedings of the American Society for Clinical Oncology Abstract #2020, 2008. e-Pub 2008.
Kim YW, Tiao N, Lafortune T, Liu TJ, Powis G, Yung WKA, Koul D. Identification of novel synergistic targets RACK-1 and galectin-1 for rational drug combinations with PI3 Kinase inhibitors using siRNA synthetic lethality screening. Proceedings of the 99th American Association of Cancer Research Abstract #2761, 2008. e-Pub 2008.
Koul D, Shen R, Edge J, Henry V, Webb D, Bankson J, Ronen SM, Powis G, Kirkpatrick DL, Yung AWK. Cellular and in vivo activity of a new PI3K inhibitor - PX866 for treatment of human glioblastoma. Proceedings of the 99th American Association of Cancer Research Abstract #3731, 2008. e-Pub 2008.
Liu JL, Mao Z, LaFortune TA, Liu TJ, Garnett J, Yung WKA. Nuclear PTEN-mediated autophagy is independent of mTOR inhibition in U251MG cells. Proceedings of the 99th American Association of Cancer Research Abstract #3367, 2008. e-Pub 2008.
Jiang H, Xu J, Lang F, Colman H, Gomez-Manzano C, Bogler O, Latha K, Yung WKA, Fueyo J. Delta-24-RD induces autophagy in brain tumor stem cells and prolongs survival in glioma-bearing mice. Proceedings of the 99th American Association of Cancer Research Abstract #3304, 2008. e-Pub 2008.
White EJ, Jiang H, Alonso M, Piao Y, Xu J, Conrad C, Yung WKA. Atg5 is required for adenovirus-induced autophagy in cancer cells. Proceedings of the 99th American Association of Cancer Research Abstract #3357, 2008. e-Pub 2008.
Alonso MM, Gomez-Manzano C, Jiang H, Martin V, Liu D, Xu J, Yung WKA, Gilbert M, Fueyo J. Role of the silencing of the MGMT promoter in the therapeutic synergy between Delta-24-RGD and temozolomide. Proceedings of the 99th American Association of Cancer Research Abstract #1364, 2008. e-Pub 2008.
Liu JL, Mao Z, Garnett J, Bogler O, Yung WKA. Subcellular localization of PTEN is regulated by LKB1 with or without the AMPK/TSC2/mTOR signaling intermediates. Proceedings of the 99th American Association of Cancer Research Abstract #2774, 2008. e-Pub 2008.
Gilbert M, Gaupp P, Ictech S, Hess K, Groves M, Levin V, Conrad C, Puduvalli V, Colman H, deGroot J, Hsu S, De Porre P, Yung WKA. A phase I/II study of Temozolomide (TMZ) and the farnesyltransferase inhibitor (FTI), Tipifarnib (Zarnestra, Zar) in recurrent glioblastoma (GBM). Neuro-Oncology:MA-34, 2007. e-Pub 2007.
Conrad C, Maher E, Cloughesy T, Fink K, Priebe W, Madden T, Meyer C, Foster P, Groves M, Gilbert M, Levin V, Puduvalli V, Colman H, Yung WKA. Results of a phase I trial with the novel anthracycline derivative RTA-744 in patients with recurrent primary brain tumors. Neuro-Oncology:MA-33, 2007. e-Pub 2007.
Penas-Prado M, Puduvalli V, Groves M, Conrad C, Gilbert M, Levin VA, Yung WKA. Temozolomide plus 13-Cis-Retinoic Acid (TMZ/CRA) as first line chemotherapy for newly diagnosed glioblastoma multiforme (GBM): A retrospective study. Neuro-Oncology:MA-31, 2007. e-Pub 2007.
Alonso MM, Gomez-Manzano C, Xu Y, Piao Y, Jiang H, Yokoyama T, Yung WKA, Lang F, Fueyo J. . Delta-24-RGD in Combination with RAD001 Induces Autophagic Cell Death and 80% of Long Term Survivors. Neuro-Oncology, 2007. e-Pub 2007.
Koul, Dimpy, Shen R, Edge J, Kondo Y, Webb D, Bankson J, Ronen SM, Lu Y, Powis G, Kirkpatrick DL, Yung WKA. Cellular and in vivo activity of a new PI3K inhibitor-PX866 for treatment of Human Glioblastoma. Neuro-Oncology:ET-28, 2007. e-Pub 2007.
deGroot J, Li L, Yung WKA. Mechanisms of AMPA receptor mediated invasion. Neuro-Oncology:IN-08, 2007. e-Pub 2007.
Wen P, Puduvalli V, Kuhn J, Reid J, Cloughesy T, Yung WKA, Drappatz J, Lamborn K, Gilbert M, Butowski N, Levin V, Chang S, Kesari S, Robbins HI, McGovern R, Richon V, Frankel S, Ames M, Zweibel J, Prados M. Phase I study of Vorinostat (Suberoylanilide Hydroxamic Acid (SAHA) in combination with Temozolomide in patients with malignant gliomas (NABTC 04-05). Neuro-Onology:MA-13, 2007. e-Pub 2007.
Alonso MM, Gomez-Manzano C, Xu J, Piao Y, Jiang H, Yung WKA, Lang F, Fueyo J. Adenoviruses Downmodulate MGMT Increasing Sensibility of Brain Tumor Stem Cells to Temozolomide: A Mechanistic Study. Neuro-Oncology, 2007. e-Pub 2007.
Popoff S, Aldape K, Wong S, Conrad C, Lang F, Sai K, Yung WKA, Priebe W, Colman H. Regulation of glioblastoma stem cell self-renewal by stat3. Neuro-Oncology:SC-18, 2007. e-Pub 2007.
Conrad CA, Maher, E, Cloughesy T, Groves M, Gilbert M, Madden T, Levin V, Priebe W, Meyer C, Yung W. Final results of a phase I trial with novel anthracycline derivative RTA-744 in patients with primary brain tumors. Proceedings of the 43rd Annual ASCO Meeting Abstract # 2062, 24(18S):Part I/II:90s, 2007. e-Pub 2007.
Robins HI, Wen PY, Chang SM, Kuhn J, Lamborn K, Cloughesy T, Gilbert MR, Yung WK, Dancey J, Prados MD. Phase I study of erlotinib and CCI-779 (temsirolimus) for patients with recurrent malignant gliomas (MG) (NABTC 04-02). Proceedings of the 43rd Annual ASCO Meeting Abstract #2057, 24(18S):Part I/II:89s, 2007. e-Pub 2007.
Grewal J, Groves MD, Bekele BN, Yung WA. The role of HER2/neu, estrogen, and progesterone receptor status in the risk of survival of breast cancer leptomingeal metastasis. Proceedings of the 43rd Annual ASCO Meeting Abstract # 1152, 24(18S):Part I/II:604s, 2007. e-Pub 2007.
Wen PY, Puduvalli V, Kuhn J, Reid J, Cloughesy T, Yung WA, Chang SM, Robbins HI, McGovern R, Ames M, Prados MD. Phase I study of vorinostat (suberoylanilide hydroxamic acid) in combination with Temozolomide (TMZ) in patients with malignant gliomas (NABTC 04-03). Proceedings of the 43rd Annual ASCO Meeting Abstract # 2039, 24(18S):Part I/II:84s, 2007. e-Pub 2007.
DeGroot JF, Gilbert MR, Hess KR, Hanna T, Groves M, Conrad C Aldape K, Colman H, Puduvalli V, Yung WA. Phase II study of combination Carboplatin and erlotinib in patients with recurrent glioblastoma multiforme. Proceedings of the 43rd Annual ASCO Meeting Abstract # 2024, 24(18S):Part I/II:81s, 2007. e-Pub 2007.
Choi W, Jiang R, Khan A, Yung WKA, Gerner E, Hamilton SR, Zhang W. Polyamine catabolism drug N1, N11-diethylnorspermine caused cell death in glioblastoma cells via inhibition of mTOR-regulated protein initiation. Proceedings of the American Association of Cancer Research Abstract #4076, 2007. e-Pub 2007.
Liu TJ, LaFortune T, Yung WKA, Maira SM, Stauffer F, Garcia-Echevrria C. A novel PI3K inhibitor elicits multifaceted antitumor activities in human gliomas. Proceedings of the American Association for Cancer Research:Abstract # 4878, 2007. e-Pub 2007.
Yuji P, Jiang H, Xu J, Alonso, Lee O, Conrad C, Yung A, Gomez-Manzano C, Fueyo J. Delta24-RIVER oncolytic adenovirus-targeting mutant-EGFR glioma cells. Proceedings of the American Association for Cancer Research (AACR) Annual Meeting Abstract #3297, 2007. e-Pub 2007.
Koul D, Shen R, Edge J, Ivado E, Kondo Y, Powis G, Kirkpatrick L, Yung WKA. Targeting PI3K in human glioblastoma with PX-866, a small molecule PI3K inhibitor. Proceedings of the American Association for Cancer Research Abstract #278, 2007. e-Pub 2007.
Lee OH, Fueyo J, Xu J, Fuller G, Aldape K, Colman H, Gumin J, Lang F, Yung WKA, Gomez-Manzano C. Glial Tie2 is co-expressed with stem cell-like markers and mediates adhesion of neoplastic astrocytes to tumoral vascular structures. Neuro-Oncology 8(4):392, 2006. e-Pub 2006.
Liu JL, Liu TJ, Aldape KD, Mao Z, LaFortune TA, Yung WKA. Nuclear PTEN as a potential therapeutic molecule in GBM. Neuro-Oncology 8(4):398, 2006. e-Pub 2006.
Siker ML, Berkey B, Porter K, Nelson D, Curran W, Michalski J, Souhami L, Chakravarti A, Yung W, DelRowe J, Coughlin C, Mehta MP. Age as an independent prognostic factor in patients with glioblastoma: An RTOG and ACoS National Cancer Base Comparison. Neuro-Oncology 8(4):408, 2006. e-Pub 2006.
Alonso MM, Gomez-Manzano C, Jiang H, Lee OH, Piao Y, Lang F, Yung WKA, Fueyo J. Combination therapy of D24-RGD with temozolomide and RAD001 with oncolytic adenoviruses induces the regression of glioma xenografts and significantly prolongs survival. Neuro-Oncology 8(4):409, 2006. e-Pub 2006.
Gilbert MR, Gaupp P, Liu V, Conrad C, Colman H, Groves M, Puduvalli V, Levin V, Hsu S, Horowitz J, Yung W. A phase I study of temozolomide (TMZ) and the farnesyltransferase inhibitor (FTi), Ionafarnib (Sarazar, SCH66336) in recurrent glioblastoma. Supplement to Journal of Clinical Oncology Proceedings of the American Society for Clinical Oncology Annual Meeting Annual Meeting 24(18S) Part I of II:72s, Abstract #1556, 2006. e-Pub 2006.
Chang SM, Lamborn K, Wen P, Deangelis L, Fink K, Lieberman F, Yung A, Robins I, Cloughesy T, Junck L, Prados M. Phase II study of POLY-ICLC in recurrent anaplastic glioma: A North American Brain Tumor Consortium Study. Proceedings of the American Society for Clinical Oncology Annual Meeting 24(18S) Part I of II:70s, #1550, 2006. e-Pub 2006.
Fox S, Berkey B, Knisely J, Chakravarti A, Yung WA, Curran W, Robins H, Brachmen D, Henderson R Mehta M, Movas B. Prospective neurocognitive effects and qualify of life (QOL) in patients with multiple brain metastases receiving whole brain radiation (WBRT) + thalidomide on Radiation Therapy Oncology Group (RTOG) trial 0118. Supplement to Journal of Clinical Oncology Proceedings of the American Society for Clinical Oncology Annual Meeting 24(18S) Part I of II:490s, #8589, 2006. e-Pub 2006.
Alonso MM, Alemany R, Gomez-Manzano C, Cascallo M, Lang FF, Jing X, Henry V, Yung AWK, Fueyo J. New alliance against gliomas: Treatment with oncolytic adenovirus ICOVIR-5 in combination with TMZ or RADOO1 significantly improves survival in glioma xenografts. Proceedings of the American Association for Cancer Research 47:946, Abstract #4017, 2006. e-Pub 2006.
Liu TJ, LaFortune T, DeGroot JF, Yung WKA. Synergistic therapeutic potential of inhibiting mTOR and IGF-IR pathways. Neuro-Oncology 8(4):415, 2006. e-Pub 2006.
Wen PY, Yung WKA, Lamborn K, Cloughesy T, DeAngelis LM, Fine HA, Chang SM, Robins HI, Fink K, Abrey LE, Lassman AB, Mehta M, Kesari S, Kim L, Stiles C, Egorin M, Kaplan R, Murgo A, Prados MD. Phase II study of imatinib mesylate (ST1571) for patients with recurrent meningiomas (NABTC-01-08). Neuro-Oncology 8(4):454, #TA-66, 2006. e-Pub 2006.
Pelloski CE, Zhang L, Lin E, Bahr K, McDonald JM, Yung WKA, Colman H, Woo SY, Heimberger AB, Suki D, Prados M, Chang S, Barker III F, Buckner JC, Ballman KV, Furth AF, James CD, Aldape KD. EGFRvIII status defines distinct subtypes of glioblastoma: An analysis of 649 cases. Neuro-Oncology 8(4):462, 2006. e-Pub 2006.
Gilbert MR, Gonzalez J, Hunter K, Hess K, Chang E, Puduvalli V, Groves M, Colman H, Conrad C, Levin V, Woo S, Mahajan A, Hsu S, de Groot J, Yung WKA. A phase I study for a factorial design of does-dense temozolomide (TMZ) alone and in combination with permutations of thalidomide (THAL), Isotretinoin (CRA) and/or Celecoxib (CEl) as post-chemoradiation adjuvant therapy for newly diagnosed glioblastoma (GBM). Neuro-Oncology 8(4):442, 2006. e-Pub 2006.
Liu TJ, LaFortune T, Honda T, Ohmori O, Jackson D, de Groot J, Yung WKA. A dual inhibitor of focal adhesions kinase (FAK) and insulin-like growth factor-1 receptor (IGF-IR) kinase suppresses glioma proliferation in vitro and in vivo. Neuro-Oncology 8(4):415, 2006. e-Pub 2006.
Koul D, Shen R, Edge J, Liu TJ, Powis G, Kirkpatrick DL, Yung WKA. Phosphatidylinositol 3-kinase (PI3K) pathway – A therapeutic target for human glioblastoma. Neuro-Oncology 8(4):414, 2006. e-Pub 2006.
Mayes DA, Hu Y, Teng Y, Wu X, Panda K, Liu L, Siegel E, Tan F, Yung WKA. PAX6 suppresses the invasiveness of glioblastoma cells and the expression of the matrix metalloproteinase 2 gene. Neuro-Oncology 8(4):434, 2006. e-Pub 2006.
Jiang R, Choi W, Yung WKA, Gerner E, Hamilton SR, Zhang W. Spermine analog N1, N11-diethylnorspermine inhibits mTOR-regulated protein initiation and causes anoikis in glioblastoma cells. Neuro-Oncology 8(4):413, 2006. e-Pub 2006.
Puduvalli VP, Giglio P, Groves MD, Hess KR, Gilbert MR, Mahankali S, Jackson E, Levin VA, Conrad CA, Hsu S, Colman H, Ritterhouse M, Ictech S, Yung WKA. Phase II trial of irinotecan and thalidomide in adult patients with recurrent glioblastoma multiforme. Neuro-Oncology 8(4):450, 2006. e-Pub 2006.
Liu TJ, LaFortune T, Tiao N, Zhou Y, de Groot J, Lane H, Fuller G, Lu Z, Yung WKA. . Neuropilin-l, a hypoxic responsive gene, regulates glioma cell invasion via activation of focal adhesion kinase (FAK) and mitogen-activated kinase (MAPK) signaling pathways. Neuro-Oncology 8(4):434, 2006. e-Pub 2006.
Jiang H, Lee OH, Aoki H, Kondo S, Lang FF, Kondo Y, Yung WKA, Fueyo J. Delta-24-RGD induces autophagy in cancer stem cells. Neuro-Oncology 8(4):413, 2006. e-Pub 2006.
Raj VR, Griffin S, Teng Y, Hess KR, Yung WKA, Linskey ME, Zhou YH. The expression of ASPP2, BCCIP, BIRC5, TP53 in glioma: Correlation with p53 mutation and tumor grade. Neuro-Oncology 8(4):424, 2006. e-Pub 2006.
de Groot JF, Lu L, Liu TJ, Fuller G, Yung WKA. shRNA knockdown of AMPA receptors inhibits glioma proliferation. Neuro-Oncology 8(4):410, #ET-06, 2006. e-Pub 2006.
Wen PY, Chang SM, Kuhn J, Lamborn K, Robins HI, Cloughesy T, Gilbert MR, Yung WKA, Mehta M, DeAngelis LM, Abrey LE, Kesari S, Drappatz J, Lassman AB, Dancey J, Prados MD. Phase I study of erlotinib (Tarceva) and temsirolimus (CCI-779) for patients with recurrent malignant gliomas (NABTC 04-02. Neuro-Oncology 8(4):454, #TA-65, 2006. e-Pub 2006.
Puduvalli VK, Giglio P, Groves MD, Hess KR, Gilbert M, Mahankali S, Hsu S, Colman H, Conrad C, Levin VA, Yung WKA. Phase II study of the combination of thalidomide and irinotecan in patients with recurrent anaplastic gliomas not on enzyme inducing anticonvulsants. Proceedings of the 41st Annual Meeting of the American Association of Clniical Oncology (ASCO) 24(18S):1564, 2006. e-Pub 2006.
Jiang H, Olson MV, Xu J, O-H L, Piao Y, Yung WKA, Fueyo J. Exportin 1-mediated nuclear export of adenovirus E1A protein: A novel target for generation of oncolytic viruses. Proceedings of the American Association for Cancer Research (AACR) 97th Annual Meeting 47:702,, 2006. e-Pub 2006.
Mayes DA, Wu X, Liu TJ, Yung WKA, Zhou YH. PAX6 alone and synergistically with PTEN suppresses the expression of vascular endothelial growth factor in glioblastoma cells. Proceedings of the American Association for Cancer Research (AACR) 97th Annual Meeting 47:249, #1057, 2006. e-Pub 2006.
Olson MV, Johnson DG, Aldape KD, Fuller GN, Jiang H, Yung WKA, Guha A, Gomez-Manzano C, Fueyo-Margareto J. Transgenic mouse model provides the first direct evidence supporting the oncogenic role of E2F1 in brain. Proceedings of the American Association for Cancer Research (AACR) 97th Annual Meeting 47:643, #2735, 2006. e-Pub 2006.
Aldape K, Conrad CA, Prados M, Reardn T, Cloughesy T, Yung WKA. Analyses of EGF and VEGF signaling pathways in recurrent glioblastoma patients win a Phase I study of single agent AEE788 #3292, 2005. e-Pub 2005.
Olson M, Medrano D, Jiang H, Gomez-Manzano C, Alonso M, Aldape K, Price R, Yung WKA, Fueyo J. Developmental abnormalities and oncogenesis in the brain of a transgenic E2F1 mouse model, 2005. e-Pub 2005.
Groves MG, Puduvalli V, Gilbert M, Conrad CA, Liu V, Hess K, Yung WKA, Levin VA. Matrix metalloproteinase inhibitor-induced joint-related toxicity predicts prolonged progression-free survival in recurrent high-grade glioma trials, 2005. e-Pub 2005.
Alonso M, Alemany R, Gomez-Manzano C, Yung WKA, Sawaya R, Jiang H, Fueyo J. Re-targeting the Rb-pathway with an improved D24-RGD oncolytic adenovirus, 2005. e-Pub 2005.
O-H L, Xu J, Colman H, Popoff S, Alonso M, Fuller G, Bekele N, Lang F, Yung WKA, Fueyo J, Gomez-Manzano C. Existence of a Tie2 Signaling Pathway in Gliomas: Implications for Multi-compartmental Targeting, 2005. e-Pub 2005.
Gomez-Manzano C, Holash J, Xu J, Lee OH, Fueyo J, Rudge J, Zhou X, Bekele BN, Aldape K, Yung WKA. The soluble decoy receptor for VEGF, VEFG Trap, induces antiglioma effect in vivo, 2005. e-Pub 2005.
Alonso M, Alemany R, Gomez-Manzano C, Yung WKA, Jiang H, Fueyo J. Icovir-2, an old friend with a new face: E2F-1 mediated glioma selectivity for Delta24-RGD. Society of Neuro-Oncology (together with World Federation of Neuro-Oncology and European Association of Neuro-Oncology, 2005. e-Pub 2005.
Unni E, Koul D, Yung WKA, Sinha R. Se-methylselenocysteine inhibits phosphatidylinositol 3-kinase pathway in mouse mammary epithelial tumor cells. Breast Cancer Research 7:R699-R707, 2005. e-Pub 2005.
Sinha R, Unni E, Singh U, Koul D, Yung WKA. Sse-methylselenocysteine inhibits phosphatidylinositol 3-kinase pathway in mouse mammary epithelial tumor cells. Breast Cancer Research 7:R699-R707, 2005. e-Pub 2005.
Reardon D, Cloughesy T, Conrad C, Prados M, Xia J, Mietlowski W, Dugan M, Mischel P, Friedman H, Yung A. A phase I study of AEE788, a novel multi-targeted inhibitor of Ebb and VEGF receptor family tyrosine kinases in recurrent GBM patients. J of Clinical Oncology 23(16S):3063, 2005. e-Pub 2005.
Liu TJ, Lafortune T, de Groot J, Yung WKA. Down-regulation of neuropilin-I expression by RAD001 attenuates glioma cells invasions. Proceedings of the 96th Annual Meeting of the American Association for Cancer Research (AACR) 46::64, #272, 2005. e-Pub 2005.
Reardon D, Cloughesy T, Conrad C, Prados M, Xia J, Mietlowski W, Dugan M, Mischel P, Friedman H, Yung A. A phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, in recurrent GBM patients. Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO) 23(16S, Part I of II):#3063, 2005. e-Pub 2005.
Puduvalli V, Giglio P, Groves MD, Hess KR, Jackson E, Mahankali S, Gilbert M, Levin VA, Conrad C, Hsu S, Yung WKA. Phase II trial of thalidomide in combination with irinotecan in adults with recurrent glioblastoma multiforme. Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO) 23(16S, Part 1 of II):120s, #1524, 2005. e-Pub 2005.
Liu L, Yung WKA, Zhou YH. The expression of VEGF, CDK4, PAX6, EGFR, IGFBP2, PTEN, MMP2 and P53 in patients with oligodendrogliomas: Relationship to 5-year mortality. Proceedings of the American Association for Cancer Research, (AACR) 46:1149, #4866, 2005. e-Pub 2005.
Liu JL, Aldape KD, Mao Z, Yung WKA. Cytoplasmic translocation of PTEN tumor suppressor is mediated by PI3K/Akt/mTOR/p70S6K signaling cascades. Proceedings of the 96th Annual Meeting of the American Association for Cancer Research (AACR) 46:236, #1011, 2005. e-Pub 2005.
Yung WKA, Lieberman FS, Wen P, Robin I, Gilbert M, Chang S, Junck L, Cloughesy T, Lamborn K, Prados M. Combination of temozolomide (TMZ) and irinotecan (CPT-11) showed enhanced activity for recurrent malignant gliomas: A North American Brain Tumor Consortium (NABTC) phase II study. Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO) 23(16S, Part 1 of II)::119s, #1521, 2005. e-Pub 2005.
Olson M, Alonso M, Medrano D, Sheng X, Gomez-Manzano C, Jiang H, Yung WKA, Fueyo J. E2F1 Transcriptionally Activates PTEN. Proceedings of the American Association for Cancer Research, (AACR) 46:661, #2808, 2005. e-Pub 2005.
Knisely JPS, Berkey BA, Chakravarti A, Yung WKA, Curran WJ, Robbins HI, Movsas B, Brachman DG, Henderson RH, Mehta MP. RTOG 118: A phase III study of conventional radiation therapy alone vs conventional radiation therapy plus thalidomide for multiple brain metastases. Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO) 23(16S, Part 1 of II):114s, #1500, 2005. e-Pub 2005.
Jiang H, Medrano D, Gomez-Manzano C, LeMoine M, Alemany R, Olson M, Alonso M, Conrad C, Yung WKA, Fueyo J. Downmodulation of E1A Protein Expression as a Novel Strategy to Design Cancer Selective Adenoviruses. Proceedings of the 96th Annual Meeting of the American Association for Cancer Research (AACR) 46:312, #1340, 2005. e-Pub 2005.
Gomez-Manzano C, Holash J, Xu J, Lee OK, Fueyo J, Rudge J, Bekele N, Aldape K, Yung WKA. Treatment of glioma-bearing mice with VEGF Trap results in significant prolongation of survival. Proceedings of the 96th Annual Meeting of the American Association for Cancer Research (AACR) 46:712, #3029, 2005. e-Pub 2005.
Groves MD, Puduvalli V, Gilbert MR, Conrad CA, Hsu S, Colman H, Hess K, Levin VA, Yung WKA. . A phase II study of temozolomide plus pegylated interferon alfa-2b for recurrent anaplastic glioma and glioblastoma multiforme. Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO) 23(16S, Part 1 of II):118s, #1519, 2005. e-Pub 2005.
Cloughesy T, Yung A, Vrendenberg J, Aldape K, Eberhard D, Prados M, Vandenberg S, Dlencke B, Mischel P. Phase II study of erlotinib in recurrent GBM: Molecular predictors of outcome. Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO) 23(16S, Part 1 of II):115s, #1507, 2005. e-Pub 2005.
Alonso M, Alemany R, Gomez-Manzano C, Yung WKA, Jiang H, Fueyo J. Oncolytic adenovirus Icovir-2 shows improved therapeutic index than D24-RGD for glioma. Proceedings of the American Association for Cancer Research, (AACR) 46:312, #1341, 2005. e-Pub 2005.
Reardon D, Friedman H, Yung WKA, Brada M, Conrad C, Provenzale J, Jackson E, Serajuddin H, Chen B, Laurent D. A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). Proceedings of the 40th Annual Meeting of the American Society of Clinical Oncology 23:110, #1513, 2004. e-Pub 2004.
Conrad C, Friedman H, Reardon D, Provenzale J, Jackson E, Serajuddin H, Laurent D, Chen B, Yung WKA. A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). Proceedings of the 40th Annual Meeting of the American Society of Clinical Oncology 23:110, #1512, 2004. e-Pub 2004.
Prados M, Yung W, Wen P, Junck L, Fink K, Cloughesy T, Robins I, Chang S, Kuhn J. Phase I study of ZD1839 plus temozolomide in patients with malignant glioma. A study of the North American Brain Tumor Consortium. Proceedings of the 40th Annual Meeting of the American Society of Clinical Oncology 23:108 #1504, 2004. e-Pub 2004.
Yung A, Vredenburgh J, Cloughesy T, Klenke BJ, Mischel PS, Bigner DD, Aldape K, Vanderburg S, Prados M. Erinotinib HCL for glioblastoma multiforme in first relapse, a phase II trial. Proceedings of the 40th Annual Meeting of the American Society of Clinical Oncology 23:120, #1555, 2004. e-Pub 2004.
Lee OH, XU J, Fueyo J, Lang FF, Yung WKA, Gomez-Manzano. The blood vessel-destabilizer tool: Angiopoietin-2 as antiglioma treatment, 2004. e-Pub 2004.
Groves MD, Liu TJ, Hess KR, Forman AD, Hsu SH, Gilbert MR, Colman H, Puduvalli VK, Conrad CA, Yung WKA. Cerebrospinal fluid VEGF levels as a biomarker of neoplastic meningitis. Neuro-Oncology 6(4):352, 2004. e-Pub 2004.
Wen PY, Yung WKA, Lamborn K, Peng, B, Dahia P, Abrey, L, Raiser J, Cloughesy T, Fink K, Gilbert M, Chang, S, Junck L, Schiff D, Lieberman F, Fine H, Mehta M, Robins JI, DeAngelis LM, Hess, Groves M, Puduvalli VK, Levin V, Conrad C, Kuhn J, Maher E, Hayes M, Silberman S, Letvak L, Capdeville R, Kaplan R, Murgo A, Stiles C, Prados MD. Phase I/II study of Imatinib Mesylate (ST1571) for patients with recurrent malignant gliomas (NABTC 98-08). Neuro-Oncology 6(4):385, 2004. e-Pub 2004.
Groves MD, Baumgartner KE, Conrad CA, Chamberlain M, Hsu S, Glantz M, Gilbert M, Forman A Puduvalli V, Colman H, Yung WKA. A phase II study of intrathecal topotecan in patients with meningeal malignancies. Neurology #PO6.047, 62 (Suppl 5): A475, 2004. e-Pub 2004.
Gilbert MR, Hess K, Gaupp P, Groves M, Puduvalli V, Levin V, Conrad C, Colman H, Hsu S, DePorre P, Yung WKA. A Phase I study of Temozolomide (TMZ) and the farnesyltransferase inhibitor (FTI), Tipifarnib (Zarnestra, R115777) in recurrent glioblastoma: A dose and schedule intensive regimen. Neuro-Oncology 6(4):375, 2004. e-Pub 2004.
Koul D, Bergh S, Shen R, Yung WKA. Targeting integrin linked kinase (IL:K) pathway in human glioblastoma. Proceedings of the 95th Annual Meeting of the American Association for Cancer Research (AACR) (45):1200, #5205, 2004. e-Pub 2004.
Tohnya TM, Sparreboom A, Fine HA, Yung A, Wen P, Cloughesy T, Junck L, Lieberman F, Prados M, Figg WD. A pharmacokinetic (PK) study of SU-5416 in patients on enzyme-inducing anti-epileptic drugs (EIAED) by the North American Brain Tumor Consortium. Proceedings of the 95th Annual Meeting of the American Association for Cancer Research (AACR) (45):91, Abstract #401, 2004. e-Pub 2004.
Koul D, Shen R, Yung WKA. Characterization of PTEN associated proteins. Proceedings of the 95th Annual Meeting of the American Association for Cancer Research (AACR) (45):815, Abstract #3533, 2004. e-Pub 2004.
Gomez-Manzano C, Xu J, Fueyo J, Aldape K, Bekele BN, Lemoine M, Fuller G, Yung WKA. Significant correlation of Angiopoietin-2 and Nestin expression in human glioblastomas. Proceedings of the 95th Annual Meeting of the American Association for Cancer Research (AACR) (45):830, #3599, 2004. e-Pub 2004.
Zhou YH, Hess KR, Yung WKA. Prognostic model for glioma patients. Proceedings of the 95th Annual Meeting of the American Association for Cancer Research (AACR) (45):245, Abstract #1078, 2004. e-Pub 2004.
Jiang H, Gomez-Manzano C, Medrano D, Cass A, Alonso M, Alemany R, Yung WKA, Fueyo J. The level of E1A as a factor for tumor selectivity in oncolytic adenoviruses. Proceedings of the 95th Annual Meeting of the American Association for Cancer Research (AACR) (45):275, Abstract #1202, 2004. e-Pub 2004.
Lieberman FS, Cloughesy T, Fine H, Kuhn J, Lamborn K, Malkin M, Robbins HI, Yung WA, Wen P, Prados M. NABTC phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas. Proceedings of the 40th Annual Meeting of the American Society of Clinical Oncology 23:109, #1510, 2004. e-Pub 2004.
Alonso MM, Gomez-Manzano C, Aldape K, Jiang H, Xu J, Kondo Y, Fueyo J, Yung WKA. E2F1 upregulates telomerase: Cell-cycle related telomerase activity in sarcoma cells. Proceedings of the 95th Annual Meeting of the American Association for Cancer Research (AACR) (45):830, #986, 2004. e-Pub 2004.
Sebti SM, Paquete S, Kuhn JG, Prados M, Robins HI, Deangelis LM, Change SM, Schiff D, Wen P, Yung WKA, Gilbert M, Fink K, Greenberg H, Junck L, Abrey LE, Lieberman FS, Mp M, Raizer JJ, Hess K, Cloughesy TF. The farnesyltransferase inhibitor Zarnestra suppresses protein farnesylation, not geranylgeranylation, in peripheral blood monocytes of patients with recurrent malignant glioma treated with Zarnestra in Phase I/II clinical trials. Proceedings of the 95th Annual Meeting of the American Association for Cancer Research (AACR) (45):920, #3985, 2004. e-Pub 2004.
Groves M, Conrad C, Chamberlain M, Hsu S, Gilbert M, Forman A, Levin V, Puduvalli V, Colman H, Yung WKA. A phase II study of intrathecal topotecan in patients with meningeal malignancies. Neuro-Oncology 5(4):350, 2003. e-Pub 2003.
Koul D, Shen R, Bergh S, Yung WKA. Characterization of PTEN associated proteins. Neuro-Oncology 5(4):290, 2003. e-Pub 2003.
Cloughesy TF, Kuhn J, Wen P, Chang SM, Schiff D, Greenberg H, Junck L, Robins I, DeAngelis LM, Yung A, Groves M, Fink K, Abrey LE, Lieberman F, Mehta MP, Raizer JJ, Lamborn K, Prados M. Two Phase II trials of R115777 (Zarnestra) in patients with recurrent glioblastoma multiforme (GBM): A comparison of patients on enzyme-inducing anti-epileptic drugs (EIAED) and not on EIAED at maximum tolerated dose respectively: A North American Brain Tumor Consortium (NABTC) Report. Neuro-Oncology 5(4):349, 2003. e-Pub 2003.
Priebe W, Fokt I, Lee S, Yung WKA, Lang FF, Madden T, Conrad CA. Targeting glioblastoma with new DNA-binding agents. Clinical Cancer Research 9(16):#AA159; 243, 2003. e-Pub 2003.
Okcu MF, Selvan MS, Wang LE, Stour L, Erana R, Airewele G, Adatto P, Hess K, Ali-Osman F, Groves M, Yung WKA, Levin VA, Wei Q, Bondy ML. Glutathione S-transferase polymorphisms and survival in primary malignant glioma. Neuro-Oncology 5:313, 2003. e-Pub 2003.
Kunwar S, Prados M, Chang S, Lang F, Aldape K, Yung A, Gutin P, Raizer J, Piepmeier J, Baehring J, Berger M, McDermott M, Sherman J, Grahn A, Croteau D, Puri R. Peritumoral convection-enhanced delivery of IL13-PE38QQR in patients with recurrent malignant glioma: Phase I interim results. Neuro-Oncology 5(4):351, 2003. e-Pub 2003.
Zhou YH, Hess KR, Yung WKA. Prognosis model for astrocytic malignant glioma patients. Neuro-Oncology 5(4):329, 2003. e-Pub 2003.
Priebe W, Fokt I, Lee S, Yung WKA, Lang FF, Madden T, Conrad CA. A159 targeting glioblastoma with new DNA-binding agents. American Association for Cancer Research/National Cancer Institute/ European Organization for Research and Treatment of Cancer International Conference Molecular Targets and Cancer Therapeutics Discovery, Biology, and Clinical Applications. Clinical Cancer Research 9(16):#AA 159:243, 2003. e-Pub 2003.
Hongxia C, Lang F, Yung WKA, Liu TJ. Protective role of PP1 np53-mediated apoptosis. Neuro-Oncology 5:289, 2003. e-Pub 2003.
Fueyo J, Gomez-Manzano C, Yung WKA, Sawaya R, Lang FF. Dose dependence antiglioma effect of Delta-24-RGD in the intracranial U-87 MG animal model. Neuro-Oncology 5:300-301, 2003. e-Pub 2003.
Reardon D, Friedman H, Yung W, Brada M, Conrad C, Provenzale J, Jackson E, Serajuddin H, Laurent D, Reitsma D. Preliminary phase I trial results: PTK787/ZK 222584 (PTK/ZK), an oral VEGF tyrosine kinase inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GMB). Neuro-Oncology 5(4):355, 2003. e-Pub 2003.
Gomez-Manzano C, Aldape KD, Fueyo J, Xu J, Stolarek R, Hu CH, Lang FF, Yung WKA. blood vessel-destabilizer tool: Angiopoietin-2 as antiglioma treatment. Neuro-Oncology 5:283, 2003. e-Pub 2003.
Koul D, Bergh S, Shen R, Yung WKA. Targeting PTEN/PI3K pathway in human glioblastoma. Neuro-Oncology 5(4):290-291, 2003. e-Pub 2003.
Conrad CA, Ji Y, Gumin J, Lang FF, Sawaya R, Yung WKA, Gomez-Manzano C, Fueyo J. Direct comparison of the antiglioma effects Delta-24-hyCD and Ad-hyCD. Neuro-Oncology 4(4):298, 2003. e-Pub 2003.
Wang LE, Bondy ML, Shen H, El-Zein R, Aldape K, Puduvalli V, Levin VA, Yung WKA, Wei Q. Polymorphism of DNA double-strand break repair gene XRCC7 and risk of glioma. Neuro-Oncology 5(4):315, 2003. e-Pub 2003.
Gomez-Manzano C, Fueyo J, Xu J, H-J L, Courmier FW, Hu CH, Liu TJ, Yung WKA. Angiopoietin-2 downmodulates VEGF-A: Balancing act in gliomas. Neuro-Oncology 5:282-283, 2003. e-Pub 2003.
Gilbert MR, Hess K, Liu V, Groves M, Puduvalli V, Conrad CA, Levin V, Yung WKA. Combination therapy using radiation and cytostatic agents: A cautionary tale. Neuro-Oncology 4(4):343, 2003. e-Pub 2003.
Yung WKA. Oral presentation. A phase I trial of single-agent PTK 787/ZK 222584 (PTK/ZK), an oral VEGFR tyrosine kinase inhibitor, in patients with recurrent glioblastoma multiforme. Proceedings of the Society Of Clinical Oncology Annual Meeting 22, 2003. e-Pub 2003.
Chang SM, Yung WKA, Kuhn J, Schiff D, Fine H, Mehta M, Robins I, Junck L, Hess K, Prados M. Phase II study of neoadjuvant BCNU and Temozolomide for newly diagnosed anaplastic glioma. Proceedings from the American Society of Clinical Oncology Thirty-Ninth Annual Meeting 22:103, 2003. e-Pub 2003.
Yung WKA, Friedman H, Conrad C, Reardon D, Provenzale J, Jackson E, Leeds N, Serajuddin H, Laurent D, Reitsma D. A phase I trial of single agent PTK 787/ZK 222584 (PTK/ZK), an oral VEGFR tyrosine kinase inhibitor, in patients with recurrent glioblastoma multiforme. Proceedings from the American Society of Clinical Oncology Thirty-Ninth Annual Meeting 22:99, 2003. e-Pub 2003.
Gilbert MR, Wen P, Lieberman F, Robins I, Mehta M, Yung WKA, Chang S, Junck L, Cloughesy T, Prados M. Phase I/II study of combination Temozolomide (TMZ) and irinotecan (CPT-11) for recurrent malignant gliomas: A North American Brain Tumor Consortium (NABTC) Study. Proceedings from the American Society of Clinical Oncology Thirty-Ninth Annual Meeting 22:103, 2003. e-Pub 2003.
Gilbert M, Kuhn J, Lamborn K, Wen P, Lieberman FS, Robins I, Mehta M, Yung WKA, Chang S, Junck L, Cloughsey T, Prados M. M. D. Anderson Cancer Center and North American Brain Tumor Consortium, Phase I/II Study of Combination Temozolomide (TMZ) and Irinotecan (CPT-11) for Recurrent Malignant Gliomas: A North American Brain Tumor Consortium (NABTC) Study. Phase II trial of fenretinide in patients with recurrent malignant gliomas: A North American Brain Tumor Consortium Study Proceedings:22, 2003. e-Pub 2003.
Reardon D, Friedman HS, Yung WKA, Brada M, Conrad C, Provenzale J, Jackson EF, Serajuddin H, Laurent D, Reitsma D. A phase I trial of PTK787/ZK 222584 (PTK/ZK), an oral VEGF tyrosine kinase inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). Proceedings from the American Society of Clinical Oncology Thirty-Ninth Annual Meeting 22:103, 2003. e-Pub 2003.
Puduvalli VK, Yung WKA, Prados M, Kuhn J, Hess K, Groves M, Levin V, Chang S, Zweibel J, Cloughsey T. Phase II trial of fenretinide in patients with recurrent malignant gliomas – A North American Brain Tumor Consortium Study. Proceedings from the American Society of Clinical Oncology Thirty-Ninth Annual Meeting 22:105, 2003. e-Pub 2003.
Wang LE, Wei Q, Qiao Y, Bruner JL, Yung WKA, Levin VA, Bondy ML. Modulation of gamma-ray induced mutagen sensitivity by polymorphism of DNA repair gene, XRCC3 and risk of glioma: A case-control analysis. Proceedings of the 94th Annual Meeting of the American Association of Cancer Research (AACR) 44:1336 #5823, 2003. e-Pub 2003.
Zhou YH, Tan F, Hess KR, Yung WKA. PAX6 expression in gliomas: Relationship in tumor grade and survival. Proceedings of the 94th Annual Meeting of the American Association for Cancer Research (AACR) 44:116-117 #510, 2003. e-Pub 2003.
Sebti SM, Paquette S, Kuhn JG, Prados M, Robins HI, DeAngelis LM, Chang SM, Schiff D, Wen P, Yung WKA, Gilbert M, Fink K, Greenberg H, Junck L, Abrey LE, Lieberman FS, Mehta MP, Raizer JJ, Hess K, Cloughesy TF. Inhibition of farnesyltransferase (not geranylgeranyltransferase I) enzyme activity and the process of HDJ-2 (not Rap1) in peripheral blood monocytes of patients with recurrent malignant glioma treated with Zarnestra in phase I/II clinical trails. Proceedings of the 94th Annual Meeting of the American Association for Cancer Research (AACR) 55:1117 #4871, 2003. e-Pub 2003.
Zhou YH, Tan F, Shi YX, Glas T, Wathen K, Hess KR, Gumin J, Lang F, Yung WKA. The role of PAX6 in glioblastoma formation: A putative novel suppression pathway. Proceedings of the 94th Annual Meeting of the American Association for Cancer Research (AACR) 44:242 #1056, 2003. e-Pub 2003.
Chao HX, Lang FF, Shono T, Yung WKA, Liu TJ. Involvement of protein phosphatase I in p53-mediated apoptosis. Proceedings of the 94th Annual Meeting of the American Association for Cancer Research (AACR) 44:755-756 #3307, 2003. e-Pub 2003.
Hongxia C, Lang F, Yung WKA, Liu TJ. Protective role of PP1 np53-mediated apoptosis, 2003. e-Pub 2003.
Groves M, Conrad C, Chamberlain M, Hsu S, Gilbert M, Forman A, Levin V, Puduvalli V, Colman H, Yung WKA. A phase II study of intrathecal topotecan in patients with meningeal malignancies. Neuro-Oncology 5(4):350, 2003. e-Pub 2003.
Gomez-Manzano C, Fueyo J, Xu J, H-J L, Courmier FW, Hu CH, Liu TJ, Yung WKA. Angiopoietin-2 downmodulates VEGF-A: Balancing act in gliomas. Neuro-Oncology, 5:282-283, 2003 5:282-283, 2003. e-Pub 2003.
Jiang H, Medrano D, Gomez-Manzano C, Courmier F, Yung WKA, Fueyo J. Oral presentation. Replication competent adenoviruses with impaired p300/CBP binding express low E1A proteins levels: implication for oncolytic therapy. Neuro-Oncology 5:301-302, 2003. e-Pub 2003.
Okcu MF, Selvan MS, Wang LE, Stour L, Erana R, Airewele G, Adatto P, Hess K, Ali-Osman F, Groves M, Yung WKA, Levin VA, Wei Q, Bondy ML. Glutathione S-transferase polymorphisms and survival in primary malignant glioma. Neuro-Oncology 5:313:#GE-14, 2003. e-Pub 2003.
Gomez-Manzano C, Aldape KD, Fueyo J, Xu J, Stolarek R, Hu CH, Lang FF, Yung WKA. The blood vessel-destabilizer tool: Angiopoietin-2 as antiglioma treatment. Neuro-Oncology 5:283, 2003. e-Pub 2003.
Groves MD, Tremont-Lukats IW, Conrad, CA, Cloughnessy T, Gilbert MR, Prados M, Schiff D, Yung WKA. A phase II trial of temozolomide plus thalidomide (NABTC 99-04) for recurrent glioblastoma multiforme. Neuro-Oncology, Proceedings from Fifth Congress of the European Association of Neuro-Oncology, Florence, Italy 4, Supplement 1:#169, 2002. e-Pub 2002.
Reardon D, Friedman H, Yung WKA, Provenzale J, Jackson E, Needs N, Conrad CA, Forbes A, Henry A, Huang J, Laurent D, Dugan M. PTK787/ZK 222584 plus Temozolomide in the treatment of adults with recurrent glioblastoma multiforme. Neuro-Oncology 4(4), 2002. e-Pub 2002.
Groves MD, Puduvalli V, Gilbert M, Conrad C, Hess K, Yung WKA, Levin V. A phase II study of Temozolomide plus Marimastat for recurrent anaplastic glioma (AG). Neuro-Oncology 4(4):369, 2002. e-Pub 2002.
Gomez-Manzano C, Fueyo J, Lemoine M, Yung WKA, Fuller GN. Neoangiogenesis development in the intracranial U-87 MG animal model. Neuro-Oncology 4(4):308, 2002. e-Pub 2002.
Levin VA, Choucair A, Flynn PJ, Jaeckle KA, Kyritsis AP, Yung WKA, Bruner JM, Prados MD, Gleason MJ, Ictech SE, Hess KR. Phase III randomized study of post-irradiation chemotherapy with DFMO-PCV versus PCV for anaplastic gliomas. American Association for Cancer Research 43, 2002. e-Pub 2002.
Fueyo J, Gomez-Manzano C, Jiang H, Lemoine M, Stolarek R, Courmiker F, Jasti S, Conrad C, Yung WKA. Oncolytic adenoviruses, CPT-11, and Topisomerase I: Mechanisms underlying chemosensitization. Neuro-Oncology 4(4):322, 2002. e-Pub 2002.
Chao H, Lang FF, Yung WKA, Liu TJ. Involvement of DNA-PKcs in Ad-p53 induces apoptosis in human glioma cell lines. American Association for Cancer Research 43, 2002. e-Pub 2002.
Lu Y, Liu JH, Zhang J, Wang H, Koul D, McMurray J, Fang X, Yung WKA, Siminovitch KA, Mills GB. Involvement of Src family protein tyrosine kinases and the SHP-1 tyrosine phosphatase in the phosphotyrosine-dependent regulation of PTEN activity. American Association for Cancer Research 43, 2002. e-Pub 2002.
Wang LE, Bondy ML, Qiao Y, Bruner JL, Yung WKA, Levin VA, Wei Q. Modulation of sensitivity to radiation by p53 codon 72 polymorphism in a glioma case-control study. Association for Cancer Research 43, 2002. e-Pub 2002.
Chang S, Wen P, Greenberg H, Schiff D, Fine H, Yung A, Fink K, Mehta M, Khun J, Cloughesy T, DeAngelis L, Hess, K, Dancy J, Prados M. Phase I study of CCI-779 in patients with recurrent glioma (MG) on enzyme inducing antiepileptic drugs (EIAEDS). Neuro-Oncology 4(4):367, 2002. e-Pub 2002.
Liu JL, Sheng X, Koul D, Yung WKA. Cell cycle-dependent subcellular localization of PTEN/MMAC tumor suppressor is regulated by PI3K signaling cascades. Neuro-Oncology 4(4):315, 2002. e-Pub 2002.
Sheng X, Liu TJ, Gallick G, Yung WKA. Promoter analysis of PTEN/MMAC1 tumor suppressor gene. American Association for Cancer Research 43, 2002. e-Pub 2002.
Koul D, Parthasarathy R, Shen R, Liu TJ, Yung WKA. PTEN Tumor suppressor gene inhibits matrix metalloproteinase-2 gene expression and invasion in human glioma cells. Neuro-Oncology 4(4):338, 2002. e-Pub 2002.
Reardon D, Friedman H, Yung WKA, Provenzale J, Jackson E, Leeds N, Conrad CA, Walker A, Henry A, Huang J, Laurent D, Dugan M. A phase I trial of Temodar plus PTK787/ZK222584 (PTK/ZK), a novel oral VEGF inhibitor, for patients with recurrent glioblastoma. Neuro-Oncology 4(4):375, 2002. e-Pub 2002.
Conrad CA, Nakamizo A, Gumin J, Ji Y, Gilbert MR, Yung WKA, Lang FF. Glioma Xenograft Models for the Evaluation of Signal Transduction Inhibitors in Combination with Cytotoxic Chemotherapy: Survival, Pathologic and Molecular Correlates. Neuro-Oncology 4(4):322, 2002. e-Pub 2002.
Koul D, Parthasarathy R, Ruijun S, Davies M, Jasser S, Chintala S, Rao J, Sun Y, Benvenisite, Liu TJ, Yung WKA. MMAC/PTEN tumor suppressor gene inhibits matrix metalloproteinase-2 gene expression and invasion in human glioma cells. American Association for Cancer Research 43, 2002. e-Pub 2002.
Fueyo J, Gomez-Manzano C Alemany R, Lemoine M, Stolaraek R, Jasti S, Courmier F, Jiang H, Lamfers M, Dirven C, Curiel D, Yung WKA. Oncolytic adenovirus for glioma therapy. Neuro-Oncology 4:s35, 2002. e-Pub 2002.
Gomez-Manzano C, Fueyo J, Jiang H, Stolarek R, Lemoine M, Jasti S Courmier F, Glass TL, Lee HY, Hu M, Liu TJ, Conrad C, Yung WKA. Transfer of PTEN to human glioma cells results in transcriptional downregulation of VEGF in normaxia. Neuro-Oncology. Proceedings from Fifth Congress of the European Association of Neuro-Oncology, Florence Italy 4, Supplement 1:#164, 2002. e-Pub 2002.
Yung WA, Seiferheld W, Maor M, Groves M, Schultz C, Vermeulin S, Nelson D. Conventional Radiation Followed by Recombinant Interferon-Beta for Newly Diagnosed Glioblastoma: A RTOG (Radiation Therapy Oncology Group)Phase II Study (RTOG 97-10). Int J Radiat Oncol Biol Phys 51 (3 Suppl):206, 2001. e-Pub 2001.
Phuphanich S, Levin VA, Yung WKA, Forsyth P, Maestro R, Perry J. The Marimastat Glioblastoma Study Group, Elliott M, Baillet M, Moffitt Ca Ctr, UTMDACC, Tom Baker Ca Ctr, London Ca Ctr, British Biotech. A Multicenter, Randomized, Double-Blind, Placebo (PB) Controlled Trial of Marimastat (MT) In Patients with Glioblastoma Multiforme (GBM) or Gliosarcoma (GS) Following Completion of Conventional, First-Line Treatment. Proc of Amer Society of Clinical Oncol 20:52a, 2001. e-Pub 2001.
Yung WKA, Seiferheld W, Donahue B, Richards R, Kerlin K, Hug E, Curran W, Fine H. A RTOG (Radiation therapy Oncology Group) Phase II Study of Conventional Radiation Therapy Plus Thalidomide Followed by Thalidomide Post XRT for Supratentorial Glioblastoma. Proc of Amer Society of Clinical Oncol 20:52a, 2001. e-Pub 2001.
Y-H Z, Shi Y, Glass L, Zheng J, Saunders G, Yung WKA. A New Role of PAX6 in Suppression of Glioma. Proc of Amer Assoc of Ca Research 42:396, 2001. e-Pub 2001.
Groves MD, Lemoine M, Gomez-Manzano C, Mitlianga P, Yung WKA, Fueyo J. E2F-1 Increases the Chemosensitivity of Human Glioma Cells to Temozolomide and BCNU. Neurology (Suppl) 56:A407, 2001. e-Pub 2001.
Fueyo J, Gomez-Manzano C, Fuller NG, Khan A, Lemoine MG, Lang FF, Conrad C, Yung WKA. Treatment of Gliomas Xenografts with D24 Oncolytic Adenovirus: A Pathological Study. Neurology (Suppl) 56:A407, 2001. e-Pub 2001.
Groves MD, Lemoine MG, Gomez-Manzano C, Mitlianga P, Yung WKA, Fueyo J. E2F-1 Increases the Chemosensitivity of Human Glioma Cells to Temozolomide and BCNU. Neurology (Suppl) 56:A480, 2001. e-Pub 2001.
Gomez-Manzano C, Fueyo J, Glass T, Hu M, Lee H, He J, Mitlianga P, Lemoine MG, Tj L, Yung WKA. Treatment with MMAC/PTEN Modifies the Antiangiogenic Phenotype of Glioma Cells. Proc of Amer Society of Clinical Oncol 20:261a, 2001. e-Pub 2001.
Parthasarathy R, Benveniste E, Sun Y, Yung WKA, Liu TJ. Overexpression of E2F-1 decreases MMP-2 activity and reduces the invasive ability of gliomas. Proceedings of the American Association of Cancer Research 42:712, 2001. e-Pub 2001.
Fueyo J, Khan A, Gomez-Manzano C, Shono T, Lemoine M, Alemany R, Curiel DT, Y-X S, Liu, TJ, Levin VA, Yung WKA, Lang FG. Treatment of Intracranial Gliomas with D24-RGD. Neuro-Oncology 2:263, 2000. e-Pub 2000.
Cerrato J, Wang M, Yung WKA, Liu TJ. Inability of Activating CD95-FAS Pathway Contributes To The Apoptotic Resistant Phenotype of Glioma Cells Following Ad-53 Infection. Neuro-Oncology 2:254, 2000. e-Pub 2000.
Y-H Z, Glass T, Zheng JB, Yung WKA, Saunders G. PAX6 Function in the Suppression Pathways of Gliomas. Neuro-Oncology 2:305, 2000. e-Pub 2000.
Gilbert M, Olson J, Yung WKA, Prados M, Reaman GH, Zakonen S, Friedman HS. Preradiation Treatment of Newly Diagnosed Anaplastic Astrocytoma (AA) and Glioblastoma Multiforme (GBM) Using Temozolomide (TMZ). Neuro-Oncology 2:264, 2000. e-Pub 2000.
Prados M, Kuhn J, Yung WKA, Robbins HI, Fink K, Greenberg H, Junck L, Cloughsey T, Chang S, Fine H, Schiff D, Nicholas MK, Jaeckle KA, Hess K, Wen P. Phase-1 Study of CPT-11 Given Every 3 Weeks in Patients with Recurrent Brain Tumors, A North American Brain Tumor Consortium Study. Neuro-Oncology 2:287, 2000. e-Pub 2000.
Gomez-Manzano C, Fueyo J, Glass T, Koul D, H-Y L, Y-X S, Liu TJ, Yung WKA. MMAC/PTEN Downregulates VEGF in Gliomas. Neuro-Oncology 2:265, 2000. e-Pub 2000.
Jaeckle KA, Yung WKA, Prados M, Hess KR. Phase II Evaluation of Temozolomide and 13-CIS Retinoic Acid (Isotretinoin; CRA) for the Treatment of Recurrent ANC Progressive Malignant Gliomas (NABTC 98-03). Proc of the American Society of Clinical Oncology 19:166A, 2000. e-Pub 2000.
Lemoine M, Groves MD, Gomez-Manzano C, Mitlianga P, Levin VA, Kyritisis AP, Yung WKA, Fueyo J. E2F Enhances Temozolomide and BCNU Anti-Glioma Effect. Neuro-Oncology 2:278, 2000. e-Pub 2000.
Robins HI, Prados M, Rao DR, Chang S, Yung WKA, Hess K, Schiff D, Greenberg H, Fink K, Nicolas K, Kuhn J, Mehta MP. A Phase II Trial of Thymidine and Carboplatin for Recurrent Malignant Glioma: A North American Brain Tumor Consortium (NABTC) Study. Proc of the American Society of Clinical Oncology 19:166a, 2000. e-Pub 2000.
Lang FF, Fuller GN, Prados M, Sawaya R, Yung WKA. Preliminary Results of a Phase I Clinical Trial of Adenovirus-Mediated p53 Gene Therapy for Recurrent Glioma: Biological Studies. Neuro-Oncology 2:277, 2000. e-Pub 2000.
Prados M, Yung WKA, Fine H, Greenberg H, Junck L, Chang S, Nicholas MK, Robbins HI, Mehta M, Fink K, Schiff D, Jaeckle KA, Kuhn J, Hess K, Schold C. A Phase 2 study of BCNU and Temozolomide for recurrent glioblastoma multiforme: A North American Brain Tumor Consortium Study. Neuro-Oncology 2:287, 2000. e-Pub 2000.
Koul D, Yao Y, Liu TJ, Abruzze JL, Reddy SAG, Yung WKA. Regulation of NFkB and AP-1 Activation Through MMAC/PTEN: Evidence for a Novel Mechanisim. Neuro-Oncology 2:275, 2000. e-Pub 2000.
Levin VA, Hess KR, Yung WKA, Kyritisis A, Jaeckle KA, Leeds NE, Bruner JM, Gleason MJ, Maor MH. Phase II Study of Accelerated Fractionation Radiation Therapy with Carboplatin Followed by PCV for the Treatment of Anaplastic Gliomas. Neuro-Oncology 2:278, 2000. e-Pub 2000.
Jaeckle KA, Yung WKA, Prados M, Hess KR. NABTC 98-03: Phase II Evaluation of Temozolomide and 13-cis Retinoic Acid (Isotretinoin; cRA) for the Treatment of Recurrent and Progressive Malignant Gliomas. Neuro-Oncology 2:271, 2000. e-Pub 2000.
Gomez-Manzano C, Mitlianga P, Koul D, Y-H L, McDonnell TJ, Glass T, Liu TJ, Fueyo J, Yung WKA. E2F Transcriptionally Upregulated BCL-2. Neuro-Oncology 2:265, 2000. e-Pub 2000.
Jaeckle KA, Ortegon J, Kyritisis A, Yung WKA, Groves MD, Puduvalli V, Levin VA. Salvage Therapy with Etopside and Carboplatin for Late Stage Recurrent Malignant Gliomas. Neuro-Oncology 2:271, 2000. e-Pub 2000.
Mitlianga P, Gomez-Manzano C, Lemoine M, Hu M, Liu TJ, Levin VA, Yung WKA, Kyritisis AP, Fueyo J. E2F Enhances p53 Anti-Glioma Effect. Neuro-Oncology 2:282, 2000. e-Pub 2000.
Groves MD, Jaeckle KA, Puduvalli V, Hess KR, Yung WKA, Levin VA. A Phase II Study of Temozolomide (Temodar®) Plus Marimastat For Recurrent Glioblastoma Multiforme (GBM). Neuro-Oncology 2:266, 2000. e-Pub 2000.
Clarke JL, Ennis MM, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Lamborn KR, Prados MD, NABTC. Surgery at recurrence, prognosis for glioblastoma. Neuro-Oncology.

Book Chapters

Gomez-Manzano C, O-H L, Xu J, Fueyo J, Yung WKA. Neovascularization of malignant gliomas. In: Molecular Neuro-Oncology: Gliomas Methods and Protocols. Humana Press, 2018.
Hsu S, Yung WKA. Tumors of the nervous system. In: MD Anderson Manual of Medical Oncology. McGraw-Hill, 2018.
de Groot J, Yung WKA. Small molecule based therapies. In: Neuro-Oncology: The Essentials. Thieme Publishers, 2018.
Weathers, S, O'Brien, BJ, de Groot, JF, Yung, WA. Targeted Therapy in Solid Tumors, 177-189, 2015.
Janus TJ, Yung WKA. Primary Neurological Tumors. In: Textbook of Clinical Neurology. 3rd. Saunders, an imprint of Elsevier Inc, 1053-1080, 2007.
Jiang H, McCormick F, Gomez-Manzano C, Curiel D, Lang F, Yung WKA. Replicating viruses for brain tumor treatment. In: Gene Therapy for Neurological Disorders. Taylor & Francis Group, 293-325, 2006.
Conrad C, Yung WKA. Systemic chemotherapy for metastatic tumors of the central nervous system. In: Brain Tumors. Humana Press Inc, 267-278, 2004.
Hsu SH, Yung WKA. Chemotherapy for brain metastases. In: Intracranial Metastases Current Management Strategies. Futura/Blackwell Publishing, 183-195, 2004.
Stolarek R, Fueyo J, Gomez-Manzano C, Jiang H, Yung WKA. Gene-based therapy for gliomas: Targeting the cancer genomes. In: Genomic and Molecular Neuro-Oncology. Jones & Bartlett Publishers, 281-301, 2003.
Stolarek R Fueyo J, Gomez-Manzano C, Jiang H, Yung WKA. Gene-based therapy for gliomas: Targeting the Cancer Genomes. In: Genomic and Molecular Neuro-Oncology. Jones & Bartlett Publishers, 2003.
Yung WKA. Glial tumors. In: Encyclopedia of the Neurological Sciences. Academic Press, 455-464, 2003.
Gomez-Manzano C, Fueyo J, Yung WKA. Gene therapy approaches for glioma. In: Brain Cancer. American Cancer Society Atlas Series. BC Decker Inc, 219-237, 2001.
Milosavljevic VP, Conrad CA, Yung WKA. Principles of chemotherapy for adult primary brain tumors. In: Cancer of the Nervous System. Lippincott, Williams, and Watkins, 2001.
Yung WKA, Janus T. Primary Neurological Tumors. In: The Textbook of Clinical Neurology. 2nd. W B Saunders Company, 933-956, 1999.
Yung WKA, Bruner JM, Sawaya RE. Brain Tumors. In: Clinical Neurology. Lippincott-Raven, 1-66, 1998.
Yung WKA, Kaba SE. Biologic response modifiers. In: Textbook of Gliomas. W B Saunders Company, 1998.
Yung WKA, Janus T. Primary Neurological Tumors. In: The Textbook of Clinical Neurology. W B Saunders Company, 933-956, 1997.
Gomez-Manzano C, Fueyo J, Kyritsis AP, Yung WKA. Tumor suppressor gene therapy for brain tumors. In: Gene Transfer and Therapy for Neurological Disorders. Humana Press Inc, 225-239, 1997.
Milosavljevic VP, Conrad CA, Yung WKA. Principles of chemotherapy for adult primary brain tumors. In: Cancer of the Nervous System. Blackwell Science, 1996.
Kyritsis A, Yung WKA. Molecular genetics and tumor suppressor genes in gliomas. In: Cerebral Glioma. Bailliere Tindale, 933-956, 1996.
Flowers A, Yung WKA. Carcinamatosis meningitis and acute cord compression by tumor. In: Cancer in the Nervous System. 4th. Mosby-Year Book, 227-230, 1995.
Yung WKA, Sawaya R, Curran W, Fuller GN. Intracranial metastatic central nervous system tumors. In: Cancer in the Nervous System. Churchill Livingstone, 1995.
Levin VA, Yung WKA. Chemotherapy: Current and future role and expectations. In: Malignant Cerebral Glioma. American Association of Neurosurgeons, 207-216, 1990.
Griem JL, Yung WKA, Marks JE, Steward W, Mullen FJ. Treatment of glioblastoma multiforme. In: Tumors of the Nervous System. John Wiley & Son Inc, 63-68, 1974.

Books (edited and written)

Yung WKA. Bailliere's Clinical Neurology. Bailliere Tindale, 1996.

Letters to the Editor

Holtzman, SH, Cohen, R, Levin, JM, Maraganore, J, Albers, J, Aoun, JE, Audia, JE, Bailey, MP, Barrett, P, Bartel, D, Bienamie, JJ, Blum, RI, Boger, J, Bollenbacher, J, Bonney, MW, Booth, B, Bradbury, DM, Brandicourt, O, Braunwald, E, Carpenter, AE, Chang, HE, Cheruvu, P, Christensen, G, Church, GM, Clayman, MD, Cooney, CL, Cox, GF, Curley, SJ, Dahiyat, B, DePinho, RA, Diekman, J, Doerfler, D, Dornbusch, D, Douglas, RH, Dunsire, D, Ebright, RH, Eskridge, W, Flesher, GJ, Fong, K, Formela, JF, Foster-Cheek, K, Francois, C, Franken, MP, Franklin, H, Fu, YX, Gage, LP, Gardner, P, Gardner, J, Genead, M, Yung, WA. Chinese scientists and US leadership in the life sciences. Nature biotechnology 37: 1261-1263, 2019.
Wen PY, Schiff D, Cloughesy TF, Reardon DA, Batchelor TT, Chabner BA, Flaherty K, de Groot JF, Gilbert MR, Galanis E, Chang SM, Schwartz GK, Peereboom D, Mehta MP, Yung WK, Grossman SA, Prados MD, DeAngelis LM. It Is Time to Include Patients With Brain Tumors in Phase I Trials in Oncology. J Clin Oncol 29: 3211-3, 2011.

Patents

A Tumor Suppressor Designated TS10Q23.3. Patent Number: 6,262,242 B1.

Less

CV information above last modified March 06, 2026

Wai-Kwan Alfred Yung, M.D.

About Dr. Wai-Kwan Alfred Yung

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Other Articles

Editorials

Abstracts

Book Chapters

Books (edited and written)

Letters to the Editor

Patents

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson